{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Request successful!\n",
      "\"APIVrs: 1.01.05\"\n",
      "\"DataVrs: 2023:03:27 01:55:10.393\"\n",
      "\"Expression: solid+tumor\"\n",
      "\"NStudiesAvail: 446552\"\n",
      "\"NStudiesFound: 13020\"\n",
      "\"MinRank: 1\"\n",
      "\"MaxRank: 1000\"\n",
      "\"NStudiesReturned: 1000\"\n",
      "\"Field Names: PrimaryOutcomeMeasure,PrimaryOutcomeTimeFrame,OverallStatus,LastKnownStatus,LastUpdatePostDate\"\n",
      "\n",
      "\"Rank\",\"PrimaryOutcomeMeasure\",\"PrimaryOutcomeTimeFrame\",\"OverallStatus\",\"LastKnownStatus\",\"LastUpdatePostDate\"\n",
      "1,\"Relief degree of tumors\",\"The last injection\",\"Not yet recruiting\",,\"February 28, 2023\"\n",
      "2,\"Prevalence of solid tumors in RASopathies\",\"5 years\",\"Recruiting\",,\"March 9, 2023\"\n",
      "3,\"Solid tumor biological insights\",\"Study completion\",\"Completed\",,\"June 12, 2014\"\n",
      "4,\"Adverse Events(AE)|Objective Response Rate (ORR)|Disease Control Rate (DCR）|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS)\",\"6 month|Up to 36 months|Up to 36 months|Up to 36 months|Up to 36 months|Up to 36 months\",\"Recruiting\",,\"December 21, 2022\"\n",
      "5,\"To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors|Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors|To Determine the Pharmacokinetics of AZD1775 in Patients With Refractory Solid Tumors.\",\"Date treatment consent signed to date off study, approx.19 mo/8 d for A1, 3 mo/28 d for A2, 10 mo/28 d for A3, 2 mo/14 d for A4, 20 mo/24 d for A5, 10 mo/23 d for A6, 4 mo/23 d for A7, 14 mo/11 d for A8, 15 mo/24 d for A9, and 77 mo/6 d for A10.|Date treatment consent signed to date off study, approx.19 mo/8 d for A1, 3 mo/28 d for A2, 10 mo/28 d for A3, 2 mo/14 d for A4, 20 mo/24 d for A5, 10 mo/23 d for A6, 4 mo/23 d for A7, 14 mo/11 d for A8, 15 mo/24 d for A9, and 77 mo/6 d for A10.|Pre-Treatment (Baseline) and Cycle 1 Days 1 and 3 (Arms 3 and 7) or Days 1 and 5 (Arms 1-2, 5-6, and 8)\",\"Completed\",,\"July 26, 2021\"\n",
      "6,\"Identify exceptional responders with cancer to standard of care chemotherapy\",\"9 years\",\"Enrolling by invitation\",,\"February 1, 2023\"\n",
      "7,\"Maximum Tolerated Dose (MTD) in Participants With Any Solid Tumor (Phase Ib)|Clinical Benefit Rate for Patients With Advanced Breast Cancer (ABC) (Phase II)\",\"Up to 24 months|Up to 24 months\",\"Completed\",,\"February 3, 2021\"\n",
      "8,\"Adverse events that are related to treatment\",\"2 years\",\"Unknown status\",\"Recruiting\",\"November 18, 2020\"\n",
      "9,\"molecular profiling of solid tumors\",\"5 years\",\"Recruiting\",,\"February 26, 2021\"\n",
      "10,\"Maximum tolerated dose (MTD) or recommended clinical dose|Dose-limiting toxicity(DLT)|Incidence and degree of Adverse Events and Serious Adverse Events [Safety]\",\"Up to 16 weeks|Up to 16 weeks|Up to 100 weeks\",\"Not yet recruiting\",,\"May 3, 2022\"\n",
      "11,\"Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)\",\"From 6 months postdose of last participant up to 3 years 5 months\",\"Active, not recruiting\",,\"October 13, 2022\"\n",
      "12,\"Percent of good quality tumor samples obtained\",\"Once at study enrollment\",\"Active, not recruiting\",,\"October 12, 2022\"\n",
      "13,\"ORR(Objective Response Rate)\",\"Up to three months\",\"Unknown status\",\"Enrolling by invitation\",\"August 20, 2019\"\n",
      "14,\"MTD of pioglitazone and carboplatin\",\"Baseline, 6 Weeks\",\"Completed\",,\"May 13, 2016\"\n",
      "15,\"Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.|Changes in patients' ctDNA longitudinal samples through treatment, and when available, of primary tumor and metastasis.\",\"24 months|24 months\",\"Completed\",,\"January 31, 2020\"\n",
      "16,\"Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan and capecitabine when given in combination with a fixed dose of oxaliplatin in patients with advanced solid tumors.\",\"Treatment cycle is four weeks, repeated every six weeks in the absence of disease progression or unacceptable toxicity.\",\"Completed\",,\"June 11, 2010\"\n",
      "17,\"Number of patients with serious and non-serious adverse events\",\"From screening to safety follow-up (30 days after last dose)\",\"Terminated\",,\"September 2, 2022\"\n",
      "18,\"Determine the MTD and DLT(s) of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors.|Establish the recommended dose of G-202 to be used in Phase II studies.|Determine the pharmacokinetics of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors.\",\"2 years|2 years|2 years\",\"Completed\",,\"December 10, 2015\"\n",
      "19,\"Disease response measured with consistent imaging utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1|Incidence and severity of study treatment-related adverse events measured by the Common Terminology Criteria for Adverse Events (CTCAE) v. 5\",\"12 months|12 months\",\"Recruiting\",,\"March 31, 2022\"\n",
      "20,\"To determine the recommended phase 2 dose (RP2D) of the combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.\",\"28 days\",\"Completed\",,\"February 20, 2020\"\n",
      "21,\"Objective Response Rate(ORR)\",\"up to 36 months\",\"Recruiting\",,\"April 29, 2019\"\n",
      "22,\"Recommended Phase 2 dose(RP2D) (Applicable for: phase I stage in various solid tumor types).|Disease control rate (Applicable for: phase II in cohorts of Colorectal Cancer, Nasopharyngeal Carcinoma and Non-Small Cell Lung Cancer) .\",\"21 days.|18-24months.\",\"Recruiting\",,\"October 19, 2022\"\n",
      "23,\"Occurrence of dose limiting toxicities (DLTs) within a patient during the DLT evaluation period in Part 1.|Occurrence of treatment emergent adverse event (TEAE) within a patient including Grade ≥3, serious, fatal TEAE by relationship.|Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAE.\",\"up to 21 days|through study completion, an average of 6 months|through treatment completion, an average of 4 months\",\"Recruiting\",,\"March 2, 2023\"\n",
      "24,\"Determine the maximum tolerated dose of docetaxel, cisplatin, and capecitabine in patients with advanced solid tumors.\",\"Every 21 days\",\"Completed\",,\"January 13, 2014\"\n",
      "25,\"Two-year progression-free survival in patients with high-risk solid tumors\",\"up to 2 years\",\"Recruiting\",,\"February 21, 2023\"\n",
      "26,\"Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age.\",\"At the end of Month 1\",\"Completed\",,\"June 2, 2021\"\n",
      "27,\"To determine the safety and toxicity of nelfinavir in human subjects with solid tumors and to determine the maximum tolerated dose in this group of patients.\",,\"Completed\",,\"December 17, 2019\"\n",
      "28,\"Summary of Objective Response Rate Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors\",\"Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months\",\"Terminated\",,\"October 5, 2021\"\n",
      "29,\"safety profile of combination of Talazoparib and Selinexor in advanced/ metastatic solid tumors using NCI CTCAE toxicity grading version 5.0.\",\"5 years\",\"Recruiting\",,\"September 5, 2021\"\n",
      "30,\"To evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.\",\"baseline through end of treatment\",\"Completed\",,\"September 25, 2017\"\n",
      "31,\"Determination of Recommended Phase 2 Dose (RP2D)\",\"28 Days\",\"Recruiting\",,\"September 23, 2022\"\n",
      "32,\"To determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors\",\"Anticipated completion date December 2008\",\"Completed\",,\"May 28, 2015\"\n",
      "33,\"The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03\",\"Up to 28 days\",\"Completed\",,\"July 25, 2022\"\n",
      "34,\"Number of Participants With Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD) of MK1775 in Combination With 5-FU/CDDP Determined by Number of DLTs Per Dose Level: Locally Advanced or Metastatic Esophageal, Head and Neck, or Gastric Cancer\",\"Cycle 1 (21 days)|Cycle 1 (21 days)\",\"Terminated\",,\"July 17, 2018\"\n",
      "35,\"Evaluate the potential for QT/QTc interval prolongation of TH-302 in patients with solid tumors\",\"2 years\",\"Unknown status\",\"Active, not recruiting\",\"June 2, 2016\"\n",
      "36,\"Determine maximum tolerated dose and anti-tumor activity of BMS-863233 when administered to subjects with advanced and/or Metastatic solid tumors\",\"Every 28 days until the MTD is reached\",\"Terminated\",,\"October 12, 2015\"\n",
      "37,\"Incidence of treatment-related adverse events as assessed by CTCAE v4.0\",\"2 years\",\"Unknown status\",\"Recruiting\",\"June 9, 2017\"\n",
      "38,\"Overall survival (OS)|The number of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.|The types of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.\",\"3 years|3 years|3 years\",\"Recruiting\",,\"January 20, 2023\"\n",
      "39,\"Safety of infusion of autologous CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells\",\"2 years\",\"Unknown status\",\"Recruiting\",\"June 7, 2017\"\n",
      "40,\"Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Safety Population)|Percentage of Participants With TEAEs (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Safety Population)|Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Efficacy Evaluable Population)|Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Efficacy Evaluable Population)\",\"From post first dose up to 28 days after the last dose, up to 5 years 9 months|From post first dose up to 28 days after the last dose, up to 5 years 9 months|From post first dose up to 5 years 9 months post dose|From 26 days (CR and PR) and 54 days (SD) up to 5 years 9 months post dose\",\"Completed\",,\"July 16, 2020\"\n",
      "41,\"Maximum tolerated dose|Dose-limiting toxicity\",\"after initial 28 day cycle|Courses repeat every 28 days for up to 24 months in the absence of unacceptable toxicity.\",\"Completed\",,\"August 28, 2012\"\n",
      "42,\"Incidence of MSI-H across different cancer types in Chinese patients\",\"Two years\",\"Unknown status\",\"Recruiting\",\"July 24, 2018\"\n",
      "43,\"To determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.\",\"8 weeks\",\"Completed\",,\"February 25, 2014\"\n",
      "44,\"Part 1 Dose Escalation: Incidence of treatment emergent adverse events (TEAEs)|Part 1 Dose Escalation: Severity of treatment emergent adverse events (TEAEs), according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0|Part 1 Dose Escalation: Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy|Part 2 Dose Expansion: Overall Response Rate (ORR)\",\"Day 1 through to 30 days after last dose (approximately 4 cycles (84 days plus 30 day follow-up )); Each cycle is 21 days|Day 1 through to 30 days after last dose (approximately 4 cycles (84 days plus 30 day follow-up )); Each cycle is 21 days|Day 1 through to start of dose expansion phase (approximately 1 year)|Day 1 through 30 days after last dose, estimated to be 5 months\",\"Recruiting\",,\"February 24, 2023\"\n",
      "45,\"Determine the recommended Phase 2 dose of 177Lu-FAP-2286 (Phase 1)|Objective response rate (ORR) (Phase 2)\",\"From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)|From first dose of study drug until disease progression (up to approximately 2 years)\",\"Recruiting\",,\"August 29, 2022\"\n",
      "46,\"To determine the maximum tolerated dose (MTD)in subjects with advanced solid tumor|To determine DLT (Dose Limiting Toxicity) in subjects with advanced solid tumor\",\"Each subject can be given up to 2 cycles of SCB01A. Each cycle will be 21 days.|Each subject can be given up to 2 cycles of SCB01A. Each cycle will be 21 days.\",\"Completed\",,\"October 19, 2017\"\n",
      "47,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators.\",\"From Baseline until disease progression (up to 2 years)\",\"Not yet recruiting\",,\"December 29, 2021\"\n",
      "48,\"Event free survival|Overall survival\",\"6 months|6 and 12 months\",\"Unknown status\",\"Not yet recruiting\",\"September 15, 2016\"\n",
      "49,\"Maximum Tolerated Dose (MTD) of Ixazomib and Erlotinib in Advanced Cancer Participants\",\"28 days\",\"Active, not recruiting\",,\"October 24, 2022\"\n",
      "50,\"Urinary, fecal, and respiratory excretion of 14C from FTD and urinary and fecal excretion of 14C from TPI|PK parameters of total radioactivity (AUC0-inf, AUC0-last, Cmax, Tmax, and T1/2) in whole blood and plasma after a single dose of TAS-102|Metabolic profile of FTD and TPI in plasma, urine, and feces|PK parameters of FTD, FTY, and TPI in plasma (Cmax, Tmax, AUC0-last, AUC0-inf, T1/2, CL/F, and Vd/F)\",\"Day 1 through day 8 (through 168 hours postdose)|Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose|Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose. Urine and feces samples will be collected at 24-hour intervals through 168 hours postdose.|Blood will be collected immediately prior to dosing (0 hour) and at 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours postdose.\",\"Completed\",,\"June 16, 2017\"\n",
      "51,\"To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of GSK1363089 administered orally (up to twelve different doses) to subjects with solid tumors\",\"3 years\",\"Completed\",,\"July 31, 2017\"\n",
      "52,\"Phase 1: To determine the Recommended phase 2 dose (RP2D) of niraparib and neratinib in patients with advanced solid tumors|Phase 1b: To evaluate clinical benefit (≥4-month progression-free survival [PFS]) of niraparib and neratinib in patients with platinum-resistant ovarian cancer.\",\"4 Months|4 months\",\"Recruiting\",,\"November 7, 2022\"\n",
      "53,\"To determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of daily oral administration of GSK1363089 in subjects with solid tumors\",\"2 years\",\"Completed\",,\"July 26, 2017\"\n",
      "54,\"Dose Limiting Toxicity|Adverse Event\",\"up to Day 28|up to 24 months\",\"Not yet recruiting\",,\"December 14, 2022\"\n",
      "55,\"To identify the dose limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients with advanced solid tumors.\",\"Along the study\",\"Completed\",,\"November 4, 2015\"\n",
      "56,\"The safety of ScTIL210\",\"24 weeks post infusion\",\"Recruiting\",,\"July 16, 2021\"\n",
      "57,\"Maximum Tolerated Dose (MTD) of perifosine monotherapy in children with cancer\",\"conclusion of the study\",\"Completed\",,\"August 1, 2017\"\n",
      "58,\"Incidence of treatment-related adverse events\",\"up to 2 years\",\"Unknown status\",\"Not yet recruiting\",\"August 11, 2016\"\n",
      "59,\"To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.\",\"24 months\",\"Completed\",,\"December 23, 2015\"\n",
      "60,\"To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors\",\"No time frame\",\"Completed\",,\"July 23, 2012\"\n",
      "61,\"Maximum Tolerated Dose (MTD)\",\"Day 1 to 28 ( Cycle 1)\",\"Unknown status\",\"Recruiting\",\"January 15, 2019\"\n",
      "62,\"Determine perioperative PET/CT imaging combined with intraoperative use of handheld gamma probe is feasible during surgical procedure to resect malignancy.\",\"up to five years\",\"Completed\",,\"April 4, 2016\"\n",
      "63,\"ORR\",\"up to approximately half past one year\",\"Recruiting\",,\"January 4, 2023\"\n",
      "64,\"Incidence of treatment-related adverse events of infusion of autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells\",\"2 years\",\"Unknown status\",\"Recruiting\",\"August 3, 2018\"\n",
      "65,\"To determine the safety of OMP-21M18 in subjects with previously treated solid tumors\",\"continuous\",\"Completed\",,\"September 10, 2020\"\n",
      "66,\"To determine the safety, maximum tolerated dose(MTD)of IPI-504 in combination with docetaxel in patients with advanced solid tumors and recommend the Phase II dose of the combination of drugs.\",\"Weekly\",\"Completed\",,\"March 6, 2012\"\n",
      "67,\"1. Tumor vessel identification (# tumor vessels visualized per high power field)|2. Tumor vessel density (# tumor vessels per square cm area observed)|3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)|4. Tumor blood flow (velocity, mm/sec)\",\"12-15 minutes|12-15 minutes|12-15 minutes|12-15 minutes\",\"Recruiting\",,\"April 5, 2022\"\n",
      "68,\"Compare the proportion of patients for whom a genomically identified recommended therapy could be initiated using the large NGS panel from FoundationOne versus the limited CONTROL panel.\",\"28 months\",\"Completed\",,\"May 9, 2022\"\n",
      "69,\"Incidence of Bacteriemia in a High Dose Busulfan, Melphalan and Thiotepa Chemotherapy Regimen With Autologous Peripheral Blood Stem Cell Rescue in Patients With High Risk and Relapsed or Refractory Pediatric Solid Tumors\",\"3 months\",\"Terminated\",,\"January 25, 2022\"\n",
      "70,\"To determine the dose limiting toxicity and safety of bi-weekly courses of rBBX-01 in patients with resistant solid tumor malignancies.\",\"Four bi-weekly 5 day courses\",\"Completed\",,\"July 15, 2013\"\n",
      "71,\"To quantify the occurrence of adverse events (AEs) reported in all subjects who received study drug|To determine the occurrence of treatment-emergent adverse events (TEAs)|To determine the occurrence of treatment-related adverse events meeting the criteria for dose limiting toxicities (DLTs)\",\"From enrollment up to 30 days after last dose|From first dose up to 30 days after last dose|From first dose up to 28 days\",\"Completed\",,\"March 16, 2022\"\n",
      "72,\"Pharmacodynamic effects as measured by changes in biomarkers in pre- and post-dose tumor and blood specimens\",\"Approximately 1 year\",\"Terminated\",,\"August 26, 2021\"\n",
      "73,\"To determine the maximum tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.|To define the dose limiting and other toxicities of the combination therapy|To determine the dosing that should be used in future safety and efficacy (Phase II) trials\",,\"Terminated\",,\"September 14, 2006\"\n",
      "74,\"To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors: NCI CTCAEv5 Common Toxicity Criteria|To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer|To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study: NCI CTCAEv5 Common Toxicity Criteria|To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with Abraxane given intravenously at 100 mg/m2 once weekly for 3 weeks in the dose escalation and expansion stages of the study\",\"From first dose up to 21 days after last dose|From first dose up to 21 days after last dose|From first dose up to 21 days after last dose|From first dose up to 28 days after last dose\",\"Active, not recruiting\",,\"January 17, 2023\"\n",
      "75,\"Cancer-related mortality after solid organ transplantation\",\"1985-2016 cohort\",\"Unknown status\",\"Not yet recruiting\",\"June 12, 2020\"\n",
      "76,\"Detection by Polymerase Chain Reaction (PCR) of specific genetic alterations|Detection of specific genetic alterations of tumoral cells in peripheral samples\",\"at the inclusion|Up to 6 years\",\"Unknown status\",\"Active, not recruiting\",\"August 10, 2020\"\n",
      "77,\"Number of patients with Adverse Events and/or Serious Adverse Events\",\"18 weeks\",\"Active, not recruiting\",,\"August 24, 2022\"\n",
      "78,\"Determine the safety and tolerability, including the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD), of a 2-day pulse of AC480IV both as monotherapy and in combination with docetaxel in patients with advanced solid tumor malignancies.\",\"18 months\",\"Withdrawn\",,\"November 1, 2015\"\n",
      "79,\"Incidence of adverse events\",\"Up to 6 months\",\"Recruiting\",,\"March 23, 2022\"\n",
      "80,\"Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs)|Tolerability of NKTR-214 as Evaluated by Incidence of Dose Limiting Toxicities (DLTs)\",\"30 days after last dose, approximately 533 days|30 days after last dose, up to 533 days\",\"Completed\",,\"July 29, 2021\"\n",
      "81,\"To evaluate the safety and tolerability of veliparib/TMZ combination in subjects with solid tumors\",\"Continuous starting with Day1 and 30 Days following last dose.\",\"Completed\",,\"November 21, 2012\"\n",
      "82,\"PFS|OS\",\"1 year|3 years\",\"Completed\",,\"September 14, 2020\"\n",
      "83,\"Ⅰa (Dose-Escalation Stage): Maximum tolerated dose (MTD) for HS-20093|Ⅰb (Dose-Expansion Stage): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\",\"Up to day 21 from the first dose|From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months\",\"Recruiting\",,\"February 15, 2023\"\n",
      "84,\"Maximum Tolerated Dose\",\"2 months\",\"Completed\",,\"September 2, 2021\"\n",
      "85,\"Safety and Tolerability - Evaluation of AEs and DLT\",\"Adverse event evaluation was done during treatment and follow-up. DLT evaluation was done during cycle 1\",\"Terminated\",,\"September 11, 2019\"\n",
      "86,\"Documentation of the Quality of CTCs from Patients with Solid Tumors|Documentation of the Characterization of CTCs from Patients with Solid Tumors\",\"Through study completion, an average of 5 years|Through study completion, an average of 5 years\",\"Completed\",,\"September 28, 2022\"\n",
      "87,\"Determination of the MTD of 2X-121 monotherapy.|Determination of the MTD of dovitinib given in combination with 2X-121 (MTD).\",\"Evaluated after up to approximately 2 years|Evaluated after up to approximately 2 years\",\"Recruiting\",,\"February 2, 2023\"\n",
      "88,\"Dose-limiting toxicity (DLT)|Maximum Tolerated Dose (MTD)\",\"3 years|3 years\",\"Completed\",,\"April 26, 2017\"\n",
      "89,\"Number of participants with dose limiting toxicities\",\"Up to 2 years\",\"Terminated\",,\"October 2, 2015\"\n",
      "90,\"Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)\",\"2 years\",\"Unknown status\",\"Not yet recruiting\",\"November 5, 2019\"\n",
      "91,\"Incidence of treatment-emergent and serious adverse events in patients treated with IO-202 and IO-202 + pembrolizumab|Dose-limiting toxicities (DLTs) with IO-202 and IO-202 + pembrolizumab|Study discontinuations due to adverse events (AEs)\",\"From first dose of IO-202 until the end of treatment which is up to 2 years from the first treatment date|From the first dose of IO-202 and IO-202 + pembrolizumab until 21 days after 1st treatment|From the first dose of IO-202 IO-202 and IO-202 + pembrolizumab up to 2 years from the first treatment.\",\"Recruiting\",,\"January 11, 2023\"\n",
      "92,\"To determine the safety of OMP-59R5 in subjects with previously treated solid tumors\",\"continuous\",\"Completed\",,\"September 9, 2020\"\n",
      "93,\"To establish the DLT and the MTD of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system.\",\"Duration of trial\",\"Completed\",,\"February 13, 2015\"\n",
      "94,\"Pharmacodynamic optimal dose of sirolimus by evaluation of p70s6 kinase inhibition in peripheral blood mononuclear cells (PBMC) and normal skin|Correlation of target tissue inhibition in tumor tissue with PMBCs and normal skin\",,\"Completed\",,\"August 9, 2010\"\n",
      "95,\"To establish the safety, tolerability, and recommended Phase 2 dose of KW 2450 administered orally in subjects with advanced solid tumor who have not responded to standard therapy or for whom no standard therapy is available\",\"28 days\",\"Completed\",,\"September 10, 2010\"\n",
      "96,\"Number of participants experiencing toxicities|Maximum tolerated dose (MTD)\",\"3 years|2 years\",\"Completed\",,\"December 8, 2022\"\n",
      "97,\"Objective response rate assessed by Independent Review Committee per Response Evaluation Criteria in Solid Tumors Version 1.1\",\"Up to 2 years\",\"Recruiting\",,\"December 15, 2022\"\n",
      "98,\"Maximum tolerated dose of HLX20 in solid tumors patients\",\"1 year\",\"Completed\",,\"June 3, 2022\"\n",
      "99,\"To define the maximum tolerated dose and dose-limiting toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies.|To determine the incidence and severity of other toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies.\",\"3 years for MTD to be determined, DLT occurs in 1st cycle only|30 days after end of treatment\",\"Completed\",,\"June 3, 2015\"\n",
      "100,\"PFS|OS\",\"2 year|3 years\",\"Completed\",,\"May 28, 2020\"\n",
      "101,\"To determine the safety of OMP-18R5 in subjects with previously treated solid tumors\",\"Subjects will be assessed for dose limiting toxicity from Days 0-28. Adverse events will be reported through 30 days after the last dose.\",\"Completed\",,\"September 9, 2020\"\n",
      "102,\"The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation\",\"14 Days (1 cycle)\",\"Completed\",,\"November 23, 2016\"\n",
      "103,\"The primary outcome is to determine the safety and toxicity of ixabepilone and dasatinib in combination in patients with metastatic or locally advanced/unresectable solid tumors that have progressed through standard therapy.\",\"From study start until completion of study followup. This can vary greatly between patients, but on average patients received treatment for 4 cycles (12 weeks).\",\"Completed\",,\"August 5, 2020\"\n",
      "104,\"Explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies, by assessment of AEs, lab findings, physical examinations, vital signs, cardiac monitoring and ophthalmological examinations\",,\"Completed\",,\"March 12, 2013\"\n",
      "105,\"Feasibility and safety of temsirolimus and pazopanib when given in combination to patients with advanced solid tumors.\",\"Every 4 weeks (Cycle)\",\"Completed\",,\"March 28, 2012\"\n",
      "106,\"Dose limiting toxicities (DLTs) of the combination of LDE225 with paclitaxel in patients with advanced solid tumors\",\"until up to 4 weeks after start of trial therapy\",\"Completed\",,\"December 6, 2019\"\n",
      "107,\"MTD and / or a RP2D of EVT801 when administered daily to subjects with advanced or metastatic solid tumours.|Adverse event (AE) safety information for EVT801\",\"24 months|36 months\",\"Recruiting\",,\"April 7, 2022\"\n",
      "108,\"Number and grade of adverse events by participant related to PDM08.|Dose limiting toxicity (DLT)\",\"6 weeks for each cohort.|6 weeks.\",\"Completed\",,\"January 7, 2013\"\n",
      "109,\"To determine the pharmacokinetics (PK) of erlotinib when administered in combination with sorafenib on a continuous schedule in Refractory Solid Tumors in patients who are smokers and in patients who are nonsmokers.\",\"3 months\",\"Completed\",,\"July 2, 2014\"\n",
      "110,\"The maximum tolerate dosage\",\"4 weeks\",\"Unknown status\",\"Recruiting\",\"October 21, 2010\"\n",
      "111,\"Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS0728.|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Phase 1 and 2)|Objective Response Rate using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) (Phase2)\",\"21-day cycles|Safety monitoring will begin at the informed consent obtained and continue up to 30 days after the last dose of TAS0728 or until new antitumor therapy, whichever is earlier.|3 years\",\"Terminated\",,\"March 20, 2023\"\n",
      "112,\"Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.\",,\"Withdrawn\",,\"April 8, 2011\"\n",
      "113,\"Recommended Phase 2 Dose\",\"Baseline to toxicity [up to end of Cycle 1 (cycle = 21 or 28 days)]\",\"Completed\",,\"March 15, 2019\"\n",
      "114,\"Incidence of dose-limiting toxicity within 2 days of single administration and 28 days of continuous administration.|Determine the recommended phase II dose\",\"From first dose up to 28 days|From first dose up to 28 days\",\"Recruiting\",,\"January 28, 2022\"\n",
      "115,\"Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)\",\"31 months\",\"Completed\",,\"May 2, 2017\"\n",
      "116,\"Safety (Phase 1) - Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events|Efficacy (Phase 2) - Response Evaluation Criteria in Solid Tumors using RECIST v1.1\",\"End of each dosing cycle (Day 21 of 21-day cycle)|Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year\",\"Recruiting\",,\"March 6, 2023\"\n",
      "117,\"Number of patients with adverse events\",\"3 years\",\"Recruiting\",,\"June 16, 2020\"\n",
      "118,\"To assess the safety and tolerability of intravenously infused CCI-001 in patients with recurrent and/or metastatic solid tumours by determining the dose-limiting toxicity (DLT) of the compound.|To determine, during the dose escalation phase, the recommended dose of intravenously infused CCI-001 for the dose expansion phase of the trial.\",\"Cycle 1 (28 days)|Cycle 1 (28 days)\",\"Recruiting\",,\"July 14, 2022\"\n",
      "119,\"To determine the safety and tolerability of AZD2281 in combination with Cisplatin (eg Adverse Events, Pharmacokinetic for AZD2281, overall response rate) to patients with advanced solid tumours.\",\"Weekly visits for routine monitoring visits\",\"Active, not recruiting\",,\"March 22, 2023\"\n",
      "120,\"The rate of toxicities after TAA-T infusion\",\"45 days\",\"Recruiting\",,\"October 26, 2022\"\n",
      "121,\"Dose-limiting toxicities (DLT) and/or subsequent maximum dose|Dose at which there is no additional differential effect of L-NNA on the tumor vasculature as measured by dynamic contrast-enhanced computed tomography (DCE-CT)|Pharmacokinetic (predominantly AUC-dependent specific vascular effects) dependent effects (duration and magnitude of effect on blood flow/volume) in the tumor tissue compared to renal tissue using data from volumetric assessments via DCE-CT\",,\"Terminated\",,\"March 5, 2015\"\n",
      "122,\"maximum tolerated dose\",\"1-3 months\",\"Completed\",,\"December 22, 2021\"\n",
      "123,\"Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS-116 (Part A)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Parts A, B and C)|Objective Response Rate using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) (Part C)\",\"21 days in Cycle 1|Safety monitoring will begin at the informed consent obtained and continue up to 28 days after the last dose of TAS-116 or until new anti-tumor therapy, whichever is earlier.|Up to 2 Years\",\"Completed\",,\"October 1, 2019\"\n",
      "124,\"To identify the Maximum Tolerated Dose (MTD) of PQR309 administered in different (continuous and intermittent) dosing schedules. To evaluate efficacy of PQR309 in selected patient population: • Solid tumors with PI3K/mTOR activation • Human Papilloma|Objective response rate (ORR) according to the response evaluation• Solid tumors with PI3K/mTOR activation • Human Papilloma Virus (HPV) positive Head and neck squamous cell carcinoma (HNSCC) containing activating PIK3CA mutations\",\"In average 1 year|in average 2 years\",\"Completed\",,\"March 22, 2019\"\n",
      "125,\"• To determine the safety of OMP-54F28 in subjects with previously treated solid tumors\",\"Subjects will be assessed for dose limiting toxicities from Days 0-28. Adverse events will be reported through 30 days after the last dose.\",\"Completed\",,\"August 11, 2020\"\n",
      "126,\"Incidence of treatment-related adverse events as assessed by CTCAE v4.0\",\"2 years\",\"Unknown status\",\"Recruiting\",\"June 9, 2017\"\n",
      "127,\"Complete evaluation of untreated lesions with physical examination and appropriate X-rays and/or scans will be performed four to six weeks after the last DC injection.|Immunological evaluation will be performed two weeks after the last DC injection.\",,\"Terminated\",,\"April 21, 2015\"\n",
      "128,\"Toxicity\",\"Cycle 1 1st MoAb tx (Day 7), then Day 1 of ea subsequent cycle\",\"Completed\",,\"June 28, 2016\"\n",
      "129,\"Adverse Events|Objective Response Rate (ORR)|Disease Control Rate (DCR）|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS)\",\"6 months|Up to 36 months|Up to 36 months|Up to 36 months|Up to 36 months|Up to 36 months\",\"Recruiting\",,\"December 22, 2022\"\n",
      "130,\"Dose escalation： MTD determination|Cohort expansion：Preliminary assessment of change in tumor size\",\"DLT evaluation period, defined as from the first ERY974 injection until 7 days after the third injection|From the date of informed consents obtained until disease progression: at screening , week 6,12,18 and subsequently every 3 months up to 38 months\",\"Completed\",,\"August 22, 2019\"\n",
      "131,\"To obtain blood samples, ascites and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer.\",\"Ongoing\",\"Active, not recruiting\",,\"January 20, 2023\"\n",
      "132,\"Phase 1 Safe and Tolerable Phase 2 Dose.|Phase 2 Objective Response Rate (Partial Response (PR) + Complete Response (CR)).|Number of Participants With Adverse Events\",\"1 year|up to 18 weeks|31.5 months\",\"Completed\",,\"October 19, 2015\"\n",
      "133,\"Number of Patients with Dose Limiting Toxicity\",\"three months\",\"Recruiting\",,\"February 14, 2023\"\n",
      "134,\"Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors\",\"Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose\",\"Completed\",,\"August 11, 2020\"\n",
      "135,\"To determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of daily oral dosing of DFP-11207 in patients with solid tumors|For food effect study: To assess PK profiles of DFP-11207 under fed and fasted conditions\",\"Continuous starting on day of first dose (Day 1) up to 30 days after last dose|Cycle 1, Day 1: pre dose, 4, 10, 24, and 48 hrs post-dose; Day 14: 2, 10 and 24 hrs post-dose; Day 16: pre-dose, 4, 10, and 24 hrs post-dose; Day 18: pre-dose; Day 23: 2 hrs post-dose; Day 29: 2 and 24 hrs post-dose. Cycle 2, Day 1: pre-dose\",\"Completed\",,\"January 29, 2019\"\n",
      "136,\"Best Objective Response Rate\",\"Up to 24 weeks\",\"Terminated\",,\"August 28, 2019\"\n",
      "137,\"Safety and feasibility of combining RAD001 with carboplatin and etoposide in advanced solid tumors, with emphasis on SCLC.\",\"Up to 1 year from start of treatment\",\"Terminated\",,\"January 9, 2018\"\n",
      "138,\"Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day|DLT of E7080 Repeatedly Administered Twice a Day\",\"up to 4 weeks|up to 4 weeks\",\"Completed\",,\"October 7, 2016\"\n",
      "139,\"Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.\",\"18 months\",\"Terminated\",,\"December 16, 2016\"\n",
      "140,\"Safety and tolerability indexes\",\"2 years\",\"Not yet recruiting\",,\"June 2, 2022\"\n",
      "141,\"To determine the maximum tolerated dose (MTD) of EMD 1204831 in subjects with advanced solid tumors\",\"After first cycle of treatment\",\"Terminated\",,\"October 22, 2013\"\n",
      "142,\"To evaluate AE,SAE and DLT of SYHA1801.|To evaluate the MTD of SYHA1801\",\"28 days|through study completion, an average of 1 year\",\"Recruiting\",,\"June 9, 2020\"\n",
      "143,\"to define the MTD of OVV-01|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\",\"6 months|8 months\",\"Recruiting\",,\"March 23, 2023\"\n",
      "144,\"Occurrence of study related adverse events\",\"Until week 24\",\"Unknown status\",\"Recruiting\",\"September 29, 2015\"\n",
      "145,\"MTD at which fewer than one third of patients experience dose limiting toxicity as assessed by CTCAE v4.0|Incidence of treatment-related adverse events as assessed by CTCAE v4.0|Incidence of all adverse events as assessed by CTCAE v4.0, clinically significant changes in vital signs, ECGs and clinical laboratory tests\",\"Day 28 (cycle 1)|Up to 35 days after the completion of study treatment|Up to 35 days after the completion of study treatment\",\"Terminated\",,\"February 14, 2022\"\n",
      "146,\"To assess the maximum tolerated dose of weekly taxotere, cisplatin and CPT-11 in patients with incurable solid tumor malignancies.\",\"3 years\",\"Completed\",,\"August 9, 2012\"\n",
      "147,\"Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib|Time of Maximum Plasma Concentration (Tmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib|Terminal Phase Rate Constant (λz) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma|Terminal Exponential Half-life (t1/2) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma|Area Under the Plasma Concentration-Time Curve From Time Zero to Time t (AUC(0-t))|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf))|Percentage of Area Under the Plasma Concentration Curve Extrapolated to Infinity (%AUC(Extra))|Apparent Clearance (CL/F) of Lenvatinib From Plasma|Apparent Terminal Volume of Distribution in the Terminal Phase of Lenvatinib (Vz/F)|Renal Clearance of Lenvatinib (CLr)|Percentage Recovery of 14^C- Lenvatinib Related Material in the Urine|Percentage Recovery of 14^C- Lenvatinib Related Material in the Feces\",\"Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Day 1 (pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, 8 and 12 hours), Day 2 (24 hours), Day 3 (48 hours), Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours) and Day 8 (168 hours)|Pre-dose, post-dose at 0-6, 6-12, 12-18, 18-24, 24-30, 30-36, 36-42, 42-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours|Pre-dose, post-dose at 0-6, 6-12, 12-18, 18-24, 24-30, 30-36, 36-42, 42-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours|Day 1 to Day 8\",\"Completed\",,\"June 20, 2017\"\n",
      "148,\"Objective response rate ([ORR]: Complete Response (CR) + Partial Response (PR)) based on RECIST Version 1.1|Prostate-specific antigen (PSA) response (for prostate cancer participants only) based on Prostate Cancer Working Group 2 (PCWG2) criteria|Primary PK 1|Primary PK 2|Primary PK 3\",\"through study completion, an average of 1 year|through study completion, an average of 1 year|through study completion, an average of 1 year|through study completion, an average of 1 year|through study completion, an average of 1 year\",\"Completed\",,\"April 24, 2020\"\n",
      "149,\"Composite of Pharmacokinetics of TKI258, FMI capsule (supplied in 100 mg strength) and FMI tablet (supplied in 250 mg strength), in patients with advanced solid tumors, excluding breast cancer based on PK parameters AUClast and Cmax\",\"9 days\",\"Completed\",,\"December 21, 2020\"\n",
      "150,,,\"Completed\",,\"March 7, 2011\"\n",
      "151,\"The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12.\",\"Every 2 Cycles (approximately 28 days per cycle)\",\"Completed\",,\"January 29, 2014\"\n",
      "152,\"Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\",\"8 months\",\"Completed\",,\"November 12, 2021\"\n",
      "153,\"Dose Limiting Toxicities (DLT)\",\"Up to 28 days\",\"Recruiting\",,\"January 31, 2022\"\n",
      "154,\"Safety and Tolerability\",\"up to 6 months\",\"Completed\",,\"February 10, 2022\"\n",
      "155,\"Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements|ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations\",\"up to 483 days|up to 449 days\",\"Terminated\",,\"March 20, 2023\"\n",
      "156,\"To establish the safety, tolerability, and maximum tolerated dose (MTD) of nilotinib plus paclitaxel combination in patients with refractory solid tumors\",\"Cycle 1\",\"Recruiting\",,\"March 27, 2023\"\n",
      "157,\"Number of participants with Dose-limiting Toxicities (DLTs)|Number of participants with Acute Adverse Events (AEs)|Number of participants with Serious Adverse Events (SAEs)|Objective response rate (ORR)|Objective response rate (ORR)|Objective response rate (ORR)\",\"Beginning of cycle 3, or 30 days after the second cycle has started, whichever is earlier (each cycle is 21 days)|42 days post treatment.|48 months|Up to 18 weeks post treatment|Week 18 up to 24 months post treatment|Month 24 up to end of study (approximately 48 months)\",\"Not yet recruiting\",,\"March 2, 2023\"\n",
      "158,\"Determine minimal dose\",\"2 years\",\"Completed\",,\"March 6, 2014\"\n",
      "159,\"To determine the maximum tolerated dose (MTD) of RAD001 in combination with BIBF 1120 (150mg bid or 200mg bid) (endpoint: dose-limiting toxicities)|To evaluate the tolerability of BIBF1120 and RAD001 in combination (endpoints: assessment of adverse events (AEs) according to CTC-AE V4.0)\",\"Every visit|Every visit during the study\",\"Completed\",,\"May 20, 2016\"\n",
      "160,\"To investigate the safety and tolerability IV MG1102\",\"A minimum of 9 weeks\",\"Terminated\",,\"November 26, 2015\"\n",
      "161,\"Recommended phase II dose of everolimus\",\"1 year\",\"Completed\",,\"May 25, 2015\"\n",
      "162,\"Safety evaluation indicators\",\"12 months\",\"Recruiting\",,\"July 11, 2022\"\n",
      "163,\"Feasibility of NGS on metastatic solid tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians|Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-cancer agent|Availability of recommended experimental regimens via clinical trials|Proportion of patients who have one recommended therapy|Proportion of patients who have multiple options recommended\",\"Up to 18 months|Up to 18 months|Up to 18 months|Up to 18 months|Up to 18 months\",\"Completed\",,\"October 28, 2021\"\n",
      "164,\"To characterize the safety and tolerability of LBH589, including acute and chronic toxicities in Japanese patients with advanced solid tumors.\",\"First cycle\",\"Completed\",,\"December 19, 2020\"\n",
      "165,\"Determine Maximum Tolerated Dose of BPU\",\"4 weeks (1 course of treatment for each subject)\",\"Completed\",,\"March 25, 2013\"\n",
      "166,\"Progression free survival (PFS)\",\"2 years\",\"Unknown status\",\"Recruiting\",\"November 18, 2019\"\n",
      "167,\"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.\",\"At the end of dose escalation (approximately 18 months)\",\"Completed\",,\"April 23, 2013\"\n",
      "168,\"Maximum tolerated dose|Dose-limiting toxicity\",\"measured at end of phase I|measured after every course\",\"Completed\",,\"June 11, 2010\"\n",
      "169,\"Determine the feasibility and toxicity of tandem PBSC rescue following high dose chemotherapy as consolidation in pediatric patients with high risk solid tumors.\",\"annually\",\"Unknown status\",\"Recruiting\",\"October 11, 2010\"\n",
      "170,\"Recommended phase II dose and maximum tolerated dose of sorafenib tosylate when administered in combination with cisplatin and etoposide or carboplatin and pemetrexed disodium\",\"12 months\",\"Completed\",,\"April 24, 2012\"\n",
      "171,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.03\",\"At least 45 days\",\"Recruiting\",,\"September 2, 2022\"\n",
      "172,\"Safety of TILs/CAR-TILs treatment in advanced solid cancers\",\"up to 36 months\",\"Recruiting\",,\"February 28, 2023\"\n",
      "173,\"Monotherapy (Modules 1 and 2): Progression free survival (percent) rate at 6 months using Investigator assessment according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1)|Combination therapy (Module 3): Objective response rate (ORR) using each patient's best overall response (BOR) according to RECIST 1.1\",\"At 6 months|Up to 19 months\",\"Recruiting\",,\"December 14, 2022\"\n",
      "174,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment\",\"Up to 3 years\",\"Recruiting\",,\"March 27, 2023\"\n",
      "175,\"Progression Free Survival\",\"Length of study\",\"Completed\",,\"February 21, 2014\"\n",
      "176,\"Number of Participants with Dose Limiting Toxicities (DLTs)|Incidence and nature of participants with adverse events (AEs)|To determine the Maximum tolerated dose (MTD)/Recommended Phase II dose (RP2D) of KD6001 in subjects with solid tumors\",\"Up to Day 28|Baseline until 30 days after last dose of KD6001|Baseline to study completion up to 2 years\",\"Completed\",,\"February 6, 2023\"\n",
      "177,\"To evaluate the safety and PK of 2 dose schedules of panitumumab in subjects with advanced solid tumors, refractory to or with no available standard therapy.\",\"2 years\",\"Completed\",,\"July 10, 2009\"\n",
      "178,\"Toxicity\",\"28 days following ablative therapy\",\"Active, not recruiting\",,\"January 24, 2022\"\n",
      "179,\"Study Endpoints (cohort 1 and cohort 2, part A subjects): Safety of apheresis collection|Study Endpoints (for cohort 2, part B subjects only): Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs)\",\"from baseline to study day 1|through Day 203\",\"Recruiting\",,\"March 31, 2022\"\n",
      "180,\"Adverse events of dose escalated alvocidib administered in patients with advanced solid tumors\",\"At weeks 1-4, 7-10, 11 or 12, and within 4 weeks after the completion of study treatment\",\"Terminated\",,\"February 24, 2014\"\n",
      "181,\"Maximum tolerated dose (MTD) of Hydroxychloroquine (HCQ) in combination with Vorinostat in patients with advanced solid tumors\",\"6+ months, MTD is assessed during the 1st cycle\",\"Completed\",,\"February 13, 2023\"\n",
      "182,\"adverse events|Objective response rate (ORR) per RECIST v1.1\",\"Through study completion, approximately 3 years|Through study completion, approximately 3 years\",\"Not yet recruiting\",,\"August 8, 2022\"\n",
      "183,\"The primary objectives of this Phase 1 study of pegaspargase in combination with gemcitabine are to determine the maximum tolerated dose of IV pegaspargase when administered with gemcitabine|and to determine the recommended Phase 2 dose of pegaspargase\",,\"Terminated\",,\"May 20, 2008\"\n",
      "184,\"Define the MTD of the combination of CC-5013 and paclitaxel in patients with advanced solid tumors\",\"4 weeks after the first drug administration\",\"Unknown status\",\"Active, not recruiting\",\"September 13, 2011\"\n",
      "185,\"Confirmed Objective Response Rate (ORR) as Determined by the Investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\",\"From 28 days after initial response up to 5 years\",\"Terminated\",,\"July 26, 2022\"\n",
      "186,\"Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results|Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)|Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)\",\"Up to 78 months|Up to 84 months|Up to 84 months\",\"Active, not recruiting\",,\"February 21, 2023\"\n",
      "187,\"TBR（Tumor-to-Backgroud Ratio）\",\"1 year\",\"Recruiting\",,\"February 13, 2023\"\n",
      "188,\"Relief degree of tumors\",\"3 months\",\"Completed\",,\"September 12, 2019\"\n",
      "189,\"Compare the effect of GSK1120212 on the baseline-adjusted, placebo-corrected, time-matched QTcF(QT interval corrected for heart rate by Fridericia's formula) interval duration in subjects with solid tumor cancers\",\"from baseline to day 15\",\"Completed\",,\"November 13, 2017\"\n",
      "190,\"To evaluate the effect of AV-299 (formerly SCH 900105) on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases|To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases\",\"Screening Cycle 1: Day 1, Day 3-4: Cycle 2: Day 1 Cycle 3: Day 8-14|DLTs assessed during first 4 weeks of treatment.\",\"Completed\",,\"April 12, 2012\"\n",
      "191,\"Further evaluation of dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of OH2 in patients with solid tumors|The dose-limiting toxicity (DLT) of OH2 injection and Keytruda in patients with solid tumors|The maximum-tolerated dose (MTD) of OH2 injection in combination with Keytruda in patients with solid tumors\",\"12 months|12 months|12 months\",\"Recruiting\",,\"April 4, 2022\"\n",
      "192,\"Dose-limiting toxicity （DLT）\",\"After 28 days of single infusion\",\"Recruiting\",,\"October 26, 2022\"\n",
      "193,\"1. The dose limiting toxicities with AVN944 in patients with advanced stage solid tumors; 2. Maximum tolerated dose with AVN944 in patients with advanced stage solid tumors\",,\"Withdrawn\",,\"January 10, 2014\"\n",
      "194,\"To characterize the safety and tolerability of elesclomol sodium administered once weekly to subjects with solid tumors|To determine the pharmacokinetics of elesclomol in this population when administered once weekly as a 1-hour intravenous infusion\",\"Jan 2011|Jan 2011\",\"Suspended\",,\"March 9, 2009\"\n",
      "195,,,\"Completed\",,\"January 13, 2014\"\n",
      "196,\"Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events|Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\",\"Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).|Every 9 weeks for the duration of study participation; estimated minimum of 6 months.\",\"Terminated\",,\"May 6, 2021\"\n",
      "197,\"Maximum tolerated dose and dose-limiting toxicities as determined in Part A.|Safety parameters (adverse events, laboratory data, vital signs, electrocardiogram data, Eastern Cooperative Oncology Group [ECOG] scores, and physical and neurological exams).\",\"During Cycle 1: 28 days|During Parts A and B: approximately 26 months\",\"Completed\",,\"October 14, 2022\"\n",
      "198,\"Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Treatment-limiting Toxicity (TLT)|Incidence of alterations in clinical laboratory test results|Incidence of alterations in electrocardiogram assessment|Incidence of alterations in vital signs measurements|Incidence of physical examination findings|Assessment of performance status\",\"From baseline through 6 months from the last dose of IL-2 or until the first dose of the next anticancer therapy, whichever occurs first|From baseline through 6 months from the last dose of IL-2 or until the first dose of the next anticancer therapy, whichever occurs first|From the first dose of study treatment (Day -5) to 30 days after|From baseline through study completion, an average of 2 years|From baseline through study completion, an average of 2 years|From baseline through study completion, an average of 2 years|From baseline through study completion, an average of 2 years|From baseline through study completion, an average of 2 years\",\"Recruiting\",,\"December 2, 2021\"\n",
      "199,\"Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)|Dose Escalation and Dose Expansion phase: Number of participants with adverse events|Dose Expansion phase: Overall response rate (ORR)|Expansion phase: Duration of response (DOR)\",\"First 21 days of Cycle 1|Up to 3 years|Up to 3 years - from baseline to RECIST confirmed Progressive Disease|Up to 3 years\",\"Recruiting\",,\"February 1, 2023\"\n",
      "200,\"Recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) at 28 days after treatment\",,\"Unknown status\",\"Active, not recruiting\",\"August 2, 2013\"\n",
      "201,\"hepatitis B virus (HBV) serological status\",\"Day 0\",\"Completed\",,\"August 24, 2016\"\n",
      "202,\"Determination of Maximum Tolerated Dose (MTD) of BBP-398|Determination of anti-tumor activity of BBP-398\",\"Completion of 1 Cycle (28 days)|Completion of 1 Cycle (28 days)\",\"Recruiting\",,\"December 5, 2022\"\n",
      "203,,,\"Completed\",,\"March 7, 2011\"\n",
      "204,\"dose-limiting toxicity (DLT)|Number of Adverse Events\",\"day 1-28|An expected average of 8 months\",\"Completed\",,\"June 17, 2016\"\n",
      "205,\"Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET)\",\"From date of first dose of study treatment up to 55 months\",\"Completed\",,\"August 12, 2020\"\n",
      "206,\"Maximum tolerated dose\",,\"Completed\",,\"January 13, 2014\"\n",
      "207,\"Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1\",\"Baseline to disease progression or death, up to 36 weeks.\",\"Recruiting\",,\"March 10, 2023\"\n",
      "208,\"Dose Escalation:Maximum Tolerated Dose (MTD)|Dose Expansion:Overall Response Rate\",\"One Month|6 Months\",\"Recruiting\",,\"March 20, 2023\"\n",
      "209,,,\"Completed\",,\"December 18, 2017\"\n",
      "210,\"part 1: to determine the maximum tolerated dose (MTD) of single-agent oral CEP-9722 administered daily to patients with advanced or metastatic solid tumors, as defined by first-cycle dose-limiting toxicities (DLTs)|part 2: to evaluate the safety and tolerability of the MTD of CEP-9722 identified in part 1, as defined by numbers and severity of adverse events\",\"up to 8 months|up to 8 months\",\"Terminated\",,\"July 26, 2016\"\n",
      "211,\"Maximum tolerated dose of TNF-bound colloidal gold (CYT-6091)|Toxicity\",,\"Completed\",,\"March 15, 2012\"\n",
      "212,,,\"Completed\",,\"December 18, 2015\"\n",
      "213,\"Part A & B & C: Frequency and severity of AEs as assessed by CTCAE v5.0|Part A: Frequency and type of DLT s using the CTCAE v5.0|Number of participants with an antitumor response to KBA1412 monotherapy (Part B) or to KBA1412 in combination with pembrolizumab (Part C)\",\"Through study completion, an average of 1 year|First 21 days of treatment|Approximately 24 weeks\",\"Recruiting\",,\"February 21, 2023\"\n",
      "214,\"Objective response rate (ORR) of patients with solid tumors treated with HX009 assessed by the Independent Review Committee (IRC)\",\"Approximately 1 year\",\"Active, not recruiting\",,\"April 28, 2022\"\n",
      "215,\"To determine the MTD/RD of single agent CTO in patients with advanced or metastatic solid tumors; or CTO in combination with Temodar® in patients with glioblastoma or other recurrent malignant gliomas\",\"Duration of the study\",\"Unknown status\",\"Active, not recruiting\",\"April 24, 2018\"\n",
      "216,\"DLT(dose-limiting toxicity)|ORR|DOR\",\"28 days|From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\",\"Unknown status\",\"Not yet recruiting\",\"February 21, 2020\"\n",
      "217,\"Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors|Number of participants with adverse events as assessed by CTCAE v5.0 ADG126-ADG106 combination regimens\",\"From first dose of ADG126 (Week 1 Day 1) until 21 days|From first dose of ADG126 (Week 1 Day 1) to 90 days post last dose\",\"Recruiting\",,\"February 24, 2023\"\n",
      "218,,,\"Completed\",,\"January 31, 2013\"\n",
      "219,\"Incidence of treatment-emergent adverse events (TEAEs)|Incidence of drug-related TEAEs|Incidence of treatment-emergent serious adverse events (TESAEs)|Incidence of Dose-limiting toxicities (DLTs)|Objective response rate (ORR) at recommended dose\",\"Up to 32 months|Up to 32 months|Up to 32 months|Approximately 10 months|Up to 32 months\",\"Completed\",,\"July 14, 2022\"\n",
      "220,\"To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)\",\"10 years\",\"Recruiting\",,\"February 8, 2023\"\n",
      "221,\"Incidence of adverse events, as defined by the Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) term and body system, graded according to the National Cancer Institute Common Toxicity Criteria v2.0|Maximally tolerated dose of orantinib, graded according to the NCI CTC v2.0\",\"Up to 2 years|Up to 4 weeks\",\"Completed\",,\"January 23, 2013\"\n",
      "222,,,\"Completed\",,\"May 30, 2013\"\n",
      "223,\"The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered once daily (QD) in 14 day cycles (5 days on, followed by 9 days rest) in patients with locally advanced or metastatic solid tumours.|The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered once daily (QD) in 21-day cycles (5 days on, followed by 2 days rest) in patients with locally advanced or metastatic solid tumours.|The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered twice daily (BID) in 14-day cycles (5 days on, followed by 9 days rest) in patients with locally advanced or metastatic solid tumours.\",\"Dose-limiting toxicities will be evaluated during the first 2 cycles (28 days) of AZD1775 monotherapy treatment.|Dose-limiting toxicities will be evaluated during the first cycle (21 days) of AZD1775 monotherapy treatment.|Dose-limiting toxicities will be evaluated during the first 2 cycles (28 days) of AZD1775 monotherapy treatment.\",\"Completed\",,\"December 12, 2018\"\n",
      "224,\"Tissue and cell repository for Wake Forest University Comprehensive Cancer Center investigators\",\"Day 1\",\"Recruiting\",,\"June 6, 2022\"\n",
      "225,\"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0|. Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\",\"through study completion an average of 3 years.|through study completion an average of 3 years\",\"Not yet recruiting\",,\"January 20, 2023\"\n",
      "226,\"Safety and tolerability assessed by Dose Limiting Toxicity (DLT)|Safety and tolerability assessed by adverse events (AEs)|Safety and tolerability assessed by immune-related AEs (irAEs)|Safety and tolerability assessed by serious adverse events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by 12-lead electrocardiogram (ECG)|Number of participants with vital signs abnormalities and/or adverse events related to treatment|Number of participants with physical exam abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by eastern cooperative oncology group (ECOG) performance status|Pharmacokinetics (PK) of ASP8374 in serum: AUClast|PK of ASP8374 in serum: AUCinf|PK of ASP8374 in serum: AUCinf(%extrap)|PK of ASP8374 in serum: AUCtau|PK of ASP8374 in serum: Cmax|PK of ASP8374 in serum: Ctrough|PK of ASP8374 in serum: tmax|PK of ASP8374 in serum: t1/2|PK of ASP8374 in serum: tlast|PK of ASP8374 in serum: CL|PK of ASP8374 in serum: Vz|PK of ASP8374 in serum: Vss\",\"Up to 21 days|Up to 30 days after the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first (a maximum of 109 weeks)|Up to 30 days after the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first (a maximum of 109 weeks)|Up to 90 days after the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first (a maximum of 117 weeks)|Up to 30 days after the last dose of study drug (a maximum of 109 weeks)|Up to end of treatment period (a maximum of 105 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to end of treatment period (a maximum of 105 weeks)|Up to 30 days after the last dose of study drug (a maximum of 109 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)|Up to 90 days after the last dose of study drug (a maximum of 117 weeks)\",\"Completed\",,\"May 25, 2021\"\n",
      "227,\"Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors\",\"up to 36 months\",\"Recruiting\",,\"March 2, 2023\"\n",
      "228,\"Safety and toxicity assessed weekly during treatment\",,\"Completed\",,\"September 20, 2013\"\n",
      "229,\"Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors|Number of participants with adverse events as assessed by CTCAE v5.0\",\"From first dose of ADG116 (Week 1 Day 1) until 21 days|From first dose of ADG116 (Week 1 Day 1) to 28 days post last dose\",\"Recruiting\",,\"February 9, 2022\"\n",
      "230,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)|Number of Participants Who Experience an Adverse Event (AE)\",\"Day 1 to Day 28|Day 1 up to approximately 2 years\",\"Recruiting\",,\"March 20, 2023\"\n",
      "231,\"Maximum tolerated dose (MTD) of low dose metronomic (LDM)Topotecan|Recommended phase 2 dose (RP2D) of LDM Topotecan\",\"Dose limiting toxicities (DLT) will be identified during the first cycle of therapy (28 days)|Dose limiting toxicities (DLT) will be identified during the first cycle of therapy (28 days)\",\"Completed\",,\"June 28, 2022\"\n",
      "232,\"Number of HIV patient that receive durvalumab at least during 4 months\",\"From the first dose until progression disease (at 1 year approximately)\",\"Completed\",,\"May 5, 2022\"\n",
      "233,\"To determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of CDDO when administered in adult patients with solid tumors and lymphomas.\",,\"Completed\",,\"July 2, 2017\"\n",
      "234,\"To determine the safety profile, dose limiting toxicities (DLT), and maximum tolerated dose (MTD) of C. novyi-NT in humans with treatment-refractory solid tumor malignancies when given as a single intravenous injection\",\"2 years\",\"Terminated\",,\"October 14, 2016\"\n",
      "235,\"To assess the pharmacokinetics of single dose of cediranib 20mg or 30 mg by assessment of area under the curve over the time (AUC) and maximum concentration in Chinese patients with advanced solid malignant tumours\",\"Multiple assessments in the first 6 days\",\"Completed\",,\"June 20, 2011\"\n",
      "236,\"To explore the response rate of this combination in patients with colon cancer, NSCLC, and granulosa cell ovarian cancer|To establish the safety, tolerability, and maximum tolerated dose (MTD) of oral TRC102 in combination with oral TMZ in patients with refractory solid tumors.|Evaluate the pharmacokinetic (PK) profile of oral TRC102 when administered in combination with TMZ\",\"Response rate one year|DLT determined first cycle (28 days)|First 5 days\",\"Recruiting\",,\"March 27, 2023\"\n",
      "237,\"Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1|Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)\",\"Cycle 1 (Cycle length= 28 days)|Up to 3 years|Up to 3 years\",\"Recruiting\",,\"January 17, 2023\"\n",
      "238,\"Incidence of dose limiting toxicities (DLTs)|Objective Response Rate (ORR)\",\"21-day cycle one of treatment|Until progression of disease up to 1 year\",\"Terminated\",,\"December 21, 2020\"\n",
      "239,\"Segment 1: Determine whether the steady state pharmacokinetics of 20 mg of dasatinib are affected by co-administration with ketoconazole in patients with advanced solid tumors|Segment 2: Assess the pharmacodynamic activity of dasatinib\",,\"Terminated\",,\"April 14, 2011\"\n",
      "240,\"To characterize the safety and tolerability of intravenously administered ANG1005 in patients with advanced solid tumors and metastatic brain cancer.|To identify the maximum tolerated dose (MTD) of ANG1005 in patients with advanced solid tumors and metastatic brain cancer.\",\"On-going|End of dose escalation\",\"Completed\",,\"July 31, 2014\"\n",
      "241,\"To Determine the Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With a Fixed Dose of Pembrolizumab in Subjects With Relapsed and/or Refractory Solid Tumors.|To Determine Efficacy as Measured by Progression Free Survival (PFS) in Non-small Cell Lung Cancer Patients\",\"Day 22 of cycle 1|up to 3 years\",\"Terminated\",,\"December 30, 2021\"\n",
      "242,\"Maximum-Tolerated Dose (MTD)|Dose-Limiting Toxicity (DLT)\",\"21-day period after the first dose|21-day period after the first dose\",\"Terminated\",,\"September 28, 2021\"\n",
      "243,\"Maximum Tolerated Dose (MTD) of Cisplatin (Phase I)|Maximum Tolerated Dose (MTD) of Crolibulin (Phase I)|Progression Free Survival (Phase II)|Number of Participants With Serious and Non-Serious Adverse Events (Phase I & II)\",\"3 weeks|3 weeks|6 weeks|4 years, 6 months and 26 days\",\"Completed\",,\"April 10, 2017\"\n",
      "244,\"Tumor Assessment\",\"at baseline and then once every two treatment cycles of 28 days (2 months) thereafter in the absence of clinical rapid progression of disease.\",\"Completed\",,\"July 23, 2019\"\n",
      "245,\"Define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator NAT2 genotype (NAT2 5, NAT2 6, NAT2 7, or NAT2 14) patients with solid tumors and lymphomas.\",,\"Completed\",,\"December 5, 2019\"\n",
      "246,\"Maximum Tolerated Dose (MTD): Part 1|Recommended Phase 2 Dose (RP2D): Part 1\",\"Baseline up to 42 days after the start of each increased treatment dose|Baseline up to 42 days after the start of each increased treatment dose\",\"Completed\",,\"October 19, 2015\"\n",
      "247,\"Safety Measures\",\"14 months\",\"Completed\",,\"February 10, 2022\"\n",
      "248,\"Determine the maximum target-inhibiting dose of SU5416 in patients with advanced solid tumors.\",\"1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients followed every 3 months.\",\"Completed\",,\"June 11, 2010\"\n",
      "249,,,\"Completed\",,\"July 24, 2008\"\n",
      "250,\"QTc interval\",\"Days -2, -1, 1, and 12 of Cycle 1\",\"Completed\",,\"November 9, 2015\"\n",
      "251,,,\"Completed\",,\"January 17, 2013\"\n",
      "252,\"safety and tolerability\",\"3 weeks\",\"Completed\",,\"March 26, 2014\"\n",
      "253,\"To determine the maximum tolerated dose (MTD)|To determine the dose limiting toxicity (DLT), safety\",\"2 years|2 years\",\"Completed\",,\"February 2, 2023\"\n",
      "254,\"Progression-free survival|Overall response rate|Tumor makers\",\"9 months after treatment|1 week after treatment|9 months after treatment\",\"Not yet recruiting\",,\"March 14, 2023\"\n",
      "255,\"To evaluate the safety of 89Zr-KN035 in PD-L1 positive solid tumor patients\",\"1 year\",\"Unknown status\",\"Recruiting\",\"July 26, 2021\"\n",
      "256,,,\"Completed\",,\"June 26, 2013\"\n",
      "257,\"Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.|The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.\",\"5 weeks|5 weeks\",\"Terminated\",,\"December 30, 2021\"\n",
      "258,,,\"Completed\",,\"June 18, 2013\"\n",
      "259,,,\"Completed\",,\"June 21, 2013\"\n",
      "260,\"Safety and tolerability of C. novyi-NT spore administration in patients with advanced solid tumor malignancies will be measured over a 7-day inpatient admission with routine labs and continuous adverse event assessments.\",\"2 years\",\"Terminated\",,\"January 20, 2016\"\n",
      "261,,,\"Unknown status\",\"Active, not recruiting\",\"May 15, 2013\"\n",
      "262,,,\"Completed\",,\"December 19, 2013\"\n",
      "263,\"Maximum tolerated dose of methoxyamine|Dose limiting toxicities of the combination of methoxyamine and temozolomide|Pharmacokinetics methoxyamine and temozolomide, when given alone or in combination\",\"Courses repeat every 28 days in the absence of unacceptable toxicity.|Courses repeat every 28 days in the absence of unacceptable toxicity.|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects.\",\"Completed\",,\"February 22, 2019\"\n",
      "264,,,\"Completed\",,\"December 15, 2009\"\n",
      "265,\"Number of subjects with dose limiting toxicities|Number of subjects with dose limiting toxicities|Number of subjects with dose limiting toxicities|Frequency of dose interruptions|Frequency of dose interruptions|Frequency of dose interruptions\",\"At the end of cycle 1 (Each cycle is 28 days)|At the end of cycle 1 (Each cycle is 21 days)|At the end of cycle 1 (Each cycle is 21 days)|At the end of cycle 1 (Each cycle is 28 days)|At the end of cycle 1 (Each cycle is 21 days)|At the end of cycle 1 (Each cycle is 21 days)\",\"Terminated\",,\"December 6, 2022\"\n",
      "266,\"The primary objective of this study is to evaluate the safety and tolerability of AZD0530 in Japanese patients with advanced solid malignancies by assessment of AEs, vital signs, ECG, laboratory findings, thoracic imaging and pulmonary function test.\",\"Assessed on an ongoing basis after starting daily dosing with AZD0530\",\"Completed\",,\"May 16, 2011\"\n",
      "267,\"Recommended phase II dose as assessed by NCI toxicity scale during 3-4 weeks of treatment\",\"2 years\",\"Completed\",,\"March 22, 2013\"\n",
      "268,\"Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy\",\"Cycle 1, day 8\",\"Completed\",,\"February 23, 2021\"\n",
      "269,\"The feasibility of implementing Eischens yoga interventions for solid tumor cancer patients undergoing radiation therapy. This will be measured by the success rate of recruitment and retention for 10 subjects.\",\"12 months\",\"Withdrawn\",,\"April 27, 2021\"\n",
      "270,\"Number of participants experiencing dosage limiting toxicity (DLT) in the first treatment cycle of the combination of ADG106 and PD-1 antibody.|Objective response rate (ORR) of the combination of ADG106 and PD-1 antibody in advanced solid tumors and relapsed/refractory non-hodgkin lymphoma\",\"From first dose of ADG106 and PD-1 antibody (Week 1 Day 1) until 21 days|From baseline to measured progressive disease (up to 24 months)\",\"Recruiting\",,\"January 12, 2022\"\n",
      "271,\"[Part A] Dose-limiting toxicity (DLT)|[Part A] Non-tolerated Dose (NTD)|[Part A] Maximum tolerated Dose (MTD)|[Parts A and B] Safety Analysis: summarizing adverse events (AEs) and will be based on treatment-emergent AEs (TEAEs)\",\"Through 24 months with 21 day drug treatment cycles|Through 24 months with 21 day drug treatment cycles|Through 24 months with 21 day drug treatment cycles|Through 24 months with 21 day drug treatment cycles\",\"Completed\",,\"October 20, 2020\"\n",
      "272,\"Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity\",\"At least 3 months\",\"Completed\",,\"January 10, 2018\"\n",
      "273,,,\"Completed\",,\"August 9, 2010\"\n",
      "274,,,\"Completed\",,\"December 19, 2013\"\n",
      "275,\"Maximum Tolerated Dose (MTD) and/or Dose Limiting Toxicity (DLT)\",\"At the end of Cycle 1 (each cycle is 28 days)\",\"Active, not recruiting\",,\"October 26, 2021\"\n",
      "276,,,\"Completed\",,\"June 18, 2013\"\n",
      "277,,,\"Completed\",,\"June 25, 2013\"\n",
      "278,\"Efficacy (overall response rate [ORR])\",\"Up to 6 months\",\"Active, not recruiting\",,\"March 6, 2023\"\n",
      "279,,,\"Completed\",,\"August 9, 2010\"\n",
      "280,\"Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)\",\"During Treatment Cycle 1 (Day 1 to 21)\",\"Terminated\",,\"August 23, 2017\"\n",
      "281,,,\"Unknown status\",\"Active, not recruiting\",\"September 20, 2013\"\n",
      "282,\"Number of adverse events\",\"From the date of informed consent to the date of the end of study visit estimated to be 6 months\",\"Completed\",,\"January 18, 2020\"\n",
      "283,\"Maximum tolerated dose of hydroxychloroquine\",,\"Completed\",,\"February 18, 2016\"\n",
      "284,\"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors\",\"daily for 6 weeks\",\"Completed\",,\"January 27, 2014\"\n",
      "285,\"ORR(Objective Response Rate)\",\"Up to three months\",\"Unknown status\",\"Enrolling by invitation\",\"April 29, 2019\"\n",
      "286,,,\"Completed\",,\"June 24, 2013\"\n",
      "287,\"Maximum tolerated dose (MTD) of vinflunine and pemetrexed disodium|Maximum tolerated dose (MTD) of vinflunine and continuously dosed erlotinib|Maximum tolerated dose (MTD) of vinflunine and intermittently dosed erlotinib\",\"1 year|1 year|1 year\",\"Completed\",,\"May 16, 2012\"\n",
      "288,,,\"Completed\",,\"June 24, 2013\"\n",
      "289,,,\"Completed\",,\"June 26, 2013\"\n",
      "290,,,\"Completed\",,\"June 21, 2013\"\n",
      "291,\"Adverse Events (AE)\",\"12 months\",\"Not yet recruiting\",,\"September 14, 2022\"\n",
      "292,\"Maximum tolerated dose of hydroxychloroquine\",,\"Completed\",,\"April 16, 2019\"\n",
      "293,,,\"Terminated\",,\"November 29, 2017\"\n",
      "294,\"To define a tolerable dose of oral CLA, given on a daily schedule, that maximally inhibits S14 expression in adipocytes of patients with advanced solid tumors.\",\"2 years\",\"Terminated\",,\"May 12, 2015\"\n",
      "295,\"Maximum Tolerated Dose (MTD) of Eribulin Mesylate of E7389 in Combination With Carboplatin in Subjects With Advanced Solid Tumors.\",\"21 days (first cycle)\",\"Completed\",,\"February 12, 2013\"\n",
      "296,\"Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors\",\"From the time of informed consent from signature until Day 28 after Cycle 1; Dose Escalation - Approximately 9 months\",\"Completed\",,\"May 9, 2022\"\n",
      "297,\"Safety and tolerance|Recommended Phase 2 Dose (RP2D)\",\"up to 90 days following last dose|up to 21 days following last dose level\",\"Recruiting\",,\"September 22, 2022\"\n",
      "298,\"Maximum Tolerated Dose (MTD) for Combination of Selumetinib and Olaparib in Participants with Advanced or Recurrent Solid Tumors\",\"28 days\",\"Active, not recruiting\",,\"September 2, 2022\"\n",
      "299,\"Overall Survival\",\"18 months\",\"Recruiting\",,\"May 3, 2022\"\n",
      "300,\"Better understanding of the epidemiology of CNS metastases from solid tumours|Better understanding of the epidemiology of CNS metastases from solid tumours|Better understanding of the epidemiology of CNS metastases from solid tumours|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.|Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.\",\"through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months|through study completion, approximately 96 months\",\"Recruiting\",,\"January 18, 2023\"\n",
      "301,\"Phase 1b: To determine the Recommended Phase 2 Dose of the Combination (RP2DC) of TU2218 given with Pembrolizumab in selected advanced solid tumors|Phase 2a: To evaluate the efficacy of TU2218 by evaluating the Overall Response rate (ORR) of TU2218 administered in combination with Pembrolizumab in selected advanced solid tumors\",\"During the first 21-day period (Cycle 1)|24 weeks\",\"Recruiting\",,\"March 27, 2023\"\n",
      "302,\"Dose Determination\",\"18 months\",\"Completed\",,\"March 8, 2022\"\n",
      "303,\"Determine the safety and tolerability of GL-ONC1, administered intravenously to patients with advanced solid tumors.\",\"Every 30 minutes for 2 hours after each administration of GL-ONC1, then daily until discharge and on day 8, then weekly up to day 21, then week 12 and week 24\",\"Completed\",,\"December 14, 2015\"\n",
      "304,\"Determination of recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2\",\"Treatment until documented progression or up to 8 21-day cycles (4 cycles if prior anthracyclines received). All patients followed for late toxicities, every 3 months for 1 year or until all drug related toxicities are resolved/become unrelated.\",\"Completed\",,\"July 15, 2015\"\n",
      "305,\"Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events|Determine maximum tolerated dose (MTD)\",\"28 days|20 months\",\"Completed\",,\"April 5, 2022\"\n",
      "306,\"Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose\",\"From date of first dose to off-study (or 30 days since last dose)\",\"Completed\",,\"November 13, 2014\"\n",
      "307,\"Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Experiencing Severe AEs (SAEs)\",\"From the time the participants signed the informed consent to 90 days after the final dose (Up to 3 years and 7 months)|From the time the participants signed the informed consent to 90 days after the final dose (Up to 3 years and 7 months)\",\"Completed\",,\"February 28, 2023\"\n",
      "308,\"Standardized uptake value（SUV）\",\"2 years\",\"Recruiting\",,\"June 28, 2022\"\n",
      "309,,,\"Completed\",,\"February 28, 2013\"\n",
      "310,\"Determine the number and type of adverse events to characterize the safety of PC14586|Establish the maximum tolerated dose (MTD) (Phase 1)|Establish the Recommended Phase 2 Dose (RP2D) (Phase 1)|Response rate assessment to evaluate the clinical activity / efficacy of PC14586 (Phase 2)\",\"48 months for study (Phase 1 and 2)|The first 21 days of treatment (Cycle 1) per patient|20 months for study (end of Phase 1)|48 months for study (Phase 1 and 2)\",\"Recruiting\",,\"August 16, 2022\"\n",
      "311,\"Incidence of adverse events (AE) of HX009 in patients with advanced solid tumors|Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumors\",\"Collected adverse events from signing of informed consent through at least 28 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier).|At the end of Cycle 2 (each cycle is 14 days)\",\"Active, not recruiting\",,\"February 16, 2023\"\n",
      "312,\"To estimate the rate of immune response of this immunotherapy treatment\",\"70 days\",\"Completed\",,\"November 6, 2017\"\n",
      "313,\"Confirmed Objective Response Rate (Breast, Cervical Cohorts)|Objective Response Rate - First Tumor Assessment (Other Cohorts)\",\"From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, up to 18 months|From enrollment date to first Complete or Partial Response, whichever came earlier, up to 8 or 9 weeks\",\"Completed\",,\"January 19, 2023\"\n",
      "314,\"Phase Ia：To determine the maximum tolerated dose (MTD)|2. Phase Ib/II: To evaluate clinical activity/efficacy of HS-10370 by assessment of objective response rate\",\"From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (28 days).|up to 24 months\",\"Not yet recruiting\",,\"May 10, 2022\"\n",
      "315,,,\"Unknown status\",\"Active, not recruiting\",\"December 19, 2013\"\n",
      "316,\"Dose Limiting Toxicities (DLTs)|Objective Response Rate\",\"Baseline through Cycle 1 (28 day cycle)|Baseline through measured progressive disease (estimated up to 24 months)\",\"Recruiting\",,\"March 24, 2023\"\n",
      "317,\"Objective Response Rate (ORR)\",\"Up to approximately 2 years\",\"Recruiting\",,\"April 7, 2022\"\n",
      "318,\"detection rate of 68Ga-PSMA PET/CT\",\"up to 36 months\",\"Unknown status\",\"Recruiting\",\"February 26, 2021\"\n",
      "319,,,\"Completed\",,\"February 11, 2013\"\n",
      "320,\"Incidence and severity of adverse events (AEs)\",\"Up to 1 years\",\"Recruiting\",,\"August 2, 2022\"\n",
      "321,\"Area under the plasma concentration-time curve from zero to infinity for AZD1775|Area under the plasma concentration-time curve from time zero to the time \"\"t\"\" (AUC0-t) of the last quantifiable concentration for AZD1775|Cmax: maximum plasma drug concentration for AZD1775\",\"Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose|Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose|Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose\",\"Completed\",,\"April 30, 2018\"\n",
      "322,\"Maximum tolerated dose of lenalidomide|Dose-limiting toxicity of lenalidomide\",,\"Completed\",,\"July 8, 2011\"\n",
      "323,\"Frequency of adverse events (AEs) and SAE|Severity of AEs in patients with solid tumors enrolled in the study.|Dose limiting toxicities (DLTs) BJ-001 as a single agent|Dose limiting toxicities (DLTs) BJ-001 in combination with pembrolizumab inhibitor.\",\"90 days after the last dose|From Day 1 of treatment up to 30 days after last dose|at the end of week 4 after first dose|at the end of week 4 after first dose\",\"Recruiting\",,\"June 8, 2022\"\n",
      "324,\"Functional decline - Katz (ADL)|Functional decline - Katz (ADL)|Functional decline - Lawton (IADL)|Functional decline - Lawton (IADL)|Physical decline - walking speed|Physical decline - walking speed|Physical decline - prehension force|Physical decline - prehension force|Cognitive decline - MMSE 30|Cognitive decline - MMSE 30|Quality of life - SF 36|Quality of life - SF36\",\"3 months after oncologic treatment|6 months after oncologic treatment|3 months after oncologic treatment|6 months after oncologic treatment|3 months after oncologic treatment|6 months after oncologic treatment|3 months after oncologic treatment|6 months after oncologic treatment|3 months after oncologic treatment|6 months after oncologic treatment|3 months after oncologic treatment|6 months after oncologic treatment\",\"Completed\",,\"April 4, 2019\"\n",
      "325,\"Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab|Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab|Number of Participants With Anti-Ramucirumab Antibodies\",\"Baseline to Study Completion (Up to 42 Months)|Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)|Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)\",\"Completed\",,\"August 17, 2021\"\n",
      "326,\"Change From Time-Matched Baseline in QT Interval Corrected for Heart Rate (QTc)\",\"Baseline, Cycle1 Day 1, 8,15, 22, 29, and 36: Pre-infusion, End of Infusion, 1 Hour (hr), 2, 4, 24, 48, 72 hr Post Infusion\",\"Completed\",,\"July 25, 2016\"\n",
      "327,\"Safety and tolerability of the combination of ABT-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas; Establish the maximum tolerated dose of ABT-888 with topotecan hydrochloride.\",,\"Completed\",,\"July 2, 2017\"\n",
      "328,\"To determine the safety, toxicity and maximum tolerated dose of CRLX101 when administered intravenously to subjects with advanced solid tumors.\",\"6 months\",\"Completed\",,\"May 28, 2020\"\n",
      "329,\"Dose Limiting Toxicity\",\"2 years\",\"Active, not recruiting\",,\"April 4, 2022\"\n",
      "330,\"Causality of each adverse event to Aurora B/C kinase inhibitor GSK1070916A and grading severity according to NCI CTCAE Version 4.02|Maximum-tolerated dose (MTD)\",,\"Completed\",,\"May 1, 2013\"\n",
      "331,\"To determine the safety, tolerability, dose-limiting toxicities (DLT), maximum acceptable dose (MAD) and maximum tolerated dose (MTD) of CHR-3996 when administered orally to patients with advanced or treatment refractory solid tumours\",\"After 28 days treatment\",\"Completed\",,\"November 28, 2011\"\n",
      "332,\"Frequency of adverse events (AEs) and SAEs (Phase Ⅰ)|Dose limiting toxicities (DLTs) (Phase Ⅰ)|Objective response rate (ORR) in dose expansion (Phase Ⅱa)\",\"3 months after end event visit|21 days after first dose|Baseline through up to 2 years or until disease progression\",\"Not yet recruiting\",,\"July 12, 2021\"\n",
      "333,\"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1|Maximum Tolerated Dose (MTD) of MK-2206 Administered Every Other Day (QOD) in Combination With Carboplatin and Paclitaxel|MTD of MK-2206 Administered Every Three Weeks (Q3W) in Combination With Carboplatin and Paclitaxel|MTD of MK-2206 Administered QOD in Combination With Docetaxel|MTD of MK-2206 Administered Q3W in Combination With Docetaxel|MTD of MK-2206 Administered QOD in Combination With Erlotinib|MTD of MK-2206 Administered Once Every Week (QW) in Combination With Erlotinib|Maximum Plasma Concentration of MK-2206 (Cmax)|Time to Maximum Plasma Concentration of MK-2206 (Tmax)|Minimum Plasma Concentration of MK-2206 (Ctrough)|Area Under the MK-2206 Concentration Versus Time Curve From Time Zero to 48 Hours Postdose (AUC 0-48h)\",\"Cycle 1 (Up to 21 days)|Cycle 1 (Up to 21 days)|Cycle 1 (up to 21 days)|Cycle 1 (up to 21 days)|Cycle 1 (up to 21 days)|Cycle 1 (up to 21 days)|Cycle 1 (up to 21 days)|At designated time points on Cycle 1 Day 1 (Up to 96 hours)|At designated time points on Cycle 1 Day 1 (Up to 96 hours)|At designated time points on Cycle 1 Day 1 (Up to 48 hours)|At designated time points on Cycle 1 Day 1 (Up to 48 hours)\",\"Completed\",,\"November 12, 2019\"\n",
      "334,\"Occurrence of treatment emergent adverse events (TEAEs) including Grade ≥3, serious, or fatal TEAEs by causal relationship to trial treatment|Occurrence of dose reductions and discontinuation of BNT142 due to TEAEs|Part 1: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period (Cycle 1, i.e., 21 days after the first dose) during the dose escalation|Part 2: Objective response rate (ORR)\",\"From first dose to 60 days after the last dose of BNT142|From first dose to 60 days after the last dose of BNT142|assessed during the first cycle (21 days) in each cohort|at least 48 months subsequent to first dose, are lost to follow-up, or have died\",\"Recruiting\",,\"February 23, 2023\"\n",
      "335,\"Objective tumour response rate\",\"at 12 weeks\",\"Withdrawn\",,\"January 26, 2023\"\n",
      "336,\"Safety and tolerability|Maximum Tolerated Dose and Recommended Phase 2 Dose\",\"2 Years|2 years\",\"Active, not recruiting\",,\"January 13, 2023\"\n",
      "337,\"Relative abundance and composition of immunotherapy response-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors|Relative abundance and composition of immunotherapy toxicity-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors\",\"6 months|12 months\",\"Recruiting\",,\"May 5, 2022\"\n",
      "338,\"To evaluate the tolerability and safety\",\"1 year\",\"Completed\",,\"July 4, 2011\"\n",
      "339,\"Incidence of adverse events (AE) in HX301 Monolactate Capsules in patients with advanced solid tumors|Incidence of Dose Limiting Toxicities (DLT) in HX301 Monolactate Capsules in patients with advanced solid tumors\",\"Collected adverse events from signing of informed consent through at least 30 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier)|At the end of Cycle 1（each cycle is 28 days）\",\"Active, not recruiting\",,\"February 16, 2023\"\n",
      "340,\"To detect circulating tumor DNA (ctDNA) in serial blood samples from patients with pediatric non-CNS solid tumors using low pass whole genome sequencing.\",\"10 years\",\"Recruiting\",,\"March 1, 2023\"\n",
      "341,\"Number of Participants who Experience a Dose-limiting Toxicity (DLT)|Number of Participants who Experience an Adverse Event (AE)\",\"Day 1 to Day 21|Up to approximately 3 years\",\"Recruiting\",,\"March 9, 2023\"\n",
      "342,\"Number of Participants with Dose-limiting Toxicities Following DS-1103a Combination Therapy (Dose Escalation)|Overall Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events Following DS-1103a Combination Therapy (Dose Expansion)|Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review Following DS-1103a Combination Therapy (Dose Expansion)\",\"From Cycle 1 Day 1 up to 3-month safety follow up (each cycle is 21 days)|Screening (Day -28 to 0) through long-term follow up, up to approximately 44 months|Baseline up until documented progressive disease, unacceptable toxicity, death, lost to follow-up, or withdrawal by the participant, up to approximately 44 months\",\"Not yet recruiting\",,\"March 13, 2023\"\n",
      "343,\"Event Free Survival\",\"Length of study\",\"Completed\",,\"February 20, 2014\"\n",
      "344,\"Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator\",\"Up to 2 years\",\"Completed\",,\"October 12, 2022\"\n",
      "345,\"Number of participants with treatment-related adverse events/dose limiting toxicity as assessed by CTCAE v4.0\",\"6 weeks after infusion\",\"Recruiting\",,\"October 12, 2022\"\n",
      "346,\"number of participants experiencing dose limiting toxicities|number of participants experiencing clinical or laboratory adverse events|serum pharmacokinetics of DS-8895a\",\"day 1 through day 28|from start of treatment to end of treatment, on expected average 12 weeks|Cycle 1 - days 1, 2, 4, 8 and 15; Cycle 2-days 1, 2, 4, 8 and 15; Cycle 3 and on- days 1; end of study; 45 days post last dose\",\"Completed\",,\"July 22, 2019\"\n",
      "347,\"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.\",\"At time of surgery or biospy\",\"Completed\",,\"March 27, 2023\"\n",
      "348,\"Subject incidence of Dose-limiting toxicities (DLT)|Number of subjects participants with adverse events|Plasma concentration of D-1553 as a single agent or in combination with other therapies in subjects wiht advanced or metastatic solid tumors with KRas G12C mutation.\",\"through out the DLT period, approximately 21 days|Through study completion, approximately 3 years|Through study completion, approximately 3 years\",\"Recruiting\",,\"March 29, 2022\"\n",
      "349,\"Safety and tolerability assessed by Dose Limiting Toxicity (DLT)|Safety and tolerability assessed by adverse events (AEs)|Safety and tolerability assessed by immune-related AEs (irAEs)|Safety and tolerability assessed by serious adverse events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by 12-lead electrocardiogram (ECG)|Number of participants with vital signs abnormalities and/or adverse events related to treatment|Number of participants with Physical Exam abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by ECOG performance status|Pharmacokinetics (PK) of ASP8374 in serum: AUClast (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: AUCinf (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: AUCtau (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Cmax (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Initial treatment, escalation and expansion cohorts in both monotherapy and combination therapy)|Pharmacokinetics (PK) of pembrolizumab in serum: Ctrough (Initial treatment, escalation cohorts in combination therapy)|Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Re-treatment, escalation and expansion cohorts in both monotherapy and combination therapy)|Pharmacokinetics (PK) of ASP8374 in serum: tmax (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: t1/2 (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: CL (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Vz (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Vss (Initial treatment, escalation cohorts in monotherapy only)\",\"Up to 21 days|Up to 30 days following the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first of each treatment period (Up to a maximum of 52 weeks)|Up to 30 days following the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first of each treatment period (Up to a maximum of 52 weeks)|Up to 90 days following the last dose of study drug or until initiation of a new anti-cancer treatment, whichever comes first of each treatment period (Up to a maximum of 60 weeks)|Up to 30 days from last dose in safety follow up period for each treatment period (Up to a maximum of 52 weeks)|Up to end of treatment (up to 48 weeks for each treatment period)|Up to 90 days from last dose in safety follow up period for each treatment period (Up to a maximum of 60 weeks)|Up to end of treatment (up to 48 weeks for each treatment period)|Up to 30 days from last dose in safety follow up period of each treatment period (Up to a maximum of 52 weeks)|Cycle 1 and 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (for cycle 1 only)|Cycle 1: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (for cycle 1 only)|Cycle 1 and 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (for cycle 1 only)|Cycle 1 and 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (cycle 1 only)|Cycle 2, 4, 7, 10 and 15: day 1: predose 0 hr|Cycle 2, 4, 7, 10 and 15: day 1: predose 0 hr|Cycle 5, 10 and 15: day 1: predose 0 hr|Cycle 1 and 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (cycle 1 only)|Cycle 1: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose|Cycle 1 and 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose (cycle 1 only)|Cycle 1: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose; day 22: 504 hr postdose|Cycle 7: day 1: predose 0 hr, end of dosing, 4 hr postdose; day 2: 24 hr postdose; day 3: 48 hr postdose; day 8: 168 hr postdose; day 15: 336 hr postdose\",\"Completed\",,\"May 20, 2022\"\n",
      "350,\"Maximum tolerated dose\",,\"Completed\",,\"January 13, 2014\"\n",
      "351,\"Safety and tolerability assessed by Adverse Events Characterization of the pharmacokinetic profile of gimatecan Anti-tumor activity assessed by Response Evaluation Criteria in Solid Tumors RECIST)\",,\"Completed\",,\"November 19, 2009\"\n",
      "352,\"Determine whether magnetic resonance image monitoring during radiofrequency interstitial thermal ablation can accurately predict complete destruction of focal tumor along with an adequate margin of normal tissue.\",\"Patients are followed at 2 weeks and at 3, 6, 9, and 12 months.\",\"Completed\",,\"June 11, 2010\"\n",
      "353,,,\"Completed\",,\"March 7, 2011\"\n",
      "354,\"Safety and Toxicity\",\"Toxicity will be assessed at the beginning of every cycle and on day 8 and 15 of every cycle for at least eight weeks (2 cycles). Maximum of 6 cycles.\",\"Terminated\",,\"March 28, 2012\"\n",
      "355,\"Compare FDG PET-based qualitative and quantitative tumor response assessment with standard CT immune RECIST criteria\",\"6 months after completion of standard of care treatment\",\"Completed\",,\"February 8, 2019\"\n",
      "356,\"MTD alvocidib when administered in conjunction with irinotecan hydrochloride and cisplatin\",\"Course 1\",\"Completed\",,\"February 24, 2014\"\n",
      "357,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment\",\"Up to 4 years\",\"Recruiting\",,\"March 27, 2023\"\n",
      "358,\"Overall Response Rate (ORR) - MET Exon 14 Cohort\",\"2 years\",\"Active, not recruiting\",,\"February 14, 2023\"\n",
      "359,\"The relationship between [18F]FPIA uptake and percent positive tumour cells reported as counts defined per area from whole section immunohistochemistry for PHH3.\",\"6 months\",\"Recruiting\",,\"March 17, 2022\"\n",
      "360,\"Number of patients with dose-limiting toxicity.\",\"8 weeks\",\"Completed\",,\"April 12, 2022\"\n",
      "361,\"Maximum tolerated dose (MTD)\",\"Daily for 5 consecutive days repeated every 4 weeks for 1 cycle; evaluation of 4-6 dose escalations to determine an MTD\",\"Completed\",,\"August 1, 2012\"\n",
      "362,\"Objective Response Rate (ORR)\",\"Approximately 12 months after dosed\",\"Recruiting\",,\"June 27, 2022\"\n",
      "363,\"DOSE ESCALATION PRIMARY OUTCOME (Dose Limiting Toxicities (DLTs) at cycle 1)|DOSE EXPANSION PRIMARY OUTCOME (treatment-emergent Adverse Events)\",\"At the end of Cycle 1 (each cycle is 21 days)|Through study completion, up to 5 years\",\"Recruiting\",,\"August 10, 2022\"\n",
      "364,\"To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.\",\"2 years\",\"Completed\",,\"November 2, 2018\"\n",
      "365,\"Incidence of Dose limiting toxicities\",\"4 weeks\",\"Completed\",,\"October 5, 2020\"\n",
      "366,,,\"Completed\",,\"May 30, 2013\"\n",
      "367,\"Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Treatment-emergent Serious Adverse Event (TESAE), Graded by Severity|Number of Participants With Dose-limiting Toxicities (DLTs)|Percentage of Participants With Complete Response (CR)|Percentage of Participants With Partial Response (PR)|Percentage of Participants With Stable Disease (SD)|Area Under the Plasma Concentration-Time Curve from Hour Zero to Hour 24 AUC[0-24] for ION537|Maximum Observed Plasma Concentration (Cmax) for ION537|Inhibition of Yes-associated Protein (YAP1) Expression\",\"Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)|Up to disease progression, death, start of new anticancer treatment, withdrawal of consent to study participation or end of the study, whichever occurs first (up to approximately 24 weeks for analysis)\",\"Completed\",,\"December 21, 2022\"\n",
      "368,\"Optimal Doses of Temozolomide and Bortezomib (Phase I)|Number of Patients With Clinical Anti-tumor Activity Phase II)\",\"up to 42 days|every 9 weeks to a maximum of 54 weeks\",\"Terminated\",,\"October 2, 2012\"\n",
      "369,\"AE/SAE|MTD|RP2D\",\"12 months after the last subject enrolled|12 months after the last subject enrolled|12 months after the last subject enrolled\",\"Recruiting\",,\"March 17, 2023\"\n",
      "370,\"Incidence of Treatment-Emergent Adverse Events(Safety)\",\"up to 96 weeks\",\"Recruiting\",,\"December 30, 2022\"\n",
      "371,,,\"Completed\",,\"July 24, 2012\"\n",
      "372,\"Tumor response to utidelone treatment\",\"12 months from first study treatment\",\"Recruiting\",,\"January 10, 2023\"\n",
      "373,\"Safety as assessed by NCI CTCAE v3.0|Feasibility of the drug combination|Maximum tolerated dose of temsirolimus in combination with pazopanib\",,\"Withdrawn\",,\"March 6, 2015\"\n",
      "374,,,\"Completed\",,\"April 30, 2015\"\n",
      "375,\"Change in tumor burden.\",\"22 weeks\",\"Completed\",,\"April 22, 2019\"\n",
      "376,\"Maximum Tolerated Dose (MTD)\",\"Average of 3 Months\",\"Completed\",,\"January 13, 2023\"\n",
      "377,\"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by the Common Terminology Criteria (CTC) version 2.0|DLT defined as hematologic and non-hematologic toxicities toxicities attributable to drug administration occurring during or immediately subsequent to the first course as assessed by CTC version 2.0|Pharmacokinetics of gefitinib\",\"28 days|28 days|At baseline, at 1, 2, 4, 6, 8, 12, and 24 hours after administration, at days 21 and 28, and at day 28 of subsequent courses\",\"Completed\",,\"January 23, 2013\"\n",
      "378,\"Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT)\",\"During the Run-in Phase and the first 5 weeks of treatment\",\"Completed\",,\"December 26, 2017\"\n",
      "379,\"Safety and tolerability|Preliminary anti tumor activity\",\"Up to 15 years after TK-8001 treatment (52 weeks core follow-up, 14 years long-term follow up)|Up to 15 years after TK-8001 treatment, or until disease progression\",\"Recruiting\",,\"March 14, 2023\"\n",
      "380,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108|Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108+pembrolizumab|Preliminary anti-tumor activity of IO-108 + pembrolizumab\",\"through study completion, an average of 2 years|through study completion, an average of 2 years|through study completion, an average of 2 years\",\"Recruiting\",,\"October 12, 2022\"\n",
      "381,\"Maximum Tolerated Dose (MTD) of Abraxane|Maximum Tolerated Dose (MTD) of Abraxane given with Carboplatin|Sequence-dependent toxicity\",\"28 days|21 days|28 days\",\"Completed\",,\"March 6, 2012\"\n",
      "382,\"To evaluate the toxicity and tolerability of and the maximum tolerated dose for QBI-139 in patients with advanced refractory solid tumors.\",\"Cycle 1 (three weeks)\",\"Unknown status\",\"Active, not recruiting\",\"January 28, 2015\"\n",
      "383,\"Determine the safety and toxicity profile of co-administration of disulfiram and copper gluconate for the treatment of refractory malignancies that have metastasized to the liver\",\"July 2011\",\"Completed\",,\"October 31, 2014\"\n",
      "384,\"Dose escalation part： Safety and tolerability of SHR-1701 in advanced malignancies.|Clinical expansion Part: Objective Response Rate（ORR）\",\"Up to 3/4 weeks.|Up to 6 weeks\",\"Active, not recruiting\",,\"November 8, 2022\"\n",
      "385,,,\"Completed\",,\"January 6, 2014\"\n",
      "386,,,\"Completed\",,\"February 5, 2013\"\n",
      "387,,,\"Completed\",,\"March 30, 2018\"\n",
      "388,\"Maximum Tolerated Dose (MTD) (Dose Escalation Phase)|Recommended Phase 2 Dose (RP2D) (Dose Escalation Phase)|Number of Grade 3, 4 and 5 Adverse Events (AEs) Related to TT-702 (Dose Escalation Phase)|Assess Number of Patients with Confirmed Complete Response (CR) and Partial Response (PR) (MSI/MMR and TNBC Arms Expansion Phase)|Assess Number of Patients with Confirmed CR and PR (mCRPC Arms Expansion Phase)\",\"Day 1 to Day 21|Day 1 to off-study visit (max. 13 months)|Safety data will be collected from the time of informed consent until 21 days after the last dose of TT-702. The average time from consent to the end of follow up will be presented.|Radiological assessment within 28 days before starting TT-702; end of every 3 cycles (21-day cycles) up to 6 months then every 4 cycles & treatment discontinuation and/or off-study visit (max. 13 months)|Radiological assessment (CT/MRI) within 28 days & bone scan (if required) within 8 weeks before starting TT-702; end of every 3 cycles (21-day cycles) up to 6 months then every 4 cycles & treatment discontinuation and/or off-study visit (max. 13 months)\",\"Recruiting\",,\"March 9, 2022\"\n",
      "389,\"The assessment of Treatment-related Adverse Events of SHR-A1403 in subjects with advanced solid tumors|DLT|MTD\",\"up to 24 months|up to 24 months|up to 24 months\",\"Completed\",,\"October 28, 2022\"\n",
      "390,\"CYP3A4\",\"One study day\",\"Recruiting\",,\"August 29, 2022\"\n",
      "391,\"Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Safety Run-in Cohort|Percentage of Participants Experiencing Treatment-Emergent Adverse Events|Objective Response Rate (ORR) Assessed by Response Evaluation Criteria In Solid Tumors (RECIST)\",\"Up to 5 Weeks|First dose date up to 20 months plus 30 days|Up to 20 months\",\"Completed\",,\"July 27, 2021\"\n",
      "392,,,\"Completed\",,\"September 10, 2018\"\n",
      "393,\"Determine the MTD and recommended phase 2 dose of i.v. EZN-2208 administered q3wk.\",\"2 years\",\"Terminated\",,\"February 14, 2022\"\n",
      "394,,,\"Completed\",,\"February 5, 2013\"\n",
      "395,\"MTD defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity\",\"21 days\",\"Completed\",,\"February 24, 2014\"\n",
      "396,\"Adverse events accessment, changes of physical signs, laboratory examination and 12-lead electrocardiogram.|Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of Kanitinib in subjects with advanced solid tumors\",\"2 year|2 year\",\"Completed\",,\"September 3, 2020\"\n",
      "397,\"Recommended Phase 2 Dose (RP2D) (Phase 1)|Anti-tumor Activity (Phase 2)\",\"Up to 48 months|Up to 60 months\",\"Active, not recruiting\",,\"December 8, 2022\"\n",
      "398,\"To determine the occurrence of treatment-related adverse events meeting the criteria for dose limiting toxicities (DLTs)|The recommended phase II dose for FCN-011|Overall response rate (ORR) by Response Criteria in Solid Tumors (RECIST) v1.1\",\"30 days|From first dose up to 30 days after last dose|Baseline up to approximately 1 year\",\"Recruiting\",,\"August 18, 2021\"\n",
      "399,\"Maximum tolerated dose (MTD) of BAY1436032|Number of participants with adverse events as a measure of safety and tolerability of BAY1436032|Recommended Phase II Dose (RP2D) of BAY1436032\",\"21 days|Up to 30 months|Up to 20 months\",\"Active, not recruiting\",,\"March 8, 2023\"\n",
      "400,\"Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment\",\"Up to 2 approximately years\",\"Completed\",,\"October 23, 2019\"\n",
      "401,\"MTD defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Pharmacokinetic (PK) parameters of tivantinib\",\"28 days|Pre-dose, 1, 2, 4, 6 and 8-12 hours day 1 of course 1; pre-dose day 1 of course 2\",\"Completed\",,\"July 2, 2015\"\n",
      "402,\"The change in Tumor pressure|The change in Tumor stiffness\",\"Up to 30 days|Up to 30 days\",\"Recruiting\",,\"December 12, 2022\"\n",
      "403,\"dose-limiting toxicity (DLT)|analysis of primary efficacy indicators\",\"Up to 21 days after first dose every subject|At the end of the time 3-6 months after last subject last dose\",\"Not yet recruiting\",,\"October 13, 2022\"\n",
      "404,\"MTD of tanespimycin, gemcitabine hydrochloride, and cisplatin, determined by incidence of dose-limiting toxicity (DLT) graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Adverse events, graded according to NCI CTCAE version 3.0\",\"21 days|Up to 30 days after completion of study treatment\",\"Completed\",,\"June 4, 2013\"\n",
      "405,\"The number of patients reported adverse events\",\"1-2 year\",\"Completed\",,\"July 14, 2015\"\n",
      "406,\"Overall Survival\",\"1 Year\",\"Recruiting\",,\"April 13, 2022\"\n",
      "407,\"Maximum tolerated dose (MTD) of Genasense administered as a 2-hour IV infusion once a week (Part 1) and twice a week (Part 2) to patients with solid tumors\",\"One year\",\"Completed\",,\"April 6, 2012\"\n",
      "408,\"To evaluate the safety and tolerability of U3-1287 (AMG888) in patients with advanced solid tumors|To evaluate maximum tolerated dose (MTD) of U3-1287(AMG888) when administered intravenously to patients with advanced solid tumors\",\"Lenth of study|Lenth of study\",\"Completed\",,\"July 29, 2010\"\n",
      "409,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Respiratory Rate (RR)|Change From Baseline in Pulse Rate (PR)|Change From Baseline in Body Temperature (BT)|Change From Baseline in Oxygen Saturation (OS)|Number of Participants With Notable Change in QTcF and QTcB From Baseline|Number of Participants With at Least 2-Grade Shift From Baseline in Laboratory Parameters|Number of Participants With Dose Limiting Toxicities (DLTs)|Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1B\",\"Day 1 through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|Day 1 (baseline) through 246.9 weeks (maximum observed duration)|From Day 1 to 28 days after the first dose of study drugs|Baseline (Days -28 to -1) through 54.8 months (maximum observed duration)\",\"Active, not recruiting\",,\"March 9, 2023\"\n",
      "410,\"OS\",\"1 year .\",\"Unknown status\",\"Recruiting\",\"September 3, 2019\"\n",
      "411,\"The distribution of Fluzoparib in the whole blood and plasma and whole.radioactive pharmacokinetics following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.|Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor to obtain the mass balance data and the main excretion pathway in human body.|Identification of the main metabolite and biotransformation pathway of Fluzoparib and investigation of metabolite with proportion >10% in plasma following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.|Quantitive analysis of the concentrations of Fluzoparib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.|Observation of safety following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.\",\"Up to 10 days (approx) from the start of administration.|Up to 10 days (approx) from the start of administration.|Up to 10 days (approx) from the start of administration.|Up to 10 days (approx) from the start of administration.|Up to 10 days (approx) from the start of administration.\",\"Completed\",,\"July 31, 2020\"\n",
      "412,\"Dose-limiting toxicities|Maximum-tolerated dose\",,\"Completed\",,\"November 29, 2019\"\n",
      "413,\"Progression-free survival (PFS)\",\"6 months\",\"Unknown status\",\"Recruiting\",\"May 16, 2019\"\n",
      "414,\"Feasibility rate\",\"10 weeks of treatment + 2 weeks of safety observation period\",\"Recruiting\",,\"November 15, 2022\"\n",
      "415,\"Early Rad51/deoxyribonucleic acid (DNA) damage response (DDR)|Late Rad51/DDR response\",\"At cycle 1 day 2 (1 cycle = 28 days)|At cycle 3 day 1\",\"Not yet recruiting\",,\"January 20, 2023\"\n",
      "416,\"The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.\",\"Day 0 to 4 months after the end of the study\",\"Unknown status\",\"Not yet recruiting\",\"March 21, 2018\"\n",
      "417,\"Dose limiting toxicity (DLT) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\",\"3 weeks\",\"Completed\",,\"August 30, 2016\"\n",
      "418,\"Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs)|Efficacy Expansion Cohort (Ovarian Cancer): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)|Efficacy Expansion Cohort(Urothelial Carcinoma): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)|Efficacy Expansion Cohort (GC/GEJC, Third Line): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)|Efficacy Expansion Cohort (HNSCC): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)\",\"Dose Escalation: Baseline up to Week 3|Ovarian Cancer Efficacy Expansion: Baseline up to Day 620|Urothelial Carcinoma Efficacy Expansion: Baseline up to Day 931|GC/GEJC, Third Line Efficacy Expansion: Baseline up to Day 871|HNSCC Efficacy Expansion: Baseline up to Day 1072\",\"Completed\",,\"December 20, 2021\"\n",
      "419,\"，Dose-limiting toxicity incidence (participants who experience DLT)\",\"21 day\",\"Recruiting\",,\"October 17, 2022\"\n",
      "420,\"To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.\",\"1 year after last patient is enrolled\",\"Terminated\",,\"December 11, 2013\"\n",
      "421,\"Phase Ib: Estimation of Maximum Tolerated Dose (MTD) by measuring incidence of dose limiting toxicities (DLT)|Phase II: Clinical efficacy\",\"up to 8 months|up to 14 months\",\"Active, not recruiting\",,\"January 5, 2023\"\n",
      "422,,,\"Completed\",,\"June 29, 2012\"\n",
      "423,,,\"Completed\",,\"August 9, 2012\"\n",
      "424,\"Number of Participants with Adverse Events as a Measure of Safety and Tolerability\",\"During treatment with sunitinib Adverse Events will be recorded up to 30 days after treatment. Patient will remain on treatment untill the disease progression, 1 year in average\",\"Unknown status\",\"Recruiting\",\"October 10, 2011\"\n",
      "425,,,\"Completed\",,\"June 1, 2012\"\n",
      "426,,,\"Completed\",,\"April 8, 2013\"\n",
      "427,\"Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumab|Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT)|Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumors\",\"From first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment date or disease progression whichever is earlier|From the first dose of IO-108 until 21 days post-treatment|From the first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment or disease progression, whicheer is earlier\",\"Recruiting\",,\"November 10, 2022\"\n",
      "428,\"To identify the maximum tolerated dose\",\"12 months\",\"Completed\",,\"January 25, 2017\"\n",
      "429,\"Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03|MTD\",\"24 months|24 months\",\"Active, not recruiting\",,\"November 14, 2022\"\n",
      "430,\"Recommended stereotactic body radiotherapy (SBRT) dose in combination with pembrolizumab.\",\"3 Months\",\"Active, not recruiting\",,\"March 6, 2023\"\n",
      "431,,,\"Completed\",,\"July 11, 2012\"\n",
      "432,,,\"Completed\",,\"November 30, 2012\"\n",
      "433,,,\"Completed\",,\"August 9, 2012\"\n",
      "434,\"Number of Patients With Treatment-emergent Adverse Events (TEAE)|Number of Patients With Adverse Events Qualified as Dose Limiting Toxicities (DLTs)\",\"From screening until follow-up visit (up to 12 months)|From screening until follow-up visit (up to 12 months)\",\"Completed\",,\"September 9, 2019\"\n",
      "435,\"Time-to-progression ratio (TTP)\",\"2 years (baseline to follow-up)\",\"Recruiting\",,\"November 14, 2022\"\n",
      "436,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES102|Number of participants with adverse events and serious adverse events of ES102\",\"2-3 years|2-3 years\",\"Active, not recruiting\",,\"October 21, 2022\"\n",
      "437,\"Numbers and percentage of patients with adverse events (AEs)|Maximum tolerated dose of HLX10\",\"1 year|1 year\",\"Unknown status\",\"Recruiting\",\"June 1, 2020\"\n",
      "438,\"Overall response rate|Overall disease control rate\",\"3 years|3 years\",\"Recruiting\",,\"January 10, 2023\"\n",
      "439,\"Maximum Tolerated Dose of HS-20089\",\"3 weeks after initiation of treatment\",\"Recruiting\",,\"March 2, 2022\"\n",
      "440,\"Assess the oral bioavailability of veliparib\",\"Up to 4 weeks.\",\"Completed\",,\"November 21, 2017\"\n",
      "441,,,\"Completed\",,\"December 13, 2019\"\n",
      "442,\"progression-free survival\",\"Patients will be followed for an average period of 1 year\",\"Recruiting\",,\"April 5, 2021\"\n",
      "443,\"Progression Free Survival\",\"Length of study\",\"Completed\",,\"February 21, 2014\"\n",
      "444,\"The ability of the imaging system to detect the expression of the ICG in the nodule/mass (i.e tumor) and discern the uptake of the dye by the tumor.\",\"Before surgery\",\"Completed\",,\"March 20, 2018\"\n",
      "445,\"The maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D) of BAY1895344|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A of the study|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A.1 of the study|Incidence of DLTs during Cycle 1 in dose-escalation cohorts during J-arm of the study|The incidence of serious and nonserious treatment-emergent adverse events (TEAEs)|Area under the plasma concentration of BAY1895344 vs. time curve from zero to 12 hours after single-dose (AUC[0-12]) and multiple-dose administrations (AUC[0-12]md) in Cycle 1|Maximum observed drug concentration in plasma of BAY1895344 after single-dose (Cmax) and multiple-dose administrations (Cmax,md) in Cycle 1\",\"Up to 6 months, minimum: 1 cycle (= 21days)|During Cycle 1, 1 cycle=21 days|During Cycle 1, 1 cycle=28 days|During Cycle 1, 1 cycle=21 days|After first administration of study drug up to 30 days after the last dose of study drug|Pre-dose and up to 12 hours post-dose at Day 1 of Cycle 1 and Day 10 (Part A and J-arm) or Day 17 (Part A.1) of Cycle 1|Pre-dose and up to 12 hours post-dose at Day 1 of Cycle 1 and Day 10 (Part A and J-arm) or Day 17 (Part A.1) of Cycle 1\",\"Recruiting\",,\"February 21, 2023\"\n",
      "446,\"Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)|Number of Participants With Adverse Events Possibly, Probably, or Definitely Related to Study Drug|Maximum Tolerated Dose (MTD) of PU-H71\",\"Cycle 1 (21 days)|3 years and two months and 11 days|Cycle 1 (21 days)\",\"Terminated\",,\"October 4, 2017\"\n",
      "447,\"To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors.\",\"weekly\",\"Withdrawn\",,\"May 21, 2014\"\n",
      "448,\"Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant|Changes in MET and Phospho-MET Levels\",\"Time receiving study drug, up to 22 cycles|MET and phospho-MET levels were measured on Cycle 1 Day 1 and Cycle 1 Day 8.\",\"Completed\",,\"July 1, 2022\"\n",
      "449,\"MTD of temsirolimus defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) as graded by the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events as graded by NCI CTCAE version 4.0\",\"Up to 21 days|Up to 30 days post-treatment\",\"Completed\",,\"April 10, 2014\"\n",
      "450,\"Incidence rate of dose limiting toxicities (DLT).\",\"5 years\",\"Completed\",,\"September 22, 2020\"\n",
      "451,\"To establish the safety and tolerability of weekly (days 1, 8, 15 q28-day cycle) LMP400 in patients with refractory solid tumors and lymphomas\",\"Cycle 1\",\"Completed\",,\"September 27, 2018\"\n",
      "452,,,\"Completed\",,\"February 11, 2013\"\n",
      "453,\"MTD of oral calcitriol when combined with a standard dose of gemcitabine hydrochloride and cisplatin, determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0\",\"28 days\",\"Terminated\",,\"January 12, 2016\"\n",
      "454,\"Maximum tolerated dose (MTD) of fenretinide|Toxicity as measured by type (organ affected or laboratory determination such as absolute neutrophil count), severity (NCI CTCAE v3.0), time of onset (course number), duration, and reversibility or outcome|Survival and time to failure as measured by Kaplan-Meier\",\"at end of study|ongoing|at end of study\",\"Completed\",,\"September 12, 2013\"\n",
      "455,\"Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity(DLT)\",\"up to 24 months\",\"Terminated\",,\"September 1, 2022\"\n",
      "456,\"Pharmacokinetics of Nimotuzumab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors: Single dose：Tmax，Cmax， AUC，Vc，t1/2α，t1/2β，CL. Multiple dose：Tmax，Css-min，Css-max，Css-a，t1/2β，CL，AUCss，DF.\",\"up to 9 weeks\",\"Unknown status\",\"Active, not recruiting\",\"August 19, 2015\"\n",
      "457,,,\"Completed\",,\"July 19, 2016\"\n",
      "458,\"Number of patients with adverse events (AEs), serious adverse events (SAEs), and treatment emergent adverse events (TEAEs)|Number of patients with AEs qualified as dose-limiting toxicities (DLTs)|Determination of tolerability and maximum tolerated dose (MTD) of CAL056 mesylate by DLTs using NCI CTCAE version 5.0|Evaluation of the PK profile of CAL056 mesylate: Maximum observed concentration (Cmax)|Evaluation of the PK profile of CAL056 mesylate: Time to reach Cmax (Tmax)|Evaluation of the PK profile of CAL056 mesylate: Apparent terminal elimination half-life (t½)|Evaluation of the PK profile of CAL056 mesylate: Area under the concentration-time curve (AUC)|Preliminary determination of the recommended phase II dose (RP2D) of CAL056 mesylate\",\"From screening visit until safety follow-up visit (at 28 days after the EOT) or before starting new anticancer treatment, whichever comes first (up to 1-year)|Cycle 1 (28 days)|Cycle 1 (28 days)|At Day 1 and Day 28 of Cycle 1, at Day 1 of subsequent cycles until Cycle 6 (except for Cycle 2) (each cycle is 28 days in length)|At Day 1 and Day 28 of Cycle 1, at Day 1 of subsequent cycles until Cycle 6 (except for Cycle 2) (each cycle is 28 days in length)|At Day 1 and Day 28 of Cycle 1, at Day 1 of subsequent cycles until Cycle 6 (except for Cycle 2) (each cycle is 28 days in length)|At Day 1 and Day 28 of Cycle 1, at Day 1 of subsequent cycles until Cycle 6 (except for Cycle 2) (each cycle is 28 days in length)|Cycle 1 (28 days)\",\"Recruiting\",,\"July 7, 2022\"\n",
      "459,\"Determine the maximum tolerated dose (MTD)|Recommended Phase II Dose (RP2D)|Dose-Limiting Toxicity (DLT)\",\"From first dose (Day 1) up to 30 days after last dose|From first dose (Day 1) up to 30 days after last dose|From first dose (Day 1) up to 30 days after last dose\",\"Recruiting\",,\"April 28, 2021\"\n",
      "460,\"To establish the maximum tolerated dose (MTD) and the recommended dose (RD) of F16IL2 when administered in combination with paclitaxel (Phase I).|To investigate the efficacy of F16IL2, in terms of objective response rate in combination with paclitaxel in metastatic melanoma, breast cancer and NSCLC patients amenable to taxane therapy (Phase II)\",\"28 days|8 weeks\",\"Completed\",,\"April 15, 2022\"\n",
      "461,\"The incidence of dose-limiting toxicites (DLTs)|The incidence of adverse events|The incidence of abnormal laboratory results\",\"Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of Dose Limiting Toxicities (DLTs).|Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of adverse events|Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of abnormal laboratory results.\",\"Completed\",,\"May 1, 2020\"\n",
      "462,\"maximum tolerated dose of BMS-599626\",\"28 days\",\"Completed\",,\"October 4, 2012\"\n",
      "463,,,\"Suspended\",,\"July 11, 2012\"\n",
      "464,\"Dose-limiting toxicity|Causality of each adverse event and grading severity according to NCI CTCAE Version 3.0\",,\"Terminated\",,\"May 1, 2012\"\n",
      "465,\"Number of Participants With Dose-Limiting Toxicities (DLTs)\",\"First Dose Up to 6 Weeks\",\"Completed\",,\"January 18, 2019\"\n",
      "466,,,\"Completed\",,\"April 17, 2013\"\n",
      "467,\"Dose Escalation: Number of participants with adverse events (AEs)|Dose Escalation: Maximum tolerated dose (MTD) of BGB-24714 as monotherapy and in combination with chemotherapy|Dose Escalation: Recommended Phase 2 dose (RP2D) of BGB-24714 as monotherapy and in combination with chemotherapy|Dose Expansion: Objective response rate (ORR)\",\"approximately 6 months|approximately 6 months|approximately 6 months|approximately 2 Years\",\"Recruiting\",,\"February 8, 2023\"\n",
      "468,\"Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors|Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors\",\"28 days|28 days\",\"Unknown status\",\"Recruiting\",\"May 23, 2019\"\n",
      "469,\"Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D)\",\"15 months\",\"Terminated\",,\"May 28, 2020\"\n",
      "470,\"Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Maximum tolerated dose (MTD) (if available)|Dose Limiting Toxicity (DLT )|Recommended Phase 2 dose (RP2D)|Objective response rate (ORR) (in stage Ⅱ)|Disease control rate (DCR) (in stage Ⅱ)|Duration of response (DOR) (in stage Ⅱ)|Progression-free survival (PFS) (in stage Ⅱ)|Overall survival (OS) (in stage Ⅱ)\",\"Approximately 4 years|Approximately 4 years|Approximately 1 year|Up to 28 days after first injection|Approximately 2 years|Approximately 2 years in stage Ⅱ|Approximately 2 years in stage Ⅱ|Approximately 2 years in stage Ⅱ|Approximately 2 years in stage Ⅱ|Approximately 2 years in stage Ⅱ\",\"Not yet recruiting\",,\"January 3, 2022\"\n",
      "471,\"To assess safety and tolerability of SUPLEXA in subjects with malignant solid tumour and haematologic malignancies.\",\"24 months\",\"Recruiting\",,\"December 19, 2022\"\n",
      "472,\"Incidence of Treatment-Emergent Adverse Events of ENB003 in combination with pembrolizumab, as assessed by NCI CTCAE Version 5|Efficacy of ENB003 in combination with pembrolizumab measured by tumor ORR\",\"assessed on every visit while subjects are in the study up to 2 years|up to 2 years while subjects remain in the study\",\"Recruiting\",,\"March 8, 2021\"\n",
      "473,\"Maximum tolerable dose (MTD) of irinotecan\",,\"Completed\",,\"May 5, 2014\"\n",
      "474,\"Dose Limiting Toxicity (DLT)|Overall Response (OR)\",\"Cycle 1 Days 1-28 (28 days from date of first dose of study treatment)|From date of first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to approximately 24 months\",\"Completed\",,\"January 20, 2023\"\n",
      "475,\"ThatPET/CT will be superior (15% improvement) to conventional methods of follow-up in terms of 5 year survival, cost and time to identification of new disease\",\"5 years\",\"Terminated\",,\"June 30, 2010\"\n",
      "476,\"Incidence of Dose Limiting Toxicities\",\"From day 1 to day 28 of treatment\",\"Completed\",,\"June 15, 2021\"\n",
      "477,\"To determine the maximum tolerated dose (MTD) based on toxicity analysis.|To determine the incidence and nature of dose-limiting toxicities (DLTs) of TVB-2640.\",\"1.5 years|Days 1 to 21 of cycle 1 for monotherapy cohort(s); Days 1 to 28 of cycle 1 for combination with anti-cancer agent cohort(s)\",\"Completed\",,\"August 14, 2017\"\n",
      "478,\"Safety and tolerability of combination cedazuridine with decitabine as assessed by number of participants who experience adverse events|Maximum Tolerated Dose (MTD) as determined by number of participants with of dose limiting toxicities (DLT)\",\"up to 2 years|up to 2 years\",\"Recruiting\",,\"January 5, 2023\"\n",
      "479,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration (Cmax) After a Single Dose of GDC-0449|Cmax After Multiple Doses of GDC-0449|Time to Maximum Plasma Concentration (Tmax) After a Single Dose of GDC-0449|Tmax After Multiple Doses of GDC-0449|Average Plasma Concentration at Steady State (Css, Avg) After Multiple Doses of GDC-0449|Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) After a Single Dose of GDC-0449|AUC0-24 After Multiple Doses of GDC-0449|Accumulation Index (AI) After Multiple Doses of GDC-0449\",\"Up to Week 6|-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8|-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years|-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8|-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years|-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years|-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8|-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years|-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years\",\"Completed\",,\"October 8, 2015\"\n",
      "480,\"Maximum Tolerated Dose of HS-10381\",\"4 weeks after initiation of treatment\",\"Recruiting\",,\"July 7, 2022\"\n",
      "481,,,\"Completed\",,\"August 3, 2011\"\n",
      "482,\"Maximum tolerated dose of AEG35156 in combination with docetaxel|Recommended phase II dose\",\"2-3 years|2-3 years\",\"Completed\",,\"April 8, 2020\"\n",
      "483,\"Maximum tolerated dose(MTD)|Dose-limiting toxicity(DLT)\",\"2 months|2 months\",\"Completed\",,\"April 18, 2018\"\n",
      "484,\"Single Cell Sequencing\",\"3 years\",\"Recruiting\",,\"February 9, 2022\"\n",
      "485,\"Number of participants with adverse events|Maximum Tolerated dose of RC108\",\"From the day of ICF signment to 28 days after the day of the last treatment|21 days after first treatment.\",\"Recruiting\",,\"March 7, 2023\"\n",
      "486,\"Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.\",\"Baseline and endpoint (as soon as possible after Day 21 of the last cycle)\",\"Completed\",,\"January 18, 2013\"\n",
      "487,\"To determine the maximum tolerated dose (MTD)|To determine the safety profile|pharmacokinetic profile|effect on pharmacodynamic biomarkers|antitumor activity\",\"Dose escalation will proceed according to the predetermined scheme until the stopping dose (dose > MTD) is reached due to dose limiting toxicities (DLT) occurring during the first 4-week course of treatment.|Study duration|Dosing period|Dosing period|At screening and after every 2 courses\",\"Completed\",,\"July 14, 2009\"\n",
      "488,\"Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03|Phase 1: Percentage of Participants Experiencing laboratory abnormalities Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03|Phase 1: Percentage of Participants Experiencing Dose-limiting toxicity (DLTs) per Dose level|Phase 2: Objective Response Rate (ORR) Determined by Independent Review Committee (IRC)\",\"First dose date to last dose date (Up to 15 weeks) plus 30 days|First dose date to last dose date (Up to 15 weeks) plus 30 days|First dose date up to 21 days|Up to 17 months\",\"Active, not recruiting\",,\"February 6, 2023\"\n",
      "489,\"Number of participants with Dose Limiting Toxicities (DLTs) of the MEDI9253 during the dose escalation phase|Number of participants experiencing adverse events (AEs) /serious adverse events (SAEs)|Number of participants experiencing adverse events (AEs) leading to discontinuation\",\"Single dose cohorts: From Day 1 through 14 days Multiple dose cohorts: From Day 1 through 28 days|Informed consent through 90 days post last dose of study drug, estimated to be 6 months|Informed consent through 90-Post last dose, estimated to be 6 months\",\"Active, not recruiting\",,\"February 21, 2023\"\n",
      "490,\"To estimate the intensity and distribution in critical and non-critical organs.|To estimate the intensity and distribution in critical and non-critical organs.|To estimate the intensity and distribution in critical and non-critical organs.\",\"Day 1|Day 2|Day 3\",\"Terminated\",,\"July 11, 2017\"\n",
      "491,\"Establishing the Maximum Tolerated Dose (MTD) of AZD0424 alone and in combination|Determining the causality and duration of adverse events observed during the study according to NCI CTCAE Version 4.02\",,\"Terminated\",,\"February 5, 2018\"\n",
      "492,\"Objective tumor response rate\",\"at 6 months\",\"Not yet recruiting\",,\"March 9, 2020\"\n",
      "493,\"Number of participants with related adverse events\",\"8 weeks\",\"Completed\",,\"May 19, 2017\"\n",
      "494,\"Determination of the maximum tolerated dose (MTD)\",\"During the Run-in Phase and Cycle 1 period (the first 5 weeks of treatment)\",\"Completed\",,\"February 14, 2014\"\n",
      "495,\"Number of treatment-emergent adverse events\",\"Baseline through 90 days after end of treatment, estimated up to 12 months.\",\"Active, not recruiting\",,\"June 27, 2022\"\n",
      "496,\"To determine the maximum tolerated dose (MTD) levels and recommended Phase 2 dose levels of Karenitecin when administered intravenously for 5 consecutive days with a fixed dose of Cytoxan®\",\"evaluation will extend at least 30 days following the last dose or until toxicities have resolved\",\"Completed\",,\"May 15, 2012\"\n",
      "497,\"Safety, tolerability\",\"ARQ 197 treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met\",\"Completed\",,\"July 23, 2012\"\n",
      "498,\"To characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours, assessed by blood, urine and faecal sampling\",\"Various timepoints\",\"Completed\",,\"January 14, 2009\"\n",
      "499,\"Number of adverse events and/or serious adverse events\",\"6 months\",\"Withdrawn\",,\"January 30, 2023\"\n",
      "500,\"Type and incidence of dose-limiting toxicity (DLT) by dose group|Type and incidence of adverse events (AEs) and serious adverse events (SAEs) by dose group\",\"2 years post infusion|2 years post infusion\",\"Recruiting\",,\"December 21, 2021\"\n",
      "501,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP1570 Single Agent|Number of Participants with Adverse Events (AEs)|Change from baseline to 45 days after End of Treatment (EOT) in laboratory values|Number of participants with vital sign abnormalities and/or AEs|Number of participants with electrocardiogram (ECG) abnormalities and/or AEs\",\"21 days|Up to 27 months|Baseline and 45 days after EOT|Up to 27 months|Up to 24 months\",\"Recruiting\",,\"February 6, 2023\"\n",
      "502,\"Mutation characteristics of malignant solid tumors in Chinese children.\",\"2021.8-2023.8\",\"Recruiting\",,\"October 13, 2021\"\n",
      "503,\"Quality of Life at baseline\",\"Baseline\",\"Completed\",,\"June 28, 2019\"\n",
      "504,\"Frequency of a cancer causing actionable alteration and individualized treatment recommendation.\",\"2 years\",\"Completed\",,\"February 10, 2015\"\n",
      "505,\"Dose Limiting Toxicities (DLT)|Incidence and Severity of Adverse Events|Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status\",\"21 or 28 days, depending on study part|up to 100 days post last dose|21 or 28 days, depending on study part|up to 100 days post last dose\",\"Active, not recruiting\",,\"August 24, 2022\"\n",
      "506,\"dose-limiting toxicities (DLTs)|area under the plasma concentration-time curve from 0 to the last measurable concentration (AUClast)\",\"Day 0 to Day 28|Cycle 1, Day 1: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 1, Day 8: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 2, Day 8: Pre-dose, 1, 2, 4 hours post dose Cycle 3 & 4, Day 8: Pre-dose\",\"Unknown status\",\"Recruiting\",\"April 25, 2018\"\n",
      "507,\"Incidence of all adverse events, graded according to the National Cancer Institute Common (NCI) Terminology Criteria for Adverse Events (CTCAE) version 3.0|Incidence of toxicity graded according to NCI CTCAE version 3.0\",\"Up to 30 days after last study treatment|Up to 3 months\",\"Completed\",,\"May 18, 2018\"\n",
      "508,\"Maximum tolerated dose|Toxicity\",\"21 days|105 days\",\"Completed\",,\"August 1, 2017\"\n",
      "509,\"Overall Response Rate\",\"through study completion, estimated to be 1 year after the last subject enrolled\",\"Suspended\",,\"January 12, 2023\"\n",
      "510,\"Number of Participants With Dose-Limiting Toxicities (DLT) of PF-05082566 in Combination With MK-3475\",\"First 2 cycles of treatment up to 24 months\",\"Completed\",,\"February 8, 2019\"\n",
      "511,\"Objective response rate defined as per RECIST v1.1.\",\"2.5 years\",\"Recruiting\",,\"September 26, 2022\"\n",
      "512,\"Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD)|Antitumor Activity of AG-01 by Overall Response Rate (ORR)\",\"28 days during 1st cycle|Every 56 Days\",\"Recruiting\",,\"November 28, 2022\"\n",
      "513,,,\"Completed\",,\"February 5, 2013\"\n",
      "514,\"Patients With Dose Limiting Toxicities (DLT)\",\"During the first cycle (21 days)\",\"Terminated\",,\"July 28, 2021\"\n",
      "515,\"Objective Response (OR)\",\"up to 24 weeks\",\"Completed\",,\"February 21, 2023\"\n",
      "516,\"Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)|Incidence of treatment-emergent adverse events (TEAEs) and changes in clinical laboratory values (Part 1A & 1B)\",\"Cycle 1 Day 1 up to just prior to the second dose of the study drug at Cycle 2 Day 1 (approximately 21 days)|Up to 24 months\",\"Recruiting\",,\"January 31, 2023\"\n",
      "517,\"Dose Limiting Toxicity|Adverse Event\",\"up to Day28|up to 24 months\",\"Not yet recruiting\",,\"December 13, 2022\"\n",
      "518,,,\"Completed\",,\"April 9, 2020\"\n",
      "519,\"Evaluate the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of AV-412 administered orally 3 times weekly and once weekly in subjects with relapsed or refractory solid tumor malignancies.\",\"4 weeks (1 cycle)\",\"Completed\",,\"October 4, 2011\"\n",
      "520,\"Cmax at Single Dose|AUClast at Single Dose|T1/2 at Single Dose|Ceoi at Multiple Doses\",\"day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation|day 15\",\"Completed\",,\"October 8, 2020\"\n",
      "521,\"Safety of TCD-717 given by 4-hour intravenous infusion\",\"Duration of the study\",\"Completed\",,\"August 8, 2014\"\n",
      "522,\"Safety, tolerability, and maximum tolerated dose of oral administration of XL888 when administered on an intermittent schedule to adults with solid tumors|Plasma pharmacokinetics of oral administration of XL888 when administered on an intermittent schedule\",\"Assessed at several visits during weeks 1 through 4 of the first cycle and approximately every other week each cycle thereafter|Assessed at several visits during weeks 1 through 4 of the first cycle and approximately once every four weeks each cycle thereafter\",\"Terminated\",,\"August 21, 2015\"\n",
      "523,\"Diagnostic value of multimodal imaging in primary prostate cancer patients\",\"3 Days\",\"Recruiting\",,\"March 14, 2023\"\n",
      "524,\"To characterize the safety, tolerability, and pharmacokinetics (PK) of AB0024 after multiple intravenous (IV) administrations in patients with advanced solid tumors.\",\"Day 71\",\"Completed\",,\"May 3, 2012\"\n",
      "525,\"Safety of AMG 232\",\"36 months\",\"Completed\",,\"September 2, 2021\"\n",
      "526,\"Number of Participants With a Dose-limiting Toxicity (DLT)|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an AE\",\"Cycle 1 (Up to 28 days)|Up to approximately 23 months|Up to approximately 20 months\",\"Completed\",,\"August 7, 2018\"\n",
      "527,\"Number of participants with dose-limiting toxicities (DLTs)|Overall Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per an Independent Endpoint Review Committee (IERC)\",\"During the first 3 weeks of treatment|Up to 2 years\",\"Recruiting\",,\"February 8, 2023\"\n",
      "528,\"Primary outcome 1|Primary outcome 2\",\"21 days|21 days\",\"Completed\",,\"November 17, 2021\"\n",
      "529,\"Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in healthy subjects|Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in patients with advanced solid tumor\",\"From baseline to week 12|From baseline to week 8 and through study completion, an average of 3 year\",\"Completed\",,\"July 6, 2021\"\n",
      "530,\"Safety and tolerability\",\"Weekly evaluation for the first 5 weeks (DLT period), and continued follow up until patients come off trial due to toxicity or progressive disease\",\"Unknown status\",\"Active, not recruiting\",\"April 24, 2018\"\n",
      "531,\"Incidence of DLTs by the NCI CTCAE v4.03\",\"Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid\",\"Terminated\",,\"November 21, 2018\"\n",
      "532,\"The occurrence of dose limiting toxicity\",\"28 days\",\"Completed\",,\"August 19, 2020\"\n",
      "533,\"To assess the effect of various degrees of impairment in hepatic function as measured by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) criteria, on the pharmacokinetics of panobinostat.\",\"first 7 days\",\"Completed\",,\"December 19, 2020\"\n",
      "534,\"Objective response Rate (ORR)\",\"Approximately 12 months\",\"Active, not recruiting\",,\"December 8, 2022\"\n",
      "535,\"Establish the safety and tolerability of AZD2281 in combination with cisplatin and gemcitabine in patients with solid tumors. Establish the maximum tolerated dose (MTD) for the combination of AZD2281 with cisplation and gemcitabine.\",,\"Completed\",,\"July 5, 2018\"\n",
      "536,\"Number of participants with adverse events in phase 1a|Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b\",\"From first dose to within 28 days of last dose of BGB-283, within 1 years in average|From the first administration of the investigational product to the end of the study treatment, within 1 year in average\",\"Completed\",,\"March 25, 2020\"\n",
      "537,\"To assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies\",\"PK samples will be taken until Day 16\",\"Completed\",,\"May 19, 2011\"\n",
      "538,\"Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)|Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy|NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1|Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy|Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy|NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1\",\"6 months|Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)|24 months|9 months|Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)|24 months\",\"Recruiting\",,\"January 9, 2023\"\n",
      "539,\"Safety and Pharmacokinetics\",,\"Completed\",,\"November 29, 2017\"\n",
      "540,\"Safety Assessment|Efficacy Assessment\",\"Weekly|Bi-monthly\",\"Completed\",,\"November 21, 2017\"\n",
      "541,\"Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)\",\"Up to 24 months\",\"Completed\",,\"May 13, 2021\"\n",
      "542,\"Evaluate the safety and tolerability of escalating doses of GV20-0251 in refractory advanced malignancy patients as defined in the protocol during dose escalation|Determine the recommended Phase 2 dose (RP2D) of GV20-0251 in patients with advanced and/or specific solid tumor malignancies from Cohort Expansion.\",\"12 months|36 months\",\"Not yet recruiting\",,\"December 30, 2022\"\n",
      "543,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\",\"1.5 years\",\"Terminated\",,\"July 30, 2019\"\n",
      "544,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)|Percentage of Total Cyclin-dependent Kinase (CDC2)-Positive Cells That Were Phosphorylated (pCDC2) in Skin Cells at Baseline and 8 Hours After MK-1775 Dosing|Percentage of Total pCDC2 in Skin Cells at Baseline and 24 Hours After MK-1775 Dosing|Percentage of Total pCDC2 in Skin Cells at Baseline and 48 Hours After MK-1775 Dosing|Plasma Concentration of MK-1775 at 8 Hours After Administration (C8hr) of Single or Multiple Oral Doses|Mean Urine Excretion of MK-1775 24 Hours After the Day 1 Monotherapy Dose\",\"Part 1: Up to 14 days, Part 2: Up to 28 days|Baseline, 8 hours after first MK-1775 dose|Baseline, 24 hours after first MK-1775 dose|Baseline, 48 hours after first MK-1775 dose|8 hours after MK-1775 dose|At 0-4 hours, 4-8 hours, and 12-24 hours post Day 1 dose of monotherapy\",\"Completed\",,\"April 5, 2019\"\n",
      "545,\"Incidence of dose limiting toxicities (DLTs) during the DLT period|Incidence and severity of treatment emergent adverse events (TEAEs)|Incidence and severity of serious adverse events (SAEs)|Incidence of TEAEs ≥ Grade 3|Percentage of events requiring withdrawal|Recommended phase 2 dose (RP2D) of RP3\",\"From Day 1 up to 30 days after last dose|From Day 1 up to 60 days after last dose|From Day 1 up to 60 days after last dose|From Day 1 up to 60 days after last dose|From Day 1 up to last dose (up to 8 weeks in escalation phase and up to 2 years in combination phase)|7 months\",\"Recruiting\",,\"February 1, 2023\"\n",
      "546,\"Maximum tolerated dose of cetuximab\",\"December 2007\",\"Completed\",,\"March 29, 2010\"\n",
      "547,\"Phase 1a: Incidence Rate of Dose-Limiting Toxicity (DLT)|Phase 1b: ORR Solid tumors: objective response rate (ORR) assessed by Investigator per RECIST 1.1 CTCL: ORR assessed by Investigator per global response (Olsen 2011)\",\"Within 28 days after the first dose|Assessed up to an average of 1 year\",\"Recruiting\",,\"October 7, 2022\"\n",
      "548,,,\"Completed\",,\"December 19, 2013\"\n",
      "549,\"Part 1: Number of participants assigned to the every 2 weeks regimen with dose-limiting toxicities (DLTs)|Part 1: Number of participants assigned to the every 3 weeks regimen with DLTs|Part 1 and Part 2: Number of participants with adverse events (AEs)|Part 1 and Part 2: Number of participants with any clinically significant clinical laboratory test value|Part 1 and Part 2: Number of participants with any clinically significant vital sign value|Part 1 and Part 2: Change from Baseline in arterial oxygen saturation|Part 1 and Part 2: Change from Baseline in body weight|Part 1 and Part 2: Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value|Part 1 and Part 2: Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)\",\"Cycle 1 (28 days)|Cycle 1 (21 days)|Up to approximately 93 months|Up to approximately 93 months|Up to approximately 93 months|Baseline; Up to approximately 93 months|Baseline; Up to approximately 93 months|Up to approximately 93 months|Baseline; Up to approximately 93 months\",\"Recruiting\",,\"March 13, 2023\"\n",
      "550,\"Step 1: MTD of oral CP-4126 in patients with advanced solid tumours, followed by establishing the recommended dose|Step 2: Pharmacokinetic parameters comparison of oral CP-4126 with IV gemcitabine\",\"6 months|12 months\",\"Completed\",,\"September 6, 2010\"\n",
      "551,\"Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed as of 12/01/2004])|Response Rate (Phase II)\",\"Up to 36 months|Up to 36 months\",\"Completed\",,\"December 6, 2018\"\n",
      "552,\"To assess the safety and tolerability of AMG 780 in subjects with advanced solid malignancies (including adverse event rate, incidence of dose-limiting toxicities, and determination of maximum tolerated dose)|To evaluate the pharmacokinetic (PK) parameters of AMG 780 including, but not limited to Cmax, AUC, and accumulation ratio\",\"2.5 years|2.5 years\",\"Terminated\",,\"March 4, 2015\"\n",
      "553,,,\"Completed\",,\"May 16, 2012\"\n",
      "554,\"maximum tolerated dose (MTD)\",\"28 days\",\"Withdrawn\",,\"October 22, 2020\"\n",
      "555,\"Tumor assessments should be performed at screening and then every 2 cycles. A best response according to RECIST (Response Evaluation Criteria in Solid Tumors) will be documented by the investigator for each patient.\",\"Every 6 weeks\",\"Suspended\",,\"February 4, 2009\"\n",
      "556,\"Determine the toxicity profile of the combination of dasatinib and bevacizumab|Maximjum Tolerated Dose (MTD) of the combination of dasatinib and bevacizumab|Estimates of biochemical changes in the src-FAK and src-PLC- and VEGF signal transduction pathways\",\"end of treatment|every 2 weeks for cycles 1 and 2; then every 4 weeks|at the MTD\",\"Completed\",,\"March 27, 2023\"\n",
      "557,\"Determine the recommended Phase 2 dose of the combination of lucitanib and nivolumab (Phase 1b)|Best Overall Response Rate (Phase 2)\",\"First dose of study drug through at least 100 days after end of treatment (up to approximately 2 years)|From first dose of study drug until disease progression (up to approximately 2 years)\",\"Suspended\",,\"December 20, 2022\"\n",
      "558,\"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets\",\"2 month\",\"Recruiting\",,\"February 8, 2023\"\n",
      "559,\"Incidence and severity of treatment-related adverse events and serious adverse events|Recommended Phase 2 Dose of INT-1B3\",\"Up to 24 months|Up to 24 months\",\"Recruiting\",,\"February 7, 2022\"\n",
      "560,\"Maximum tolerated dose\",,\"Completed\",,\"April 10, 2018\"\n",
      "561,\"Maximum Tolerated Dose (MTD) based upon study drug related dose limiting toxicities (DLTs)\",\"28 days\",\"Unknown status\",\"Active, not recruiting\",\"October 13, 2010\"\n",
      "562,\"Safety as measured by physical examinations, electrocardiograms, laboratory assessments, vital signs, adverse events and serious adverse events\",\"1 year\",\"Withdrawn\",,\"September 27, 2018\"\n",
      "563,\"Part 1: Proportion of subjects with Dose-Limiting Toxicity (DLT)|Part 2: Objective Response Rate (ORR)\",\"From Day 1 until disease progression or Day 28, whichever comes first|Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.\",\"Active, not recruiting\",,\"August 3, 2022\"\n",
      "564,\"To evaluate the pharmacodynamics of a panel of biomarkers following administration of ARQ 501\",\"Up to 30 hours after a single dose of ARQ 501\",\"Completed\",,\"October 19, 2011\"\n",
      "565,\"Response as assessed by RECIST criteria|Progression as assessed by RECIST criteria|Adverse events and other symptoms as assessed by NCI CTCAE v3.0\",\"30 post end of study drug estimated to be ~24 weeks|30 post end of study drug estimated to be ~24 weeks|30 post end of study drug estimated to be ~24 weeks\",\"Completed\",,\"March 24, 2017\"\n",
      "566,\"Determine Maximum Tolerated Dose (MTD) of BP31510\",\"Wach week of treatment for the duration of Cycle 1 up to 4 weeks on Arm 1 and 6 weeks for Arm 2\",\"Completed\",,\"November 8, 2019\"\n",
      "567,\"• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).\",\"{Time Frame: 12 months}\",\"Unknown status\",\"Recruiting\",\"November 24, 2014\"\n",
      "568,,,\"Completed\",,\"March 15, 2012\"\n",
      "569,\"Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF)|Intercept of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22|Concentration Slope of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22\",\"Baseline (Day -1 time matched for each time point); 1, 2, 4 and 6 hours post-dose on Day 1; pre-dose on Day 2; pre-dose, 1, 2, 4 and 6 hours post-dose on Day 22|Baseline (Day -1) to Day 22|Baseline (Day -1) to Day 22\",\"Completed\",,\"December 17, 2019\"\n",
      "570,,,\"Completed\",,\"September 10, 2018\"\n",
      "571,\"To determine the percent 100-day survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic stem cell transplantation (SCT).|To determine the incidence of treatment-related toxicity and acute and chronic graft versus host disease.\",\"100 days|100 days\",\"Completed\",,\"July 18, 2016\"\n",
      "572,\"Safety of CGTC-102 in patients with solid tumors|Efficacy of CGTC-102 in patients with solid tumors\",\"28 days|28 days\",\"Withdrawn\",,\"August 14, 2013\"\n",
      "573,\"Percentage of Participants experiencing Treatment Emergent Adverse Events (TEAEs)|Percentage of Participants Experiencing Any Clinically Significant Laboratory Abnormalities|PK Parameter: Cmax of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy|PK Parameter: AUC_last of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy|PK Parameter: AUC_0-168 of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy|Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies\",\"First dose date up to Day 38|First dose date up to Day 38|Days 1 and 8|Days 1 and 8|Days 1 and 8|Day 1 (Predose) and Day 22\",\"Recruiting\",,\"March 3, 2023\"\n",
      "574,\"Best tumor response, defined as the best objective status recorded among patients with measurable disease at baseline using Response Evaluation Criteria in Solid Tumors version 1.1|Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose, defined as the highest dose at which no more than 1/6 patients experiences dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival|Tumor necrosis\",\"From the start of the treatment until disease progression, assessed up to 3 years|Up to 3 years|4 weeks|From registration to death due to any cause, assessed up to 3 years|Up to 3 years\",\"Active, not recruiting\",,\"October 10, 2022\"\n",
      "575,\"Number of participants with Dose Limiting Toxicity (DLT) for Dose level 1200 mg and 2000 mg|Number of participants with DLT for Dose level 3000 mg|Number of participants with Adverse Events (AEs)|Number of participants with immune-related AEs (irAEs)|Number of participants with infusion-related reactions (IRRs)|Number of participants with serious AEs (SAEs)|Number of participants with complete blood count (CBC) value abnormalities and/or AEs|Number of participants with serum chemistry value abnormalities and/or AEs|Number of participants with urinalysis value abnormalities and/or AEs|Number of participants with prothrombin time/international normalized ratio (PT/INR) value abnormalities and/or AEs|Number of participants with activated partial thromboplastin time (aPTT) value abnormalities and/or AEs|Number of participants with thyroid stimulating hormone (TSH) value abnormalities and/or AEs|Number of participants with free thyroxine (free T4) value abnormalities and/or AEs|Number of participants with electrocardiogram (ECG) abnormalities and/or AEs|Number of participants with vital sign abnormalities and/or AEs|Number of participants with physical exams abnormalities and/or AEs|Eastern Cooperative Oncology Group (ECOG) performance status score|Pharmacokinetics (PK) of ASP1948 in serum: Area under the concentration-time curve (AUC) from the time of dosing to the last measurable concentration (AUClast)|PK of ASP1948 in serum: AUC from the time of dosing extrapolated to time infinity (AUCinf)|PK of ASP1948 in serum: Percentage of AUCinf due to extrapolation from the last measurable concentration to time infinity (AUCinf(%extrap))|PK of ASP1948 in serum: AUC from the time of dosing to the start of next dosing interval (AUCtau)|PK of ASP1948 in serum: maximum concentration (Cmax)|PK of ASP1948 in serum: concentration immediately prior to dosing at multiple dosing (Ctrough)|PK of ASP1948 in serum: dosing time of maximum concentration (tmax)|PK of ASP1948 in serum:dosing: terminal elimination half-life (t1/2)|PK of ASP1948 in serum: time of last measurable concentration (tlast)|PK of ASP1948 in serum: total clearance after intravenous dosing (CL)|PK of ASP1948 in serum: volume of distribution after intravenous dosing (V)\",\"Up to 28 days|Up to 21 days|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to end of treatment period (a maximum of 104 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to end of treatment period (a maximum of 104 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to end of treatment period (a maximum of 104 weeks)|Up to 30 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 108 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)|Up to 90 days after the final IP administration or initiation of a new anticancer treatment, whichever comes first (a maximum of 116 weeks)\",\"Completed\",,\"March 3, 2023\"\n",
      "576,\"Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings|Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings\",\"Baseline up to 30 days after the last dose of study drug (up to 5 years)|Baseline up to 30 days after the last dose of study drug (up to 5 years)|Baseline up to 30 days after the last dose of study drug (up to 5 years)\",\"Completed\",,\"June 22, 2020\"\n",
      "577,\"Objective response rate (ORR)|Adverse events\",\"3 years|3 years\",\"Recruiting\",,\"April 11, 2022\"\n",
      "578,\"Incidence of treatment emergent adverse events (safety and tolerability)\",\"35 months\",\"Recruiting\",,\"February 3, 2023\"\n",
      "579,,,\"Completed\",,\"February 8, 2010\"\n",
      "580,\"To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma by monitoring adverse events, clinical laboratory tests, vital signs, physical examinations, and anti-drug antibody tests.\",\"4 months\",\"Completed\",,\"March 18, 2013\"\n",
      "581,\"Dose Limiting Toxicity (DLT)|Frequency, severity, and duration of treatment-emergent AEs (TEAEs)\",\"First 28 days of treatment|Screening through 90 days after last dose\",\"Terminated\",,\"March 3, 2022\"\n",
      "582,\"Maximum Tolerated Dose (MTD) of perifosine + temsirolimus combination in children with cancer.\",\"2 years\",\"Completed\",,\"March 10, 2017\"\n",
      "583,\"Maximum tolerated dose of PR-104\",\"3 weeks (cycle 1)\",\"Completed\",,\"June 1, 2011\"\n",
      "584,\"Maximum tolerated dose of gemcitabine hydrochloride and capecitabine when combined with imatinib mesylate|Toxicity\",\"By the end of cycle 2|By the end of cycle 2.\",\"Completed\",,\"February 26, 2018\"\n",
      "585,\"Adverse Events|Maximum tolerated dose|Biomarker of OPB-111077\",\"21 days|21 days|21 days\",\"Completed\",,\"September 10, 2019\"\n",
      "586,,,\"Completed\",,\"July 11, 2012\"\n",
      "587,\"Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)|Dose Escalation and Expansion Part: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Dose Expansion Part: Percentage of Participants With Objective Response|Dose Expansion Part: Duration of Response (DOR)|Dose Expansion Part: Percentage of Participants With Disease Control\",\"Cycle 1 (Cycle length is equal to [=] 21 days)|Baseline up to 90 days after the last dose of study drug (approximately 3 years 1 month)|From date of first dose of study drug until first documentation of complete response (CR) or partial response (PR) (up to approximately 3 years 1 month)|From first documented CR or PR until first documentation of recurrent or progressive disease or death (up to approximately 3 years 1 month)]|From first dose of study drug until first documentation of CR or PR or stable disease (SD) (up to approximately 3 years 1 month)\",\"Completed\",,\"March 24, 2023\"\n",
      "588,\"The incidence of MIL97 treatment-emergent adverse events in patients with advanced or metastatic solid tumor\",\"up to 2.5 year after enrollment\",\"Recruiting\",,\"January 19, 2023\"\n",
      "589,\"To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors.\",\"End of treatment phase\",\"Completed\",,\"December 24, 2012\"\n",
      "590,,,\"Completed\",,\"January 13, 2010\"\n",
      "591,\"Number of subjects reporting adverse events|Number of subjects reporting serious adverse events|Number of subjects experiencing a dose-limiting toxicity|Change from Baseline in laboratory evaluations|Change from Baseline in vital signs|Change from Baseline in electrocardiogram evaluations|Overall Response Rate in Select Tumor Types\",\"Screening through 15 months after the last subject enters re-treatment|Screening through 15 months after the last subject enters re-treatment|First dose of study medication through 4 weeks after the first dose of study medication|Screening through 3 months after the last dose of study medication|Screening through 3 months after the last dose of study medication|Screening through 3 months after the last dose of study medication|First dose of study medication through 15 months after the last subject enters re-treatment\",\"Completed\",,\"March 6, 2020\"\n",
      "592,,,\"Completed\",,\"June 8, 2015\"\n",
      "593,,,\"Withdrawn\",,\"July 11, 2012\"\n",
      "594,\"To determine the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) and dose limiting toxicity (DLT) of oral clofarabine when administered once daily for 5 days every 28 days to adult patients with locally advanced or metastatic solid tumors\",\"Length of Study\",\"Completed\",,\"March 19, 2014\"\n",
      "595,\"Overall Response Rate|Maximum Tolerated Dose\",\"From first dose date to progression or last tumor assessment, up to four years and six months.|From Day 1 to Day 21.\",\"Completed\",,\"August 9, 2018\"\n",
      "596,\"Maximum Tolerated Dose (MTD)|Recommended Phase II Dose (RP2D)|Objective Response Rate (ORR)|Incidence of Adverse Events (AEs)\",\"DLT will be evaluated during the first 21-day treatment cycle (Cycle 1)|Day 1 to Day 21 of Cycle 1|Baseline to study completion (24 months)|After signing informed consent until 45 days after the last dose of MRG002\",\"Recruiting\",,\"May 6, 2022\"\n",
      "597,\"Proportion of patients with ototoxic hearing loss\",\"1 year after the initiation of chemotherapy\",\"Not yet recruiting\",,\"December 1, 2022\"\n",
      "598,,,\"Completed\",,\"July 2, 2012\"\n",
      "599,\"Dose Limiting Toxicities (DLTs)|Adverse Events according to CTCAE V5.0\",\"From the time of the first dose (Day 1) until the 2nd dosing (Day 28)|Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days)\",\"Recruiting\",,\"August 31, 2021\"\n",
      "600,,,\"Completed\",,\"July 18, 2012\"\n",
      "601,\"To determine the safety, tolerability, and MTD of oral aza-TdCyd administered daily for 5 days a week for 2 weeks, with one week off, in 21-day cycles\",\"Cycle 1 and Cycle 2\",\"Recruiting\",,\"March 27, 2023\"\n",
      "602,\"Incidence of adverse experiences from oral ONC201 using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\",\"Up to 4 weeks after end of study treatment\",\"Completed\",,\"May 22, 2019\"\n",
      "603,\"Safety and tolerability (CTCAE version 4.0).\",\"up to Week 16\",\"Completed\",,\"July 2, 2017\"\n",
      "604,\"Dose Escalation Study: Maximum-tolerated Dose (MTD) of SC10914|Dose Expansion Study: Recommended Phase II Dose(RP2D) of SC10914\",\"30 days|8 weeks\",\"Unknown status\",\"Recruiting\",\"December 6, 2017\"\n",
      "605,\"Maximum Tolerated Dose of RTA 402\",\"28 day cycles\",\"Completed\",,\"July 30, 2012\"\n",
      "606,\"To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)\",\"cycle 1\",\"Recruiting\",,\"March 10, 2023\"\n",
      "607,\"Maximum tolerated dose (MTD) of lenvatinib in combination with everolimus: Phase 1|Recommended Phase 2 dose (RP2D) of lenvatinib in combination with everolimus: Phase 1|Number of participants with any treatment-emergent (TE) serious adverse event (SAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus|Number of participants with any TE adverse event (TEAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus|Overall Response Rate (ORR) at Week 16 for Phase 2\",\"Cycle 1 (Day 1 to Day 28) of the Treatment Phase|Cycle 1 (Day 1 to Day 28) of the Treatment Phase|From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2 years|From date of first dose up to 28 days after the last dose of study treatment, up to approximately 2 years|Week 16\",\"Completed\",,\"January 30, 2023\"\n",
      "608,\"Frequency of Adverse Event and Severe Adverse Event|Dose limited toxicity（DLT）|Maximum Tolerated Dose（MTD）\",\"2 years|28 days|28 days\",\"Recruiting\",,\"January 26, 2023\"\n",
      "609,\"The number of patients with adverse events|The number of patients with serious adverse events|The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.|The number of patients with changes from baseline laboratory findings, ECGs and vital signs\",\"From time of Informed consent to 30 days post last dose (approximately 1 year).|From time of Informed consent to 30 days post last dose (approximately 1 year)|From first dose of study treatment until the end of Cycle 1 (approximately 21 days).|From time of informed consent to 30 days post last dose (approximately 1 year)\",\"Recruiting\",,\"November 1, 2022\"\n",
      "610,\"Safety|Incidence of graft-versus-host disease\",,\"Unknown status\",\"Active, not recruiting\",\"December 18, 2013\"\n",
      "611,\"To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.\",\"Along the study\",\"Completed\",,\"June 7, 2011\"\n",
      "612,\"Maximum Tolerated Dose (MTD) of Efavirenz|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)\",\"Up to 28 days for each dosing cohort|Up to 28 days for each dosing cohort\",\"Completed\",,\"January 27, 2021\"\n",
      "613,\"Maximum tolerated dose (MTD)\",\"Day 28\",\"Withdrawn\",,\"October 3, 2018\"\n",
      "614,,,\"Completed\",,\"January 15, 2010\"\n",
      "615,,,\"Completed\",,\"July 2, 2012\"\n",
      "616,\"Determine maximum tolerated dose (MTD) of weekly docetaxel in combination with etanercept.\",\"up to 4 years\",\"Completed\",,\"December 6, 2017\"\n",
      "617,\"The incidence of dose-limiting toxicities (DLTs) during the DLT period|Incidence and severity of treatment emergent adverse events (TEAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|Objective Response Rate (ORR)\",\"Up to 6 weeks|Approximately 90 days from last dose; up to 5 years|Approximately 90 days from last dose; up to 5 years|Approximately 90 days from last dose; up to 5 years|Approximately 90 days from last dose; up to 5 years|Up to 5 years\",\"Recruiting\",,\"February 1, 2023\"\n",
      "618,\"Maximum tolerated dose (MTD)|Recommended phase 2 dose\",\"Up to 5 years|Up to 5 years\",\"Recruiting\",,\"March 15, 2023\"\n",
      "619,\"Dose Escalation|Food Effect Cohort|Food Effect Cohort|Food Effect Cohort|Food Effect Cohort|Dose Expansion\",\"Through completion, average of 1 year|Through completion, approx 6 months|Through completion, approximately 6 months|Through completion approximately 6 month|Through completion, approximately 6 mth|Through completion, approximately 43 month\",\"Recruiting\",,\"February 1, 2023\"\n",
      "620,\"Maximum tolerated doses of vorinostat (SAHA) and capecitabine|Safety and tolerability as assessed by CTCAE v3.0\",\"1 cycle|All cycles\",\"Completed\",,\"July 23, 2015\"\n",
      "621,\"Toxicity as assessed by NCI CTCAE v3.0\",\"Completion of study\",\"Completed\",,\"April 19, 2012\"\n",
      "622,\"The dose-limiting toxicities (DLTs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumors|The maximum-tolerated doses (MTDs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumors|The biodistribution and biologic effect of OH2 injection|The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008\",\"6 months|6 months|6 months|2 years\",\"Recruiting\",,\"November 8, 2022\"\n",
      "623,\"Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719\",\"Approximately 8 months\",\"Completed\",,\"December 9, 2020\"\n",
      "624,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP1002|Number of participants with Adverse Events (AEs)|Number of participants with Serious Adverse Events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events (AEs)|Number of participants with vital sign abnormalities and/or adverse events (AEs)|Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)|Number of participants with physical exam abnormalities and/or Adverse Events (AEs)|Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scores\",\"Up to 24 months|Up to 25 months|Up to 27 months|Up to 27 months|Up to 27 months|Up to 27 months|Up to 24 months|Up to 27 months\",\"Recruiting\",,\"March 20, 2023\"\n",
      "625,\"To observe the efficacy of local tumor ablation\",\"through study completion, an average of 1 year\",\"Recruiting\",,\"October 14, 2022\"\n",
      "626,\"Maximum tolerated dose\",\"End of Cycle 1 (i.e. 21 Days)\",\"Suspended\",,\"September 29, 2014\"\n",
      "627,\"Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)|Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs|Part 2: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators|Part 2: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs|Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators\",\"Day 1 Up to Day 21|From Baseline until 4 months|From Baseline until 6 months|From Baseline until 6 months|From Baseline until 6 months\",\"Active, not recruiting\",,\"December 7, 2022\"\n",
      "628,\"Maximum tolerated dose (MTD）|Adverse events (AEs)|Phase II dose (RP2D)\",\"4 weeks|8 weeks|4 weeks\",\"Recruiting\",,\"January 19, 2022\"\n",
      "629,\"Dose-limiting Toxicities (DLTs) of IDE397|Dose-limiting Toxicities (DLTs) of IDE397 in combination with either docetaxel, paclitaxel, gemcitabine and nab-paclitaxel or pemetrexed|Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397|Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with either docetaxel, paclitaxel, gemcitabine and nab-paclitaxel or pemetrexed|Objective Response Rate (ORR) and Duration of Response (DoR)\",\"21 days following the first dose of IDE397|21 - 28 days following the first dose of IDE397|Approximately 2 years|Approximately 2 years|Approximately 2 years\",\"Recruiting\",,\"December 2, 2022\"\n",
      "630,\"Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0|Maximum Tolerated Dose of SLC-391\",\"2 years|21 days\",\"Recruiting\",,\"August 1, 2022\"\n",
      "631,\"MTD of belinostat in combination with isotretinoin determined by dose limiting toxicities graded according to NCI CTCAE 4.0\",\"21 days\",\"Completed\",,\"April 3, 2018\"\n",
      "632,\"Maximum tolerated and recommended dose (MTD) (RD)|Efficacy of F16IL2 in combination with doxorubicin\",\"28 days|8 weeks\",\"Terminated\",,\"February 25, 2014\"\n",
      "633,\"Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)\",\"Baseline up to 3 weeks\",\"Completed\",,\"September 30, 2020\"\n",
      "634,\"Dose Limiting Toxicity\",\"up to 3 weeks of OTX008 treatment\",\"Unknown status\",\"Recruiting\",\"November 9, 2012\"\n",
      "635,\"Maximum tolerated dose and recommended phase II dose\",\"28 days\",\"Completed\",,\"July 23, 2015\"\n",
      "636,,,\"Completed\",,\"September 24, 2012\"\n",
      "637,\"Maximum Tolerated Dose (MTD) of JI-101\",\"28 days (1 cycle)\",\"Completed\",,\"June 24, 2013\"\n",
      "638,,,\"Completed\",,\"July 24, 2012\"\n",
      "639,\"Determine maximum tolerated dose (MTD) of oral irinotecan\",\"length of study\",\"Completed\",,\"February 20, 2014\"\n",
      "640,\"Part1:Number of subjects with DLT in each dose group within 1 cycles (21 days) after the first drug administration|Part1:The maximum tolerated dose (MTD) of HBM4003 combined with toripalimab|Part1:Recommended Phase 2 dose (RP2D) of HBM4003 combined with toripalimab|Part2:ORR, as determined by the Investigator using RECIST 1.1\",\"approximate 21 days|approximate 21 days|approximate 21 days|maximum 2 years\",\"Not yet recruiting\",,\"December 8, 2021\"\n",
      "641,\"To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and select the recommended Phase 2 dose (RP2D).|To determine the safety and tolerability of SPX-101 in patients with solid tumors\",\"The analysis will extend through 28 days after the last administration of study drug.|The analysis will extend through 28 days after the last administration of study drug.\",\"Not yet recruiting\",,\"February 9, 2022\"\n",
      "642,\"Number of patients with adverse events.\",\"3 year\",\"Unknown status\",\"Recruiting\",\"February 19, 2018\"\n",
      "643,\"Objective response rate (ORR)\",\"At the end of every 2 cycles (each cycle is 21 days)\",\"Withdrawn\",,\"September 13, 2022\"\n",
      "644,\"Adverse events (AE), serious adverse events (SAEs), suspected unexpected serious adverse reaction (SUSAR), physical examination, etc. (CTCAE 5.0 standard)|Tolerability: Ratio of Dose reductions or interruptions|Incidence rate of dose limiting toxicities (DLTs)\",\"Up to 24 months|Up to 24 months|cycle 1 (each cycle is 21 days)\",\"Recruiting\",,\"March 22, 2022\"\n",
      "645,\"To investigate dose-limiting toxicity and estimate maximum tolerated dose.\",\"7 weeks\",\"Completed\",,\"June 11, 2020\"\n",
      "646,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Dose-limiting Toxicities\",\"From the first dose until 30 days after the last dose (approximately 2 years 7 months)|Cycle 1 (Cycle length=21 days)\",\"Completed\",,\"May 20, 2021\"\n",
      "647,\"Maximum tolerated dose\",\"End of Cycle 1 (i.e. 21 Days)\",\"Suspended\",,\"September 29, 2014\"\n",
      "648,\"To evaluate the feasibility of obtaining two serial tumor biopsies and plasma pharmacokinetics for the determination of AR-67 half life in tumor and plasma during day 1 of AR-67 treatment given on days 1, 4, 8, 12 and 15 of an every 21-day cycle.\",\"Cycle 1 days 1 and 2\",\"Completed\",,\"August 14, 2013\"\n",
      "649,\"Objective response rate (ORR)\",\"6 months\",\"Recruiting\",,\"March 7, 2023\"\n",
      "650,\"Safety Profile Measured by Grade ≥3 TEAEs\",\"3 years\",\"Recruiting\",,\"June 30, 2022\"\n",
      "651,\"Maximum tolerated dose (MTD) defined as the highest dose level tested at which =< 2/6 patients experience dose limiting toxicities (DLT) graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE) version 4.0|Incidence of adverse events (AEs) graded according to NCI CTCAE version 4.0\",\"Up to day 35|Up to 28 days post-treatment\",\"Recruiting\",,\"September 1, 2022\"\n",
      "652,\"Determination of Maximum Tolerated Dose (MTD) and establish the RP2D of BBP-398.\",\"Completion of 1 Cycle ( 28 days)\",\"Recruiting\",,\"February 1, 2023\"\n",
      "653,\"Part 1 - Adverse Event (AE)|Part 1 - RP2D Of Fruquintinib In Combination With Tislelizumab|Part 2 - Objective Response Rate (ORR)\",\"Up to 28 Days in Part 1|Up to 28 Days in Part 1|through study completion, an average of 3 years\",\"Recruiting\",,\"June 30, 2022\"\n",
      "654,\"Efficacy as measured by Objective Response Rate\",\"Approximately up to 2 years\",\"Active, not recruiting\",,\"November 10, 2021\"\n",
      "655,\"Safety Profile Measured by Grade ≥3 TEAEs\",\"3 years\",\"Recruiting\",,\"February 15, 2023\"\n",
      "656,\"Safety assessment: Adverse event|Effectiveness assessment: Disease control rate\",\"Up to 2 years|Up to 2 years\",\"Unknown status\",\"Recruiting\",\"October 20, 2020\"\n",
      "657,\"Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)|Phase 2: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\",\"Duration of study treatment and up to 90 days after the last dose [approximately 3 years]|Measured every 8 weeks for duration of study treatment [approximately 12 months]\",\"Completed\",,\"January 13, 2022\"\n",
      "658,\"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)\",\"From time of informed consent through 12 weeks after last dose of MEDI0562\",\"Completed\",,\"January 29, 2018\"\n",
      "659,\"Occurrence of Drug Limited Toxicities (DLTs)|Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).|Number of patients with changes in laboratory parameters from baseline|Number of patients with changes in electrocariogram (ECG) from baseline|Number of participants with changes in left ventricular ejection fraction (LVEF) from baseline|Number of participants with changes in Clinically Significant Vital Sign from baseline\",\"From Time of First dose through DLT observation period, 28 days|From the start of treatment until up to 90 days after the last dose of study drug|From the start of treatment until up to 30(±7) days after the last dose of study drug|From the start of treatment until up to 30(±7) days after the last dose of study drug|From the start of treatment until up to 30(±7) days after the last dose of study drug|From the start of treatment until up to 30(±7) days after the last dose of study drug\",\"Recruiting\",,\"March 24, 2023\"\n",
      "660,\"Expression status of biomarkers and their dynamic changes during treatment and follow-up|Tumor short-term response to therapeutics|Tumor long-term response to therapeutics\",\"From the date of enrollment until the date of disease progression, assessed up to 3 years|Within 1 month after the completion of radiotherapy|up to 3 years of follow-up\",\"Recruiting\",,\"December 28, 2021\"\n",
      "661,\"Determination of the safety and tolerability of BBI608 and BBI503 when administered in combination by assessing dose-limiting toxicities (DLTs)|Determination of the Recommended Phase 2 Dose of BBI608 and BBI503 when administered in combination based on DLT criteria, pharmacokinetic/pharmacodynamic observations and tolerability overall\",\"4 weeks|20 weeks\",\"Completed\",,\"April 5, 2022\"\n",
      "662,\"Incidence of Adverse Events (AEs)|Incidence of dose-limiting toxicities (DLTs)|Maximum tolerated dose (MTD) or a tolerated dose below MTD (if MTD is not reached)|Recommended expansion dose (RED)\",\"From signing of informed consent form (ICF) until 10 weeks following the last dose or start of new anticancer therapy.|First 21 days of dosing.|From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.|From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.\",\"Completed\",,\"December 22, 2022\"\n",
      "663,,,\"Completed\",,\"June 8, 2015\"\n",
      "664,\"Number Of Participants With Treatment-emergent Adverse Events (TEAEs)|Number Of Adverse Events (AEs) By The Dose Of iNKT Cell Therapy|Number Of TEAEs By The Dose Of iNKT Cell Therapy|Severity Grade Of AEs By Dose Of iNKT Cell Therapy|Number Of Dose-limiting Toxicities\",\"Baseline through 12 months|Baseline through 12 months|Baseline through 12 months|Baseline through 12 months|Baseline through first 14 days after administration\",\"Recruiting\",,\"October 24, 2022\"\n",
      "665,,,\"Completed\",,\"July 11, 2012\"\n",
      "666,\"Maximum tolerated dose (MTD) of pazopanib and GSK1120212 when combined in patients with solid tumors|Adverse events as a measure of the safety and tolerability profile of pazopanib in combination with GSK1120212 in patients with solid tumors\",\"Approximately one year|Approximately two years\",\"Completed\",,\"August 29, 2018\"\n",
      "667,\"MTD/RP2D|DLT occurrence and frequency (dose escalation phase)|AE, SAE occurrence and frequency (according to NCI CTCAE 5.0)\",\"through study completion, an average of 8 months.|The first period of LB4330 treatment (28 days for the first subject in the first dose group, 21 days for the rest subjects. If the administration is delayed, the DLT evaluation period should be extended to 7 days after the third administration)|up to 90 days following last dose\",\"Recruiting\",,\"February 1, 2023\"\n",
      "668,\"Dose limiting toxicities (DLTs) (Phase 1)|Recommended Phase 2 Dose (RP2D) (Phase 1)|Overall Response Rate (ORR) Phase 2\",\"Within 28 days of the first repotrectinib dose|Within 28 days of the last patient dosed in escalation|Two to three years after first dose of repotrectinib dose\",\"Recruiting\",,\"January 26, 2023\"\n",
      "669,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES101|Frequency of adverse events of ES101|Severity of adverse events of ES101\",\"Up to 2-3 years|Up to 2-3 years|Up to 2-3 years\",\"Terminated\",,\"April 29, 2022\"\n",
      "670,\"Safety: Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3\",\"Continuous assessment throughout the duration of the trial: starting with dosing on Day 1 until after 30 day follow-up following the last dose\",\"Completed\",,\"July 13, 2012\"\n",
      "671,\"Comparison of frequency, phenotype and transcriptional profile of the different immune subsets in the tumor following adoptive cell therapy infusion using spectral flow cytometry and RNA sequencing\",\"3 months following ACT\",\"Recruiting\",,\"August 1, 2022\"\n",
      "672,\"Percentage of Participants with Confirmed Overall Response, as Assessed by the Investigator According to RECIST v1.1 or According to RANO Criteria for Primary CNS Tumors\",\"Up to 4 years\",\"Active, not recruiting\",,\"March 6, 2023\"\n",
      "673,\"To determine the maximum tolerated doses and dose limiting toxicities of LBH589 in combination with gemcitabine when administered to patients with advanced incurable malignant solid tumors.\",\"18 months\",\"Terminated\",,\"August 19, 2013\"\n",
      "674,,,\"Terminated\",,\"April 5, 2019\"\n",
      "675,\"Toxicity evaluated according to the common toxicity criteria for adverse events (AEs) (CTCAEv4.0)\",\"2 years\",\"Completed\",,\"March 25, 2016\"\n",
      "676,\"Dose-Limiting Toxicity (DLT) in Part 1|Maximum Tolerated Dose (MTD) in Part 1|Overall Response Rate (ORR) in Part 2|Treatment-Emergent Adverse Event (TEAE) in Part 1 and 2\",\"First 28 days of treatment|First 28 days of treatment|From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years|Until 30 days after the last dosing\",\"Recruiting\",,\"December 21, 2021\"\n",
      "677,\"%PECmax|%PEAUC\",\"0 to 72 hours|0 to 72 hours\",\"Completed\",,\"October 1, 2020\"\n",
      "678,\"The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.|The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297\",\"Each visit after IMP4297 administrated (through study completion, an average of 10 months)|Within 28 days after IMP4297 administrated\",\"Completed\",,\"March 30, 2021\"\n",
      "679,\"Dose limiting toxicity\",\"Throughout the course of the study\",\"Completed\",,\"October 19, 2011\"\n",
      "680,\"Incidence of adverse events|Maximum tolerated dose and recommended phase II dose of liposomal irinotecan in combination with veliparib\",\"Up to 4 weeks|At 28 days\",\"Active, not recruiting\",,\"November 9, 2022\"\n",
      "681,\"To determine the incidence of treatment emergent Adverse Events (Safety and Tolerability) of various doses of IOS-1002 administered alone and/or in combination with a PD-1 mAb in subjects with advanced solid tumors\",\"From date of randomization until the date of first documented progression (end of study) or date of death from any cause, whichever came first, assessed up to 48 months\",\"Recruiting\",,\"March 17, 2023\"\n",
      "682,\"To determine the RP2D of NUC-1031 administered as either an I.V. weekly or twice-weekly schedule in patients with advanced solid tumours.|To further evaluate the safety profile of NUC-1031 in an expanded cohort at RP2D\",\"1.5 years|1 year\",\"Completed\",,\"August 27, 2015\"\n",
      "683,\"Progression-free survival (PFS) (Cohort I)|Best objective response (Cohort II)|Overall response rate (ORR) (Cohort II)\",\"From registration to documented disease progression or death from any cause, assessed up to 3 years|From the start of the treatment until disease progression/recurrence, assessed up to 3 years|From the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years\",\"Not yet recruiting\",,\"December 6, 2022\"\n",
      "684,\"Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2\",\"from day1 to day 42(cycle 1 and cycle2 ,each cycle is 21days)\",\"Completed\",,\"May 5, 2022\"\n",
      "685,\"Part A: Adverse Events|Part A: TRX518 peak concentration (Cmax)|Part A: Time to peak concentration (Tmax)|Part A: Area under the curve (AUC)|Part A: Define a maximum single dose at which there are tolerable side effects and/or maximum PK/PcD parameter changes|Parts B and C: Adverse Events\",\"through 30 days post last dose|various timepoints through 1 week post dose|various timepoints through 1 week post dose|various timepoints through 1 week post dose|End of Cycle 1 (Day 28)|through 30 days post dose\",\"Completed\",,\"August 14, 2019\"\n",
      "686,\"Area under the plasma concentration-time curve from zero to infinity for osimertinib|Maximum plasma concentration for osimertinib\",\"On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs post-dose|On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs post-dose\",\"Completed\",,\"November 25, 2022\"\n",
      "687,\"Number of Patients Experiencing Dose Limiting Toxicity (DLT)\",\"Each patient will be followed for 22 days\",\"Completed\",,\"February 9, 2017\"\n",
      "688,\"Adverse events|Anti-tumour activity\",\"From screening visit through study completion, an average of 1 year|information on how the event is determined and over what estimated period of time (e.g., \"\"From date of sceening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months\",\"Active, not recruiting\",,\"April 5, 2022\"\n",
      "689,\"Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants with Dose Interruptions due to TEAE|Number of Participants who Undergo Dose Reductions due to TEAE|Number of Participants Discontinue study due to TEAE\",\"Up to Day 28|Up to 12 months|Up to 12 months|Up to 12 months|Up to 12 months\",\"Recruiting\",,\"December 13, 2022\"\n",
      "690,\"Incidence of adverse events by type, frequency, severity, and causality (safety)|Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)|Incidence of serious adverse events by type, frequency, severity, and causality (safety)|Incidence of Infusion-related adverse events by type, frequency, severity, and causality (safety)|Incidence of dose-limiting toxicities (safety)|Determine the MTD|Determine the RP2D\",\"Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months|Baseline through study completion at up to approximately 24 months\",\"Withdrawn\",,\"January 26, 2023\"\n",
      "691,\"Number of Participants With At Least One Adverse Event, with Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Percentage of Participants with Objective Response as Determined By The Independent Review Facility (IRF) According To Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Arm A)|Progression-Free Survival (PFS) as determined by the Independent Review Facility (IRF) according to RECIST v 1.1 (Arm F)\",\"From screening to up to 90 days after the last dose of study drug (up to approximately 55 months)|From screening to end of study (approximately 55 months)|From randomization to the first occurrence of disease progression or death from any cause (whichever occurs first)\",\"Completed\",,\"July 9, 2021\"\n",
      "692,,,\"Completed\",,\"July 18, 2012\"\n",
      "693,\"Overall response rate (ORR)\",\"Up to the last participant having been followed for approximately 10 months, summing up to approximately 2.5 years\",\"Active, not recruiting\",,\"March 24, 2023\"\n",
      "694,,,\"Completed\",,\"August 9, 2012\"\n",
      "695,\"To determine the maximum tolerated dose (MTD)\",\"From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (28 days)\",\"Recruiting\",,\"January 26, 2022\"\n",
      "696,\"Incidence of treatment-emergent adverse events and dose-limiting toxicities (safety and tolerability) and MTD of TAS-117 in Part A|Recommended Phase 2 Dose (RP2D) of TAS-117 in Part A|Objective Response Rate (ORR) in Part B (including all patients with germline PTEN mutations in Part A)\",\"21 days for DLT evaluation, approximately 7 months for the others|21 days for DLT evaluation, approximately 7 months for the others|Approximately 6 months\",\"Active, not recruiting\",,\"March 20, 2023\"\n",
      "697,,,\"Completed\",,\"December 19, 2013\"\n",
      "698,\"Assess safety and tolerability of study drug in subjects with advanced solid tumors who have BRAF and/or NRAS mutations\",\"Up to treatment discontinuation + 30 days with an estimated treatment duration of 24 weeks\",\"Completed\",,\"May 3, 2013\"\n",
      "699,\"Evaluate the safety and tolerability of escalating doses of single agent IV T3011 Characterize DLTs and identify the MTD and/or the RP2D of single agent IV T3011\",\"Up to 2 years from first dose of T3011\",\"Recruiting\",,\"November 7, 2022\"\n",
      "700,\"Safety and Tolerability: incidence of adverse events and any dose limiting toxicity\",\"Up to 30 months\",\"Recruiting\",,\"August 3, 2021\"\n",
      "701,,,\"Completed\",,\"April 5, 2013\"\n",
      "702,,,\"Completed\",,\"December 19, 2013\"\n",
      "703,\"Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A|Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death\",\"Week 1 up to Week 4 (Part A)|Baseline up to 4 weeks after the last Sym004 administration, up to a maximum of 41.1 weeks\",\"Completed\",,\"August 23, 2017\"\n",
      "704,\"Maximum Tolerated Dose (MTD)\",\"Continual reassessment method during 28 day cycles, weekly visits for first cycle and monthly for each additional cycle\",\"Terminated\",,\"July 31, 2012\"\n",
      "705,,,\"Completed\",,\"October 23, 2012\"\n",
      "706,\"Explore the maximum tolerated dose (MTD)\",\"21 days after first dosing\",\"Recruiting\",,\"January 5, 2022\"\n",
      "707,\"Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in Only the Largest Diameter of the Tumor Lesions Are Used.\",\"12 Weeks\",\"Completed\",,\"April 11, 2012\"\n",
      "708,\"Maximum Tolerated Dose (MTD) of Pazopanib in combination chemotherapy\",\"42 days\",\"Not yet recruiting\",,\"September 19, 2018\"\n",
      "709,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Arm A)|Incidence of dose limiting toxicities (DLTs) (Arm A)|Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the combination of MM3814 and avelumab in patients with deoxyribonucleic acid (DNA) damage response (DDR) deficient advanced solid tumors\",\"Up to 1 year post treatment|Up to 28 days|Up to 1 year post treatment\",\"Recruiting\",,\"February 16, 2023\"\n",
      "710,\"Safety and tolerability of TAS-119 in combination with paclitaxel\",\"Safety monitoring will begin at the time of the first dose of TAS-119, and will continue until all patients are discontinued from treatment or until 12 months from the last patient enrolled (up to 3 years).\",\"Terminated\",,\"February 21, 2020\"\n",
      "711,\"Dose-Limiting Toxicity and Maximum Tolerated Dose of HS-10342.\",\"5 weeks\",\"Completed\",,\"March 9, 2023\"\n",
      "712,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Treatment-related Treatment-emergent Adverse Events|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03|Number of Participants Who Experienced Dose Limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)\",\"From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)|From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)|From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)|Cycle 1 only (28-day cycle)|From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)\",\"Completed\",,\"January 26, 2023\"\n",
      "713,\"MTD (maximum tolerated dose) and RD (recommended dose) of PM060184.\",\"From treatment onset to end of treatment\",\"Completed\",,\"November 1, 2015\"\n",
      "714,\"Dose Escalation Stage - the dose limiting toxicities (DLTs), using NCI CTCAE v4.0, of oral CB-5083 in subjects with advanced tumors|Dose Escalation Stage - the pharmacokinetic profile (PK) of oral CB-5083 in subjects with advanced solid tumors; parameters include AUC, Cmax, Tmax and T1/2|Dose Expansion Stage - safety and tolerability of oral CB-5083 administered to subjects with RAS mutated metastatic colorectal cancer (mCRC) at the RP2D, using NCI CTCAE v4.0|Dose Expansion Stage - safety and tolerability of CB-5083 in subjects with advanced renal-cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET) or solid tumors with RAS-MAPK mutations, if such arms are opened per Sponsor, using NCI CTCAE v4.0|Food Effect Stage - the effect of a standard meal on the plasma concentration of oral CB-5083 in subjects with advanced solid tumors\",\"the first 28 days of treatment with CB-5083|day 1 to day 5 of Cycle 1 and day 1 and day 2 of Cycle 2|day 1 of Cycle 1 through 28 days after the subjects's last treatment|from day 1 of Cycle 1 through 28 days after the subjects's last treatment|from day 1 of Cycle 1 through day 5 of Cycle 1\",\"Terminated\",,\"February 27, 2018\"\n",
      "715,\"Safety of the combined regimen of SHR2150, chemotherapy, PD-1 or CD47 antibody|Identify a RP2D of SHR2150 when given in combined regimen|Object response rate (ORR)\",\"60 days after last dose|30 days|24 month\",\"Unknown status\",\"Recruiting\",\"October 19, 2020\"\n",
      "716,\"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride alone, defined as the highest dose level at which < 2 of 6 patients experience treatment-related dose limiting toxicity (DLT) (Arms 1 and 1E)|MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and cisplatin, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 3 and 3E)|MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)\",\"Up to day 28|Up to day 28|Up to day 28\",\"Completed\",,\"July 25, 2022\"\n",
      "717,\"Objective response rate (ORR )|Duration of response (DOR)\",\"Throughout the duration of the study; up to 2 years|Throughout the duration of the study; up to 2 years\",\"Active, not recruiting\",,\"May 23, 2022\"\n",
      "718,\"Maximum Tolerated Dose (MTD) of Gemzar + Adriamycin Given with Velcade\",\"Prior to each 2 week cycle\",\"Active, not recruiting\",,\"September 23, 2022\"\n",
      "719,\"Number of participants with dose-limiting toxicities (DLTs)|Number of participants with adverse events (AEs)|Number of participants with adverse events of special interest (AESIs)|Number of participants with serious adverse events (SAEs)\",\"Up to Day 28|through study completion, an average of 1 year|through study completion, an average of 1 year|through study completion, an average of 1 year\",\"Active, not recruiting\",,\"March 10, 2023\"\n",
      "720,\"The maximum tolerated dose (MTD) in the pediatric cohort|6-month disease control rate in the adult cohort\",\"2 months after inclusion ( treatment initiation)|6 months after inclusion ( treatment initiation)\",\"Not yet recruiting\",,\"March 25, 2022\"\n",
      "721,\"Maximum tolerated dose (MTD)/RP2D of LCL161 when administered in combination with once weekly paclitaxel\",\"24 months\",\"Completed\",,\"December 19, 2020\"\n",
      "722,\"Incidence and severity of Adverse Events (AEs) in Part A|MTD of CBP-1018 in Part A|Recommended Phase 2 dose (RP2D) of CBP-1018 in Part A|ORR in Part B\",\"12 months|12 months|12 months|enrollment to end of treatment up to 3 years\",\"Not yet recruiting\",,\"June 18, 2021\"\n",
      "723,\"Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0\",\"After CAR-NK cells infusion, up to 52 weeks.\",\"Recruiting\",,\"June 8, 2022\"\n",
      "724,\"To establish the phase II recommended dose of daily oral BKM120|EXPANSION COHORT A:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim support|EXPANSION COHORT B: To obtain a preliminary description of efficacy of the regimen established in Group 1 among patients with tumors harboring PTEN mutation or homozygous deletion.\",\"2 years|2 years|2 years\",\"Completed\",,\"March 31, 2017\"\n",
      "725,\"Percent Change in Peripheral blood CRP level\",\"Baseline and Within 28 days\",\"Recruiting\",,\"March 21, 2023\"\n",
      "726,\"Evaluate the safety of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD)|Evaluate the tolerability of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD)|Confirm the recommended Phase 2 dose (RP2D)|Evaluate efficacy of MT-6402 in subjects with advanced cancer by objective response rate (ORR) with RECIST 1.1\",\"28 days (Part 1)|28 days (Part 1)|28 days (Part 2)|up to 2 years (Part 2)\",\"Recruiting\",,\"February 28, 2022\"\n",
      "727,\"Rate and Severity of Dose-limiting toxicity （DLT）|Maximum tolerated dose (MTD)\",\"up to 28 days after last dose of study drug|up to 21days following first dose\",\"Recruiting\",,\"March 14, 2023\"\n",
      "728,\"number of adverse events|maximum tolerated dose\",\"21 days|21 days\",\"Completed\",,\"February 12, 2019\"\n",
      "729,\"Percentage of Participants with Adverse Events|Percentage of Participants with Dose-Limiting Toxicities (DLTs)\",\"Up to 28 months|28 Days in Part A\",\"Completed\",,\"November 8, 2022\"\n",
      "730,\"To determine the maximally tolerated dose of SU011248 (dosed on Schedule 4/2 or 2/1) when given in combination with gemcitabine\",\"From screening until at least 28 days beyond discontinuation of study treatment\",\"Completed\",,\"April 30, 2010\"\n",
      "731,\"Determine the maximally tolerated doses and dose limiting toxicities of LBH589 in combination with paclitaxel and carboplatin. Preliminary anti-tumor activity will also be assessed.\",\"18 months\",\"Completed\",,\"December 30, 2010\"\n",
      "732,\"Maximum Tolerated Dose (MTD) of VSV-IFNβ-NIS Monotherapy and Combination Therapy\",\"21 days after VSV-IFNβ-NIS Monotherapy or Combination Therapy for each dose cohort\",\"Completed\",,\"April 27, 2022\"\n",
      "733,\"Dose limiting toxicity (DLT)|Maximum tolerated dose (MTD)\",\"cycle1 (each cycle is 28-days)|cycle1 (each cycle is 28-days)\",\"Recruiting\",,\"May 18, 2021\"\n",
      "734,\"The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities and evaluation of Adverse Events in relation to Study Drug.\",\"Cycle 1\",\"Unknown status\",\"Active, not recruiting\",\"September 18, 2014\"\n",
      "735,\"To determine the MTD and recommended Phase II dose of IMC-A12 (anti-IGFR monoclonal antibody) IV once weekly in combination with temsirolimus IV weekly to children with refractory solid tumors.|To define toxicities and characterize pharmacokinetics.\",,\"Withdrawn\",,\"July 2, 2017\"\n",
      "736,\"Dose limiting toxicities\",\"Within the first 30 days of completion of first cycle\",\"Completed\",,\"April 26, 2017\"\n",
      "737,\"Phase II: Bevacizumab plus dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer|Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.\",\"Courses repeat every 28 days in the absence of unacceptable toxicity.|at end of course 2 (each course is 28 days)\",\"Terminated\",,\"January 16, 2012\"\n",
      "738,\"Assess the safety and tolerability of CT-0508 by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors.|Assess the feasibility of manufacturing CT-0508 by describing the percentage of products passing release criteria.|Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only)\",\"14 months|12 months|14 months\",\"Recruiting\",,\"December 19, 2022\"\n",
      "739,\"To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors\",\"30 Days post treatment initiation\",\"Recruiting\",,\"April 20, 2022\"\n",
      "740,\"Dose-limiting toxicity, incidence of treatment-emergent adverse events\",\"single dose, and twice daily continuous dosing for 21 days\",\"Completed\",,\"May 13, 2019\"\n",
      "741,\"Maximum Tolerated Dose (MTD)\",\"1 year\",\"Completed\",,\"April 23, 2021\"\n",
      "742,\"Establish maximum tolerated dose of carboplatin in combination with 5'azacytidine\",\"1 year\",\"Active, not recruiting\",,\"September 24, 2021\"\n",
      "743,,,\"Completed\",,\"August 9, 2012\"\n",
      "744,\"Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors|Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma|Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Response Assessment in Neuro-Oncology (RANO) Criteria in Participants With Atypical Teratoid Rhabdoid Tumor (ATRT)|Percentage of Participants With Clinical Benefit as Determined by the Investigator According to RECIST v1.1 Criteria in Participants With Osteosarcoma|Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1 in Participants With Solid Tumors|PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma|PFS as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|PFS as Determined by the Investigator Using RANO Criteria in Participants With ATRT|Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest|Maximum Serum Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) of Atezolizumab|Atezolizumab Serum Concentration at Washout|Area Under the Concentration-Time Curve (AUC) of Atezolizumab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab\",\"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)|Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)|From baseline up to approximately 42 months|Predose (PRD; 0 hours [hr]), 0.5 hr post-infusion (P-I; infusion duration=30-60 minutes) on Day (D) 1 of Cycle (Cy) 1 and 4 (1 Cy=21 days)|PRD (0 hr) on D1 of Cy2,3,4,8, 12, 16 (1 Cy=21 days) and every 8 cycles thereafter; at any time during visit at study drug discontinuation visit, at least 90 days (maximum 150 days) after the last dose of study drug (up to approximately 42 months)|At least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)|PRD (0 hr), 0.5 hr P-I (infusion duration=30-60 minutes) on D1 of Cy1; at any time during visit on Cy1D8 (1 Cy=21 days)|PRD (0 hr) on D1 of Cy1,2,3,4,8,12,16 (1 Cy=21 days) & every 8 cycles thereafter; at any time during visit on Cy1D8, study drug discontinuation, at least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)\",\"Terminated\",,\"February 25, 2020\"\n",
      "745,\"Number of Participants With Dose-limiting Toxicities (DLT) in Part 1|Number of Participants With Adverse Events (AEs) by Seriousness|Duration of Most Frequently Observed Adverse Events (AEs)|Number of Participants With Best Overall Response (BOR) in Part 1|Number of Participants With Best Overall Response (BOR) in Part 2|Maximum Tolerated Dose (MTD) in Part 1\",\"Part 1 Baseline up to Day 28|Baseline up to 30 days after last dose|Baseline up to 30 days after last dose|Part 1 Baseline, last week (Day 15 to 23) of cycles 2, 4, 6, 8 and thereafter every 3 cycles up to 30 days after last dose|Part 2 Baseline, last week (Day 15 to 23) of cycles 2, 4, 6, 8 and thereafter every 3 cycles up to 30 days after last dose|Part 1 Day 1 up to Day 28\",\"Completed\",,\"February 11, 2013\"\n",
      "746,\"Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21\",\"Day 1 up to Day 21 of Cycle 1\",\"Completed\",,\"October 23, 2018\"\n",
      "747,\"Part 1: Percentage of Participants Reporting One or More Dose-Limiting Toxicities (DLTs) Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Part 1: Number of Participants with Clinically Significant physical examinations, electrocardiograms (ECGs), and laboratory assessments|Part 2: Overall response rate (ORR)\",\"Up to 28 days in Part 1|Up to 28 days in Part 1|up to approximately 3.5 years\",\"Recruiting\",,\"October 14, 2022\"\n",
      "748,\"Safety and toxicity evaluated according to the NCI CTCAE version 3.0|Response and progression using RECIST criteria|Response duration measured from the time complete response or partial response (whichever is first recorded) is documented until the first date that recurrent or progressive disease is objectively documented|Stable disease duration measured from the time of start of therapy until the criteria for progression are met|Pharmacokinetics\",\"Every 3 weeks|Every 6 weeks|Every 3 months|Every 3 months|cycle 1 and 2\",\"Completed\",,\"April 8, 2020\"\n",
      "749,\"Toxicity of DMXAA|Maximum tolerated dose of DMXAA|Pharmacokinetics of DMXAA|Effect of DMXAA on coagulation parameters, TNF and other cytokine production, nitric oxide, and serotonin production\",,\"Completed\",,\"March 18, 2009\"\n",
      "750,\"Maximum tolerated dose for up to 90 days after completion of study treatment|Minimum dose required for local control as assessed by RECIST one-dimensional criterion and volumetric analysis for 90 days after completion of study treatment\",\"day 1 through 90|day 1 through 90\",\"Completed\",,\"March 14, 2017\"\n",
      "751,\"Maximum Tolerated Dose of AZD5312 in pts with advanced solid tumours where androgen receptor pathway is a potential factor.|Safety and tolerability of AZD5312 in patients assessed in terms of AEs, labs, vitals, ECGs and conc. med use.|Recommended Phase 2 Dose of AZD5312 in patients with advanced solid tumours where androgen receptor pathway is a potential factor.\",\"13 months|13 months|13 Months\",\"Completed\",,\"July 14, 2016\"\n",
      "752,\"Adverse Events (AEs)|Serious Adverse Events|Adverse Events of Special Interest (AESI)|Identification of Maximum Tolerated Dose (MTD) & Incidence of Dose-limiting Toxicities (DLTs)\",\"2 years|2 years|2 years|4 weeks after the CAR-T cells infusion\",\"Not yet recruiting\",,\"March 24, 2023\"\n",
      "753,\"Maximally Tolerated Dose (MTD) of PEGPH20 when given to patients with cancer|Safety endpoints including assessment of both serious and non-serious AEs\",\"To be evaluable for MTD determination, a patient must have completed the Cycle 1 study drug doses and the associated assessments for safety and toxicity evaluation|From Day 1 of Treatment Cycle 1, thru to Follow-up (within 28 days after last dose of PEGPH20)\",\"Completed\",,\"January 29, 2014\"\n",
      "754,\"Overall Response Rate by RECIST v 1.1\",\"1 year\",\"Terminated\",,\"December 1, 2021\"\n",
      "755,\"Response confirmed by non-investigational CT or MRI, or confirmed by biopsy\",\"within the first 30 days after four-cycle treatment\",\"Unknown status\",\"Recruiting\",\"January 28, 2016\"\n",
      "756,\"Safety and tolerability of XNW7201 tablets in subjects with advanced solid tumor;|The dose-limiting toxicity (DLT) of XNW7201\",\"From date of first dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to about 6 months|At the end of Cycle 1 (each cycle is 30 days)\",\"Completed\",,\"February 16, 2023\"\n",
      "757,\"Safety and toxicity profile as assessed by NCI CTCAE version 3.0|Recommended Phase II dose of Ixabepilone when administered with Sunitinib\",\"Approximately 18-30 months|Schedule A (12 - 18 months); Schedule B (6 -12 months after Schedule A)\",\"Completed\",,\"October 9, 2015\"\n",
      "758,\"Treatment-emergent adverse events (TEAEs) up to Day 21|Objective Response Rate (ORR)\",\"in dose escalation part, an average of 21 days|through dose expansion part completion, approximately 2.5 year\",\"Recruiting\",,\"February 3, 2023\"\n",
      "759,\"Characterize the safety and tolerability of BPI-421286 in subjects with advanced solid tumor malignancies|determine the recommended Phase II dose (RP2D) and preliminarily to develop a suitable dosing regimen\",\"20 months|20 months\",\"Recruiting\",,\"April 7, 2022\"\n",
      "760,\"Objective response rate (ORR)\",\"From the time of first dose until objective disease progression, an average of 6 months\",\"Recruiting\",,\"January 4, 2023\"\n",
      "761,\"Treatment failure (changes in hemoglobin levels)\",\"From date of randomization until the week 8\",\"Terminated\",,\"August 16, 2022\"\n",
      "762,\"AEs (adverse events)|Assessment of ORR (objective response rate)|Assessment of ORR (objective response rate)|Assessment of ORR (objective response rate)|Assessment of DCR (disease control rate)|Assessment of DCR (disease control rate)|Assessment of DCR (disease control rate)|Assessment of PFS (progression free survival)|Assessment of PFS (progression free survival)|Assessment of PFS (progression free survival)\",\"Throughout the whole clinical trial, around 2 years.|For Part 2, ORR is measured on Day28 for cycle 1, and after cycle 1, ORR is measured when every 2 cycles finished (for Part 2, each cycle is 28 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 3, ORR is measured at the end of each cycle (for Part 3, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 4, ORR is measured at the end of each cycle (for Part 4, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 2, DCR is measured on Day28 for cycle 1, and after cycle 1, DCR is measured when every 2 cycles finished (for Part 2, each cycle is 28 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 3, DCR is measured at the end of each cycle (for Part 3, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 4, DCR is measured at the end of each cycle (for Part 4, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 2, PFS is measured on Day28 for cycle 1, and after cycle 1, PFS is measured when every 2 cycles finished (for Part 2, each cycle is 28 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 3, PFS is measured at the end of each cycle (for Part 3, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.|For Part 4, PFS is measured at the end of each cycle (for Part 4, each cycle is 46 days), until the date of disease progression or death, whichever came first, assessed up to 2 years.\",\"Unknown status\",\"Recruiting\",\"December 7, 2020\"\n",
      "763,\"Overall response rate (ORR) defined as the percentage of participants with a best overall response of CR or PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the investigator|ctDNA response: The proportion of participants with a <50% ratio of mean variant allele frequency (VAF) will be defined as ctDNA responders.\",\"Assessed throughout end of study, up to 5 years|6 months\",\"Recruiting\",,\"February 23, 2023\"\n",
      "764,\"Single-Photon Emission Computerized Tomography (SPECT)|Single-Photon Emission Computerized Tomography (SPECT)|Whole body planar imaging|Whole body planar imaging\",\"Week 1|Week 6|Week 1|Week 6\",\"Completed\",,\"January 14, 2013\"\n",
      "765,\"Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)|Phase 2 Cohorts: Objective Response Rate (ORR)\",\"Cycle 1 (up to 21 days)|From day of first dose to 30 days after last dose (maximum up to 13.5 months)\",\"Terminated\",,\"June 16, 2022\"\n",
      "766,\"To determine the safety and tolerability of oral CUDC-907 in subjects with advanced/relapsed solid tumors\",\"21 day cycle\",\"Completed\",,\"September 3, 2019\"\n",
      "767,\"The change from baseline in time-matched difference in QTc interval to post-baseline time points after a single 900 mg dose and multiple 600 mg BID doses of tipifarnib in subjects with Advanced Solid Malignancies\",\"7 days\",\"Recruiting\",,\"August 23, 2022\"\n",
      "768,\"MTD of decitabine, based on incidence of DLT graded according to NCI CTCAE version 3.0 (Part A)|Caspase-8 expression in bone marrow or tumor biopsy samples (Part B)\",\"Up to 28 days|Up to 28 days\",\"Completed\",,\"September 30, 2013\"\n",
      "769,,,\"Completed\",,\"March 26, 2013\"\n",
      "770,\"Maximum tolerated dose of Ceramide NanoLiposome in patients with advanced solid tumors.\",\"24 months\",\"Unknown status\",\"Recruiting\",\"February 27, 2019\"\n",
      "771,\"The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities\",\"Cycle 1\",\"Completed\",,\"September 18, 2014\"\n",
      "772,\"To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma.\",\"one week\",\"Completed\",,\"December 8, 2020\"\n",
      "773,\"Overall Response Based on RECIST V1.1 Following Oral Doses of Pexidartinib (Efficacy Analysis Set)\",\"Day 1 through Day 28 after last dose (within 18 months)\",\"Completed\",,\"April 25, 2022\"\n",
      "774,\"Determine number of patients experiencing dose limiting toxicities|Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)|Number of patients experiencing clinical or laboratory adverse events as a measure of safety and tolerability\",\"Day 1 through Day 28|17 months|Screening to 28 days after last treatment administration, or until drug related toxicities have resolved, whichever is later; or earlier than 28 days should the patient commence another anti-cancer therapy in the meantime, approximately 17 weeks.\",\"Completed\",,\"August 2, 2019\"\n",
      "775,\"the safety & feasibility of PET imaging with radiolabeled 68Ga-F(ab')2-trastuzumab fragments in pts w invasive solid tumors; by using the organ/tissue & body rt dosimetry inform following i.v. injection of 68Ga-F(ab')2-trastuzumab fragments (HERScan)\",\"conclusion of study\",\"Completed\",,\"October 26, 2020\"\n",
      "776,\"Part 1: Maximum Tolerated Dose (MTD) as Determined by Percentage of Participants with Dose Limiting Toxicities (DLTs)|Part 1: Recommended Phase 2 Dose (RP2D) as Determined by Percentage of Participants with DLTs and Cumulative Safety|Part 2: Percentage of Participants with Serious Adverse Events (SAEs)|Part 2: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Laboratory Abnormalities|Part 2: Percentage of Participants with Treatment Discontinuations and Treatment Modifications due to Adverse Events (AEs) and Laboratory Abnormalities|Part 2: Overall Response Rate (ORR)\",\"Cycle 1 (each cycle is 21 days)|Cycle 1 (each cycle is 21 days)|Up to 30 days after the last dose of study treatment (up to 13 months)|Up to 30 days after the last dose of study treatment (up to 13 months)|Up to end of study treatment (up to 12 months)|From the start of study treatment until disease progression (up to 12 months)\",\"Recruiting\",,\"February 28, 2023\"\n",
      "777,\"Number of participants with Adverse Events\",\"up to 6 months\",\"Unknown status\",\"Recruiting\",\"June 6, 2017\"\n",
      "778,\"Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only).|Number of Participants With AEs and Clinical Laboratory Abnormalities (Parts 1B and 2 Only)\",\"4 weeks on average|16 weeks on average\",\"Completed\",,\"December 13, 2021\"\n",
      "779,,,\"Completed\",,\"November 4, 2019\"\n",
      "780,\"Incidence of adverse events as defined as DLTs|Number of participants with adverse events as a measure of safety and tolerability of NeoTCR-P1 or NeoTCR-P1 in combination with nivolumab|Maximum Tolerated Dose (MTD) of NeoTCR-P1|Feasibility of manufacturing NeoTCR-P1\",\"28 days|2 years|2 years|2 years\",\"Suspended\",,\"August 18, 2022\"\n",
      "781,\"MTD of biweekly flavopiridol when given in conjunction with irinotecan hydrochloride, fluorouracil, and leucovorin\",\"8 weeks\",\"Completed\",,\"June 4, 2013\"\n",
      "782,\"Number of participants with treatment-emergent adverse events (TEAEs) categorized by severity|Maximum tolerated dose (MTD) or Maximum administered dose (MAD)|Number of participants experiencing dose-limiting toxicity (DLTs) at each dose level in the dose-escalation part of the study|Recommended dose for expansion (RDE)|Peak plasma concentration after drug administration (Cmax) of BAY3375968|Area under the concentration-time curve (AUC) of BAY3375968\",\"First administration of study treatment up to 90 days after the last dose of study treatment|Up to 21 days|Up to 21 days|Approximately 34 months|Up to 21 days after first drug administration|Up to 21 days after first drug administration\",\"Recruiting\",,\"March 22, 2023\"\n",
      "783,\"Maximum tolerated dose of everolimus in combination with sequential fluorouracil (5-FU) and leucovorin calcium, panitumumab, modified 5-FU, leucovorin calcium, and oxaliplatin (mFOLFOX6), and mFOLFOX6 with panitumumab|Toxicity as assessed by CTC version 3.0 at the beginning of each treatment course|Tumor response|Correlation of response with S6-phosphorylation and AKT-phosphorylation in archived tumor samples\",\"after the first 28 day cycle|first 28 day cycle|Every 8 weeks during treatment|3 years\",\"Completed\",,\"May 4, 2017\"\n",
      "784,\"Determine the maximum tolerated dose of E7974 in patients with Advanced Solid Tumors.\",\"Duration of each cycle will be 21 days; patients will attend a follow-up visit 30 days after last study treatment. Follow-up for safety and efficacy will occur 6 months after the last patient is accrued to the study.\",\"Completed\",,\"May 22, 2013\"\n",
      "785,\"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|MTD\",\"Up to 12 months|Up to 2 Months\",\"Recruiting\",,\"December 27, 2022\"\n",
      "786,\"Best Overall Response Rate by Investigator\",\"From first dose of study drug until disease progression (up to approximately 2 years)\",\"Terminated\",,\"August 4, 2022\"\n",
      "787,,,\"Completed\",,\"February 7, 2013\"\n",
      "788,\"Patients with dose limiting toxicities|Overall response rate|Overall response rate|Overall response rate|Overall response rate\",\"At cycle 2 (21-days cycle)|At cycle 2 (21-days cycle)|At cycle 4 (21-days cycle)|At cycle 6 (21-days cycle)|Through study completion up to Cycle 9\",\"Recruiting\",,\"May 24, 2022\"\n",
      "789,\"Hearing loss as measured by Hearing Loss Inventory, Dizziness Handicap Inventory, and audiogram every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment|Peripheral neuropathy as measured by Peripheral Neuropathy Scale every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment\",\"every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment|every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment\",\"Completed\",,\"November 24, 2014\"\n",
      "790,,,\"Unknown status\",\"Active, not recruiting\",\"December 19, 2013\"\n",
      "791,\"Subject incidence of Dose limiting toxicities (DLTs)|Subject incidence of treatment emergent adverse events|Subject incidence of treatment related adverse events|Subject incidence of changes in vital signs|Subject incidence of clinical laboratory tests\",\"28 Days|28 Days|28 Days|28 Days|28 Days\",\"Active, not recruiting\",,\"January 26, 2023\"\n",
      "792,\"Adverse Event collection and assessment\",\"at least 28 days or up to 24 weeks\",\"Terminated\",,\"March 16, 2017\"\n",
      "793,\"To define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.|To determine the incidence and severity of other toxicities of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.\",\"After completion of cycle 1 by all patients|30 days after completion of treatment\",\"Completed\",,\"March 7, 2017\"\n",
      "794,\"Part 1: DLT|Part 1: MTD|Part 1: RP2D|Part 2: ORR\",\"approximate 21 days|approximate 21 days|approximate 21 days|maximum 2 years\",\"Not yet recruiting\",,\"January 18, 2022\"\n",
      "795,\"Part 1: Number of participants with dose-limiting toxicities (DLTs)|Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)|Number of participants with any clinically significant clinical laboratory test value|Number of participants with any clinically significant vital sign value|Change from Baseline in arterial oxygen saturation|Change from Baseline in body weight|Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value|Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)|Change from Baseline in serum anti-drug antibody (ADA) titer\",\"At the end of Cycle 1 (21 days)|Up to 50 months|Up to 50 months|Up to 50 months|Baseline; up to 50 months|Baseline; up to 50 months|Up to 50 months|Baseline; up to 50 months|Baseline; up to 50 months\",\"Completed\",,\"November 28, 2022\"\n",
      "796,\"Safety and Tolerability\",\"Assessed at each visit\",\"Terminated\",,\"June 22, 2009\"\n",
      "797,\"Number of Patients With Improved Disease Control\",\"Up to 24 weeks following SRT\",\"Completed\",,\"January 10, 2022\"\n",
      "798,\"Assess the safety of EC D-3263 HCl|Determine the maximum tolerated dose of EC D-3263 HCl administered orally daily\",\"weekly|weekly\",\"Completed\",,\"May 2, 2012\"\n",
      "799,\"Overall Response Rate (Confirmed)\",\"29 months\",\"Completed\",,\"June 1, 2021\"\n",
      "800,\"Incidence of Product-Emergent Adverse Events\",\"Within 45 days of the last dose of TAA-CT of first infusion and 28 days after the final TAA CTL dose\",\"Active, not recruiting\",,\"February 3, 2023\"\n",
      "801,\"Number of patients with adverse events\",\"From the first dose of study drug until 30 days after the last dose of study drug\",\"Completed\",,\"February 21, 2023\"\n",
      "802,\"MTD|Frequency and severity of adverse events of ES102 in combination with JS001|RP2D\",\"2-4 years|2-4 years|2-4 years\",\"Recruiting\",,\"December 6, 2022\"\n",
      "803,\"Safety and Tolerability\",\"Assessed at each visit\",\"Terminated\",,\"May 14, 2009\"\n",
      "804,\"adverse events|Maximum tolerated dose\",\"1 year|4 week\",\"Unknown status\",\"Recruiting\",\"October 1, 2019\"\n",
      "805,\"To determine the tolerability, safety profile and maximum tolerated dose (MTD) of intravenous CALAA-01.\",\"3 months\",\"Terminated\",,\"November 1, 2013\"\n",
      "806,\"Incidence and severity of adverse events\",\"42 months\",\"Terminated\",,\"March 15, 2023\"\n",
      "807,\"Incidence and severity of adverse events|Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) in Patients\",\"From the time of signing ICF through 30 days after last dose of study drug or prior to start of a new anticancer therapy|From the time of the first dose of study drug through 30 days after the last dose of study drug or prior to start of a new anticancer therapy\",\"Not yet recruiting\",,\"March 24, 2023\"\n",
      "808,\"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).\",\"through study completion, an average of 2 to 3 years\",\"Recruiting\",,\"October 3, 2022\"\n",
      "809,\"evaluate the safety|evaluate pharmacokinetics\",\"during study|during study\",\"Completed\",,\"September 13, 2013\"\n",
      "810,,,\"Withdrawn\",,\"July 11, 2012\"\n",
      "811,\"Safety of STI-6643\",\"Baseline through study completion at up to approximately 31 months\",\"Recruiting\",,\"January 17, 2023\"\n",
      "812,\"Incidence of Adverse events|Incidence of Dose-limiting toxicity (DLTs)\",\"From the informed consent to 30 days post last dose|From the first dose of Cycle 1 up to the assessment prior to the planned first dose of Cycle 2 (each cycle is 21 days for Part A and 28 days for Part B)\",\"Completed\",,\"July 25, 2022\"\n",
      "813,\"To determine the maximum tolerated dose (MTD) and recommended dose (RD) of the human L19IL2 fusion-cytokine.\",\"21 days\",\"Completed\",,\"February 25, 2014\"\n",
      "814,\"The primary objective of the dose finding component is to determine the maximum tolerated dose (MTD) of HCW9218\",\"through study completion, an average of 12 months\",\"Recruiting\",,\"April 20, 2022\"\n",
      "815,\"Dose Limiting Toxicities (DLT)|Safety and tolerability assessed by Adverse Events (AEs)\",\"Up to 28 days|Time Frame: Up to 6 months\",\"Recruiting\",,\"February 1, 2022\"\n",
      "816,\"Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range\",\"Up to one year\",\"Recruiting\",,\"November 17, 2021\"\n",
      "817,\"To define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.|To determine the incidence and severity of other toxicities of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.\",\"After completion of cycle 1 by all patients|30 days after completion of treatment\",\"Completed\",,\"May 24, 2013\"\n",
      "818,\"Adverse events in part I|Dose Finding in part I|Objective Overall Response in part II|Duration of Response in part II|Progression Free Survival in part II|Overall Survival in part II\",\"Up to 2 years|Up to 2 years|Up to 2 years|Up to 2 years|Up to 2 years|Up to 2 years\",\"Recruiting\",,\"December 9, 2022\"\n",
      "819,\"Part A: Maximum Tolerated Dose and RP2D in solid tumours|Part B: Tolerability|Part C: Recommended Phase 2 Dose (RP2D) and Tolerability|Pharmacokinetics\",\"24 months|24 months|24 months|24 months\",\"Completed\",,\"April 7, 2020\"\n",
      "820,\"Define RP2D|Incidence, nature, and severity of AEs, with severity determined according to NCI CTCAE, v5.0\",\"1.5 years|5 years\",\"Recruiting\",,\"April 15, 2022\"\n",
      "821,\"Type, incidence and severity of AEs and serious adverse events (SAEs)|Incidence of dose-limiting toxicities (DLTs)|Maximum tolerated dose (MTD)|Recommended dose for expansion (RDE)\",\"From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)|4 weeks after first study drug administration|From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)|From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)\",\"Recruiting\",,\"November 9, 2022\"\n",
      "822,\"Determination of Dose Limiting Toxicities and Maximum Tolerated Dose\",\"First cycle\",\"Completed\",,\"February 21, 2011\"\n",
      "823,\"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination\",\"10 Weeks\",\"Completed\",,\"June 23, 2015\"\n",
      "824,\"Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces.|Pharmacokinetics: AUC (0-t) for Total Radioactivity in Plasma|Pharmacokinetics AUC (0-t) for Eribulin in Plasma\",\"312 hours postdose|Between Days 1 and 8 of Cycle 1|Between Days 1 and 8 of Cycle 1\",\"Completed\",,\"March 9, 2012\"\n",
      "825,\"Incidence of Dose Limiting Toxicities (DLT) in the dose escalation part\",\"4 weeks\",\"Completed\",,\"December 19, 2020\"\n",
      "826,\"MTD/RP2D|Occurence of DLT|Numbers of DLT|Occurence of AE and SAE（NCI CTCAE 5.0）|Frequency of AE and SAE（NCI CTCAE 5.0）\",\"1 month|1 month|1 month|7 months|7 months\",\"Recruiting\",,\"April 27, 2021\"\n",
      "827,\"Dose-limiting toxicity (DLT)|Maximum tolerated dose (MTD)\",\"28 days of single infusion|28 days of single infusion\",\"Recruiting\",,\"March 14, 2022\"\n",
      "828,\"Perform analysis of gene expression profiles. [RNA] ribonucleic acid will be isolated from fresh frozen tumor specimens and hybridized to Affymetrix gene expression arrays.\",\"5 years\",\"Recruiting\",,\"August 29, 2022\"\n",
      "829,\"Maximum tolerated dose of BEZ235 given twice daily\",\"18 months\",\"Completed\",,\"May 1, 2015\"\n",
      "830,\"Safety and tolerability|MTD and/or RP2DP2D\",\"From first dose of HS248 through 28 days after the last HS248 treatment (up to 2 years); each cycle is 28 days|The end of the study is defined as the last subject completing the last visit, study treatment for 2 years, loss to follow-up, death or withdrawal of informed consent, whichever occurs first\",\"Recruiting\",,\"March 8, 2023\"\n",
      "831,\"Phase 1:|Phase 2:\",\"28 days|16 weeks\",\"Recruiting\",,\"February 8, 2023\"\n",
      "832,\"Safety Assessment by rate of Adverse Events (AEs)|Dose limiting toxicities (DLTs) of RTX-224\",\"up to 30 months|up to 30 months\",\"Terminated\",,\"December 9, 2022\"\n",
      "833,\"Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)|Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)|Part 1: Number of Participants Who Experience a Treatment-related Adverse Event|Part 2: Objective Response (OR) Rate\",\"Day 1 to Day 28|Day 1 to 28 days after last dose (a maximum of 2 years)|Day 1 to 28 days after last dose (a maximum of 2 years)|Up to approximately 2 years\",\"Recruiting\",,\"March 24, 2023\"\n",
      "834,\"MTD defined as the dose level in which 1 of 6 patients experiences DLT assessed using CTCAE version 4.0\",\"21 days\",\"Completed\",,\"July 24, 2014\"\n",
      "835,\"Evaluate the occurrence of DLTs during the first cycle in Part 1|Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment|Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2|Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1\",\"21 days of Cycle 1|By the global end of trial date, approximately within 36 months|Approximately within 36 months|Approximately within 36 months\",\"Recruiting\",,\"February 13, 2023\"\n",
      "836,\"To evaluate the safety and tolerability of single agent SX-682.|To determine the MTD of SX-682 followed by M7824 and CV301 vaccines in participants with advanced or metastatic solid tumors.|To determine the RP2D of SX-682 with M7824 and CV301 vaccines in participants with advanced or metastatic solid tumors.|To evaluate preliminary efficacy based on objective response rate (ORR), in each disease cohort separately.\",\"DLT observation period (first 4 weeks)|Period of Safety lead-in (monotherapy)|1-2 years|1-2 years\",\"Active, not recruiting\",,\"July 12, 2022\"\n",
      "837,\"Phase I: Determination of the Maximum Tolerated Dose (MTD) and Recommended Dose (RD)|Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR)\",\"day 1-29|within day 42\",\"Completed\",,\"September 23, 2011\"\n",
      "838,\"Maximum Tolerated Dose (MTD) of Eribulin-LF|Dose Limiting Toxicities at the Indicated Dose Levels, as an Assessment of Dosing Frequency\",\"Schedule 1: Cycle 1 (21 days); Schedule 2: Cycle 1 (28 days)|Cycle 1 of Dose Escalation part in Schedule 1 and Schedule 2\",\"Completed\",,\"July 23, 2019\"\n",
      "839,\"Maximally tolerated dose of alpelisib in combination with cisplatin, based upon evaluation of dose-limiting toxicities and adverse events|Recommended phase 2 dose of alpelisib in combination with cisplatin, based upon evaluation of dose-limiting toxicities\",\"Up to 21 days|Up to 30 days after the last administration of the study treatment\",\"Terminated\",,\"January 10, 2020\"\n",
      "840,\"Adverse Events of rSIFN-co of recombinant interferon-α administered in solid Tumor|Recommended dose (RD) of rSIFN-co\",\"Up to 12 weeks after the last treatment|Cycle 1 of treatment\",\"Completed\",,\"September 27, 2019\"\n",
      "841,\"To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of XL999 administered as a single 4-hour intravenous (IV) infusion in subjects with solid tumors\",\"Inclusion until 30 days post last treatment\",\"Completed\",,\"February 19, 2010\"\n",
      "842,,,\"Unknown status\",\"Active, not recruiting\",\"December 19, 2013\"\n",
      "843,\"Dose-limiting Toxicities (DLTs) in Phase I Portion|Tumor Overall Response Rates (ORRs) in Phase II Portion\",\"From start of the treatment to end of cycle 1, which are 4 weeks|In every 2 cycles up to end of the treatment, an expected average of 16 weeks\",\"Unknown status\",\"Recruiting\",\"May 18, 2015\"\n",
      "844,,,\"Unknown status\",\"Active, not recruiting\",\"September 17, 2013\"\n",
      "845,\"Dose Limiting Toxicity\",\"During the first 28-day Cycle\",\"Completed\",,\"June 21, 2017\"\n",
      "846,\"Number of Participants with Adverse Events as a Measure of Safety\",\"From time of informed consent through 12 weeks after last dose of investigational product\",\"Active, not recruiting\",,\"February 23, 2023\"\n",
      "847,\"Maximum tolerated dose (MTD) of HR19024\",\"21-day cycle (tri-weekly)\",\"Recruiting\",,\"September 1, 2022\"\n",
      "848,\"Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0|Part 1 - Maximum Tolerated Dose|Part 2 - RECIST|Part 2 - RANO|Part 2 - INRC\",\"6 months|6 months|6 months|6 months|6 months\",\"Terminated\",,\"July 22, 2021\"\n",
      "849,\"Explore the maximum tolerated dose (MTD)\",\"21 days after first dosing\",\"Recruiting\",,\"December 8, 2021\"\n",
      "850,\"Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met|Establish maximum tolerated dose\",\"2 years|1.5 years\",\"Active, not recruiting\",,\"November 1, 2022\"\n",
      "851,\"Number of Subjects With Any Dose Limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Number of Subjects With Treatment-Related Adverse Events\",\"Day 1, 3, 8, 14, 17 of Cycle 1 (for Regimen 1 and 3); Day 1, 3, 8, 15, 19 of Cycle 1 (for Regimen 2)|Cycle 1 (Day 1 to Day 21)|Baseline up to 158.01 weeks\",\"Completed\",,\"August 24, 2022\"\n",
      "852,\"To evaluate the safety and tolerability of AZD0530 in combination with carboplatin and/or paclitaxel regimens with solid tumours by assessment of AEs, physical examination, BP, pulse, ECG, laboratory findings, PFTs and thoracic CT scans.\",\"Assessed at each visit\",\"Completed\",,\"September 22, 2010\"\n",
      "853,\"Safety\",\"From time of informed consent through 12 weeks after last dose of investigational product\",\"Completed\",,\"March 13, 2019\"\n",
      "854,\"To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies\",\"3.5 years|3.5 years|3.5 years|3.5 years\",\"Completed\",,\"December 16, 2014\"\n",
      "855,\"Maximum tolerated dose of PR-104\",,\"Completed\",,\"March 2, 2011\"\n",
      "856,\"Dose-limiting toxicity（DLT）|Objective response rate (ORR)|Duration of response (DOR)\",\"28 days|up to 2 years|up to 2 years\",\"Active, not recruiting\",,\"March 7, 2023\"\n",
      "857,\"adverse events (AEs)\",\"from the first dose injection to 28 days after the last dose injection, assessed up to 36 weeks\",\"Active, not recruiting\",,\"November 1, 2021\"\n",
      "858,\"To evaluate the safety and tolerability of IAE0972 in Phase I|Objective response rate (ORR) in Phase IIa\",\"28 days after last medication, an average of 1 year|Baeline until disease progression, assessed up to 36 months\",\"Not yet recruiting\",,\"May 31, 2022\"\n",
      "859,\"Maximum Tolerated Dose (MTD) of OPB-31121\",\"4 Week Cycle\",\"Completed\",,\"February 12, 2013\"\n",
      "860,\"Dose Limiting Toxicities (DLT)\",\"Up to 28 days\",\"Recruiting\",,\"January 20, 2022\"\n",
      "861,\"Number of subjects with any dose limiting toxicity (DLT)|To determine the maximum tolerated dose (MTD)\",\"From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).|From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).\",\"Unknown status\",\"Recruiting\",\"July 20, 2020\"\n",
      "862,\"Maximum tolerated dose (MTD)\",\"Blood tests on Days 1, 3, 5, then twice weekly and on Day 22 of each course; Urine tests done on Day 1 of each course and at end of Course 2.\",\"Completed\",,\"August 1, 2012\"\n",
      "863,\"Percentage of Participants with Adverse Events in Part 1 and Part 2|Percentage of Participants with Dose-Limiting Toxicities|Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Part 3|Recommended Dose for Extension (RDE) of RO7284755 in Parts 1 and 2\",\"From randomization until end of Part 1 and Part 2 (up to approximately 1.5 months)|From randomization up to day 14 (Part 1) or day 28 (Part 2)|From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)|From randomization up to day 14 (Part 1) or day 28 (Part 2)\",\"Recruiting\",,\"February 27, 2023\"\n",
      "864,\"maximum tolerated dose\",\"Three patients will be treated one at a time at a given dose level. All patients within a cohort must have completed at least once cycle (28 days) prior to initiation of the next cohort of patients.\",\"Active, not recruiting\",,\"August 25, 2021\"\n",
      "865,\"To evaluate the safety and tolerability of hCBE-11 in advanced solid tumors\",\"up to 2 years\",\"Terminated\",,\"April 26, 2013\"\n",
      "866,\"Outcome Measure:pediatric solid tumor survivors are at an increased risk for developing generalized or regional osteoporosis as a result of chemotherapy for pediatric solid tumors.\",\"3 years\",\"Completed\",,\"May 30, 2013\"\n",
      "867,\"Incidence of dose limiting toxicities (DLTs)|Incidence of adverse events (AEs) and serious adverse events (SAEs)\",\"Escalation Cycle 1 (28 days)|Up to 24 months\",\"Recruiting\",,\"August 12, 2022\"\n",
      "868,\"Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose\",\"From date of first dose to off-study (or 30 days since last dose)\",\"Completed\",,\"November 13, 2014\"\n",
      "869,,,\"Completed\",,\"December 19, 2013\"\n",
      "870,\"Safety and tolerability will include evaluation of adverse events (AE) and changes from baseline in vital signs and clinical laboratory parameters. PK endpoints will include Cl, Vd, AUC, Cmax, and t½.\",,\"Completed\",,\"October 16, 2008\"\n",
      "871,\"maximal tolerance dose (MTD) of RC48-ADC|AEs\",\"DLT will be evaluated on 28 days of observation period|Estimated 2 years\",\"Completed\",,\"July 30, 2020\"\n",
      "872,\"Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-∞)] Following a Single Dose in Cycle 1|Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-∞)] Following a Single Dose in Cycle 2|Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Docetaxel in Cycle 1|Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Docetaxel in Cycle 2\",\"Cycle 1: 0, 1, 1.5, 2, 3, 5, 7, 24, 48 and 72 hours post docetaxel infusion|Cycle 2: 0, 1, 1.5, 2, 3, 5, 7, 24, 48 and 72 hours post docetaxel infusion|Cycle 1: 0, 1, 1.5, 2, 3, 5, 7, 24, 48, and 72 hours post docetaxel infusion|Cycle 2: 0, 1, 1.5, 2, 3, 5, 7, 24, 48 and 72 hours post docetaxel infusion\",\"Completed\",,\"October 16, 2014\"\n",
      "873,\"Feasibility of exome analysis for patient with a malignant solid tumors\",\"1 month\",\"Completed\",,\"November 20, 2019\"\n",
      "874,\"Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)|Adverse events (TEAEs) and incidence after initial infusion, treatment-related adverse events and incidence, AESI and incidence of special concern\",\"3 years|3 years\",\"Not yet recruiting\",,\"March 17, 2022\"\n",
      "875,\"The frequency and severity of adverse events of ES002023|The Maximum Tolerated Dose (MTD), Optimal Biological Dose (OBD) and/or the Recommended Phase 2 Dose (RP2D) of ES002023\",\"1-3 years|1-3 years\",\"Active, not recruiting\",,\"October 20, 2022\"\n",
      "876,\"Tumor response rate\",\"12 weeks\",\"Withdrawn\",,\"June 9, 2015\"\n",
      "877,\"Determination of the long-term effect of AV0113 by counting the total survival time in days measured from inclusion time point to death.|Comparison of total survival times in days of sarcoma patients treated with AV0113 with total survival times of a cohort of matched historic control patients.|Comparison of the percentage of treatment patients still alive after 2 years with the percentage of matched historic control patients still alive after 2 years.|Comparison of the percentage of treatment patients still alive after 5 years with the percentage of matched historic control patients still alive after 5 years.|Comparison of the percentage of treatment patients still alive after 10 years with the percentage of matched historic control patients still alive after 10 years.\",\"15 years|15 Years|2 years|5 years|10 years\",\"Completed\",,\"December 29, 2015\"\n",
      "878,\"Determine the maximum tolerated dose (MTD) of irinotecan and rapamycin combination in children with refractory solid tumors.|Characterize the pharmacokinetics of rapamycin and irinotecan during the first cycle of treatment.\",\"28 days|Day1 + day8\",\"Completed\",,\"December 9, 2019\"\n",
      "879,\"Determine recommended dose of Bendamustine when used in combination with Stereotactic Radiotherapy (STR) for treatment of patients with 1-4 brain metastases.\",\"up to 4 years\",\"Completed\",,\"May 17, 2018\"\n",
      "880,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).\",\"From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 2 years.\",\"Not yet recruiting\",,\"December 14, 2022\"\n",
      "881,\"Determination of the maximum dose|Determination of the frequency and causality of each adverse event\",\"When sufficient patients have had the opportunity to complete 1 Cycle (28 days).|When sufficient patients have had the opportunity to complete 1 Cycle (28 days).\",\"Active, not recruiting\",,\"March 21, 2023\"\n",
      "882,\"Part A: Maximum Tolerated Dose (MTD) in subjects receiving AZD9150 plus durvalumab and AZD9150 plus durvalumab plus chemotherapy.|Part D: Area under the plasma concentration versus time curve at steady state [AUC(ss)] of AZD9150 administered once per week in combination with durvalumab.|Part D: Minimum plasma concentration at steady state [Ctrough (ss)] of AZD9150 administered once per week in combination with durvalumab.\",\"Through study completion (an average of 6 months). Dose-limiting toxicities (DLTs) will be assessed through 5 weeks for patients who do not receive chemotherapy or 3 weeks for patients receiving chemotherapy.|Blood samples for the PK analysis of AZD9150 will be collected at prespecified intervals during Weeks 0, 1, 5, 6, and 9.|Blood samples for the PK analysis of AZD9150 will be collected at prespecified intervals during Weeks 0, 1, 5, 6, and 9.\",\"Active, not recruiting\",,\"November 3, 2022\"\n",
      "883,\"To determine the dose limiting toxicities and the maximum tolerated dose of AZD6244 in combination with cetuximab in advanced, refractory solid tumors.|To assess for evidence of anti-tumor activity with this combination, per tumor measurements\",\"Two year|Two year\",\"Completed\",,\"December 17, 2019\"\n",
      "884,\"Safety and Tolerability|Recommended Phase 2 Dose (RP2D)|Maximum Tolerated Dose (MTD)\",\"12 months|12 months|12 months\",\"Recruiting\",,\"February 23, 2022\"\n",
      "885,\"Dose Limiting Toxicity (DLT) - Phase Ia|Objective Response Rate (ORR) - Phase Ib\",\"First cycle (21 days)|Baseline to study completion (up to 24 weeks)\",\"Completed\",,\"April 30, 2021\"\n",
      "886,\"To evaluate the safety and tolerability of XL647 administered orally as a single dose and as repeat doses\",\"First treatment until 30 days post last treatment\",\"Completed\",,\"May 13, 2022\"\n",
      "887,\"Number of Patients Experiencing a DLT|Number of Patients Correlated With Best Overall Response.\",\"baseline through cycle 1 of treatment|Every two cycles from first dose to last dose of study drugs\",\"Completed\",,\"May 8, 2017\"\n",
      "888,\"Determine dose-limiting toxicities (DLTs) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.|Determine alternative dose of interest (ADI) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.|Determine the maximum tolerated dose (MTD) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.\",\"18 months|18 months|18 months\",\"Completed\",,\"January 29, 2016\"\n",
      "889,\"Evaluation of the number of patients who successfully receive NeoTIL-ACT in combination with LDI (feasibility)|Toxicity of NeoTIL-ACT in combination with LDI|Objective response rate (ORR; efficacy of NeoTIL-ACT in combination with LDI)\",\"Evaluated for each patient at day 0|Treatment limiting toxicity (TLT) period: from day starting NMA chemotherapy to day 30 post NeoTIL infusion|Up to 6 months\",\"Recruiting\",,\"January 19, 2023\"\n",
      "890,\"Evaluate the safety and pharmacokinetics (rate of movement in the body and then the clearance) of CNTO 888 administered as multiple intravenous (IV) infusions in patients with solid tumors throughout the course of the study.\",,\"Completed\",,\"October 22, 2010\"\n",
      "891,\"Number of participants with adverse events as assessed by CTCAE v5.0.\",\"one month\",\"Completed\",,\"February 2, 2023\"\n",
      "892,\"Safety and tolerability assessed by Dose Limiting Toxicity (DLT)|Safety and tolerability assessed by adverse events (AEs)|Safety and tolerability assessed by immune-related AEs (irAEs)|Safety and tolerability assessed by infusion-related reactions (IRRs)|Safety and tolerability assessed by serious adverse events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by 12- lead electrocardiogram (ECG)|Number of participants with vital signs abnormalities and/or adverse events related to treatment|Number of participants with Physical Exam abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by ECOG performance status|Pharmacokinetics (PK) of ASP1951 in serum: AUClast|Pharmacokinetics (PK) of ASP1951 in serum: AUCinf|Pharmacokinetics (PK) of ASP1951 in serum: AUCinf%extrap|Pharmacokinetics (PK) of ASP1951 in serum: AUCtau|Pharmacokinetics (PK) of ASP1951 in serum: Cmax|Pharmacokinetics (PK) of ASP1951 in serum: Ctrough|Pharmacokinetics (PK) of ASP1951 in serum: tmax|Pharmacokinetics (PK) of ASP1951 in serum: t 1/2|Pharmacokinetics (PK) of ASP1951 in serum: tlast|Pharmacokinetics (PK) of ASP1951 in serum: CL|Pharmacokinetics (PK) of ASP1951 in serum: Vz|Pharmacokinetics (PK) of ASP1951 in serum: Vss|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUClast|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf%extrap|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCtau|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Cmax|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Ctrough|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tmax|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: t 1/2|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tlast|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: CL|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vz|Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vss\",\"Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 48 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 48 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks|Up to 10 weeks\",\"Active, not recruiting\",,\"February 21, 2023\"\n",
      "893,\"Number of participants with treatment-related adverse events as assesses by CTCAE version 4.03.|Determine the recommended phase 2 dose (RP2D) based on Dose limiting toxicities\",\"58 weeks|6 weeks\",\"Completed\",,\"November 29, 2019\"\n",
      "894,\"Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1|Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 2|Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1|Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2|Part B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] as Monotherapy\",\"Cycle 1: 0, 1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion|Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion|Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion|Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion|Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72,168, 264, 336, 408, and 504 hours post ramucirumab infusion\",\"Completed\",,\"March 8, 2022\"\n",
      "895,\"Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03\",\"At the end of Cycle 1 (each Cycle is of 21 days)\",\"Terminated\",,\"March 11, 2022\"\n",
      "896,\"Number of Participants With Dose-Limiting Toxicities (Dose Finding Phase)|Number of Participants With Treatment-emergent Adverse Events, by Severity (Dose Finding and Dose Expansion Phases)|Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP341 (Dose Finding Phase)|Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP341 (Dose Finding Phase)|Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP341 (Dose Finding Phase)|Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP341 (Dose Finding Phase)|Pharmacokinetic Parameter Clearance (CL) of JZP341 (Dose Finding Phase)|Pharmacokinetic Parameter Volume of Distribution (Vd) of JZP341 (Dose Finding Phase)|Nadir Serum Asparaginase Activity Response Rate (Dose Finding Phase)|Disease Control Rate (Dose Expansion Phase)\",\"Baseline up to Day 28|Baseline up to 5 years|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Cycle 1 Day 1: (pre- and post-dose, 4 hour [hr], 8 hr), Days 2,3,4,8,11,15 (pre- and post-dose), 22, 29; Cycle 2 Day 1 (pre- and post-dose, 8 hr), Days 4,8,15 (pre- and post-dose) and 29; Cycle 3+, Days 1 (pre- and post-dose) and 15 (each cycle, 28 days)|Baseline up to Day 14|Baseline up to Week 12\",\"Recruiting\",,\"February 9, 2023\"\n",
      "897,\"Determine the maximum tolerated dose of BMS-214662 in combination with paclitaxel.\",\"Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.\",\"Completed\",,\"June 11, 2010\"\n",
      "898,\"To assess the safety and tolerability of FB849 and to identify maximum tolerated dose (MTD)/ recommended Phase II dose (RP2D) and dosing schedule of FB849 in subjects with advanced solid tumors\",\"DLT Assessment at the end of Cycle 1(each cycle is 21 days.)\",\"Not yet recruiting\",,\"March 9, 2023\"\n",
      "899,\"Assess participants for toxicities related to study treatment\",\"1 year\",\"Not yet recruiting\",,\"March 7, 2023\"\n",
      "900,\"Maximal Tolerance Dose (MTD) of RC48-ADC\",\"DLT will be evaluated on Day 28 during cycle 1\",\"Completed\",,\"June 4, 2020\"\n",
      "901,\"DLTs in the first 2 cycles of single drug administration\",\"2 Cycles (42 days)\",\"Active, not recruiting\",,\"October 18, 2022\"\n",
      "902,\"Incidence of all adverse events graded according to NCI CTCAE, v4.0|Incidence of dose limiting toxicities (DLTs)|Pharmacokinetic property of GDC-0425: determination of plasma drug concentration|Pharmacokinetic property of GDC-0425: exposure|Pharmacokinetic property of GDC-0425: half-life|Severity of all adverse events graded according to NCI CTCAE, v4.0\",\"Up to 1 year|Up to 35 days|Up to 12 months or early study discontinuation|Up to 12 months or early study discontinuation|Up to 12 months or early study discontinuation|Up to 1 year\",\"Completed\",,\"April 12, 2017\"\n",
      "903,\"Mean (SD) Pharmacokinetic (PK) Parameter Area Under Concentration Time Curve From Zero to Infinity (AUC0-oo)|Mean (SD) Pharmacokinetic (PK) Parameter Maximum Observed Plasma Concentration (Cmax)|Best Overall Response Per Response Evaluation Criteria in Solid Tumors (RECIST)\",\"Pre-dose (-0.5h); post-dose at 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 10 hrs, 24 hrs, 48 hrs, 72hrs, 96 hrs, 120 hrs and 144 hours.|Pre-dose (-0.5h); post-dose at 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 10 hrs, 24 hrs, 48 hrs, 72hrs, 96 hrs, 120 hrs and 144 hours.|throughout the study and up to 30 days after the last dose of study drug\",\"Completed\",,\"March 27, 2012\"\n",
      "904,\"Maximum-tolerated dose and recommended phase II dose based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Toxicities as assessed by the NCI CTCAE version 4.0|Pharmacokinetics (PK) of cixutumumab|Pharmacokinetics of temsirolimus\",\"28 days|Up to 30 days after the last dose of treatment|At end of infusion, at 1, 3, 6, and 24 hours, days 1, 4, 8, 15, 22, and 28 (of course 1), and days 15 and 28 (of course 2)|At end of infusion, at 15 and 30 minutes, at 1, 3, 6, and 24 hours, days 1, 4, 7, and 28 (of course 1), and days 15 and 28 (course 2)\",\"Completed\",,\"April 29, 2014\"\n",
      "905,\"Occurrence of treatment related adverse events as assessed by CTCAE v4.03\",\"1 year\",\"Unknown status\",\"Recruiting\",\"May 7, 2019\"\n",
      "906,\"Incidence of Dose Limiting Toxicities\",\"during the first 28 days of treatment with RAF265 and MEK162\",\"Completed\",,\"September 30, 2020\"\n",
      "907,\"Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities\",\"From date of first dose to 4 weeks after administration.\",\"Active, not recruiting\",,\"May 6, 2021\"\n",
      "908,\"Dose Escalation: Evaluate up to Eighteen Subjects With Tumors Expressing TCRT-ESO-A1 and Having Dose Limiting Toxicity Adverse Events as Assessed by CTCAE-Version 5\",\"Day 28\",\"Withdrawn\",,\"September 2, 2022\"\n",
      "909,\"Incidence of treatment-emergent adverse events|Severity of treatment-emergent adverse events|Cmax of BAY1834942 after single dose|AUC(0-504) of BAY1834942 after single dose\",\"Up to 40 months|Up to 40 months|0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after drug in Cycle 1 (cycle length is 21 days)|0 (pre-dose), 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after drug in Cycle 1 (cycle length is 21 days)\",\"Completed\",,\"June 2, 2022\"\n",
      "910,\"Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs)|Number of Participants Who Experience a Dose Interruption|Number of Participants Who Experience a Dose Reduction|Number of Participants Who Experience a Dose Limiting Toxicity (DLT) During the Dose-Escalation Phase\",\"Up to approximately 3.5 years|Up to approximately 3.5 years|Up to approximately 3.5 years|Day 1 to Day 21\",\"Recruiting\",,\"February 21, 2023\"\n",
      "911,\"Dose limiting toxicity (DLT)|Maximum Tolerated Dose (MTD)\",\"up to 4 weeks|up to 4 weeks\",\"Recruiting\",,\"August 26, 2022\"\n",
      "912,,,\"Completed\",,\"April 25, 2014\"\n",
      "913,\"Adverse events evaluated by NCI CTCAE v5.0\",\"with in 2 years after the first dose\",\"Unknown status\",\"Not yet recruiting\",\"August 8, 2019\"\n",
      "914,\"Area under the concentration-time curve over the dosing interval on multiple dosing (AUC[0-τ])|Time at which the highest drug concentration occurs at steady-state (tss,max)|Average steady-state concentration (Css,av)|Minimum observed concentration at steady-state (Css,min)|Maximum observed concentration at steady-state (Css,max)|Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t])|Time at which the highest drug concentration occurs (tmax)|Maximum observed concentration (Cmax)\",\"Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)|Day 1: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 2: pre-dose (24 hours after first administration). Day 8: pre-dose. Day 15: pre-dose; 1, 2, 4, and 8 hours post-dose. Day 16: pre-dose (24 hours after administration on Day 15)\",\"Completed\",,\"September 28, 2021\"\n",
      "915,\"Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)\",\"28 days after patient enrolled\",\"Active, not recruiting\",,\"December 2, 2021\"\n",
      "916,\"Number of Participants Experiencing Dose Limiting Toxicities|Number of Participants Experiencing Adverse Events|Number of Participants Discontinuing Study Treatment Due to AEs\",\"Cycle 1 (3-week Cycle) (Up to 3 weeks)|~90 days after last treatment dose (up to ~45 weeks)|Up to ~33 weeks\",\"Completed\",,\"January 25, 2023\"\n",
      "917,\"Safety profile and effectiveness of escalating doses of ALT-803\",\"9 months\",\"Completed\",,\"April 17, 2019\"\n",
      "918,\"Safety\",\"Monitored on an ongoing basis during the study\",\"Completed\",,\"June 29, 2010\"\n",
      "919,\"Safety, tolerability, and maximum tolerated dose of XL418 with daily oral administration\",,\"Suspended\",,\"June 4, 2008\"\n",
      "920,\"Dose-limiting toxicity (DLT)|Maximum tolerated dose (MTD)|Recommended Phase 2 Dose (RP2D)|Adverse events (AEs) and serious adverse events (SAEs)\",\"the first cycle of administration, up to 21 days|the first cycle of administration, up to 21 days|the first cycle of administration, up to 21 days|from the signing of informed consent form to the end of safety follow-up period (90 days after the last dose)\",\"Recruiting\",,\"January 18, 2023\"\n",
      "921,\"Dose Limiting Toxicities (DLT)\",\"Up to 28 days\",\"Recruiting\",,\"November 29, 2022\"\n",
      "922,\"Number of participants with adverse events\",\"1 year. Subjects will continue to receive SLC-0111 for multiple cycles of 28 days if they are receiving benefit from therapy.\",\"Completed\",,\"May 17, 2016\"\n",
      "923,\"Number of subjects with DLT (Dose limiting Toxicity): dose escalation part|Number of Subjects with treatment-emergent adverse events (TEAEs)|Number of subjects with treatment-related Adverse Events (AE)\",\"Baseline up to Week 3|First trial drug administration up to 30 days after the last drug administration assessed up to 2 years|First trial drug administration up to 30 days after the last drug administration assessed up to 2 years\",\"Completed\",,\"March 21, 2022\"\n",
      "924,\"Dose-limiting toxicity (DLT)|Maximum tolerated dose (MTD）|Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)|RP2D\",\"Cycle 1 (21Days)|Cycle 1 (21 Days)|Up to 3 years|Cycle1 (21 Days)\",\"Not yet recruiting\",,\"October 4, 2022\"\n",
      "925,\"To investigate the safety and tolerability of AZD5363 to define a Recommended Dose (RD) when given orally\",\"All AEs will be collected throughout the study, from informed consent until 30 days after the end of study treatment. The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive\",\"Completed\",,\"April 26, 2016\"\n",
      "926,\"Part 1 and Part 2, cohort 1 (expansion cohort - STS): Dose-limiting toxicity (DLT)|Part 2, Cohort 2 (phase IIa - melanoma): Disease control (DC) according to RECIST 1.1\",\"Day 1 to day 28|up to 12 weeks from treatment start\",\"Recruiting\",,\"November 8, 2022\"\n",
      "927,\"Number of participants experiencing dose-limiting toxicities|Number of participants experiencing clinical and laboratory adverse events (AEs)\",\"2 Cycles (42 days)|First dose to 28 days post last dose\",\"Completed\",,\"October 18, 2022\"\n",
      "928,\"Number of Subjects Experiencing Dose Limiting Toxicity (DLT)\",\"Cycle 1 (Day 1 up to 21)\",\"Completed\",,\"August 6, 2020\"\n",
      "929,\"SARS-CoV-2 infection rate in patients with solid tumors.\",\"From June 2020 to September 2020.\",\"Completed\",,\"February 25, 2022\"\n",
      "930,\"Objective response (PR or CR), recorded according to standard solid tumor response criteria\",\"Up to 8 years\",\"Completed\",,\"June 14, 2013\"\n",
      "931,\"Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)|Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC\",\"Date of First Dose to Disease Progression or Death (up to 12 Months)|Date of First Dose to Disease Progression or Death (Up to 12 months)\",\"Active, not recruiting\",,\"June 2, 2022\"\n",
      "932,\"Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumab|Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.\",\"End of treatment visit or 30 days after last dose of study drug.|22 days\",\"Recruiting\",,\"November 17, 2022\"\n",
      "933,\"Objective response rate (ORR)|Overall survival (OS)\",\"Up to 2 years|From date of first study treatment to death due to any cause, assessed up to 2 years\",\"Recruiting\",,\"January 5, 2023\"\n",
      "934,\"Define the safety and tolerability of AT13387; establishing the MTD of At13387\",\"3 weeks\",\"Completed\",,\"July 5, 2018\"\n",
      "935,\"Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW|Dose Limiting Toxicities (DLT)|Maximum tolerated dose (MTD)|Recommended dose (RD)|Adverse Events|Plasma concentration (Cmax)|Time to achieve Cmax (Tmax)|Area under the curve|Half-life\",\"Assessed up to 24 months from time of first dose|Study Day 1 up to Day 29|Study Day 1 up to Day 29|Study Day 1 up to Day 29|Assessed up to 24 months from time of first dose|Study Day 1 up to Day 29|Study Day 1 up to Day 29|Study Day 1 up to Day 29|Study Day 1 up to Day 29\",\"Recruiting\",,\"December 7, 2022\"\n",
      "936,\"Number, frequency, and severity of adverse events (AEs)|Incidence of abnormal laboratory tests results|Changes in Eastern Cooperative Oncology Group (ECOG) performance status from baseline to subsequent scheduled visits\",\"From the time of first treatment until 12 weeks after study treatment completion|Up to 12 weeks after study treatment completion|Up to 12 weeks after study treatment completion\",\"Active, not recruiting\",,\"July 1, 2022\"\n",
      "937,\"To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.\",,\"Terminated\",,\"March 26, 2007\"\n",
      "938,\"Dose escalation: recommended clinical dose (RCD)|Dose escalation: safety assessment|Dose escalation and expansion: safety assessment\",\"Cycle 1 (28 days)|Cycle 1 (28 days)|From the first dose of study drug up to 30 days after the last dose of study drug\",\"Recruiting\",,\"January 6, 2023\"\n",
      "939,\"Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase\",\"From baseline to 12 months in the tremelimumab monotherapy phase\",\"Active, not recruiting\",,\"January 23, 2023\"\n",
      "940,\"To evaluate the safety and tolerability of CN202 administered to subjects with locally advanced or metastatic solid tumor or hematologic malignancies through adverse events as assessed by NCI-CTCAE v5.0|To evaluate the dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of CN202 when administered as a single-agent to subjects|To identify a recommended Phase II dose (RP2D) of CN202|To evaluate the anti-tumor activity of CN202 in selected solid tumors or hematologic malignancies as determined by Objective Response Rate (ORR)\",\"Measurements at Baseline till 90 days after the last dose of study drug|DLT assessed within 21 days after the first dose of CN202|Baseline to End of the Treatment assessed up to an average of 24 months|Baseline to End of the Treatment assessed up to an average of 24 months\",\"Not yet recruiting\",,\"August 31, 2021\"\n",
      "941,\"Number of participants with Adverse Events as a Measure of Safety and Tolerability|Determination of the recommended Phase 2 dose\",\"Adverse events will be assessed at baseline, while the participant is taking BBI503, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.|Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 weeks\",\"Completed\",,\"April 5, 2022\"\n",
      "942,\"Frequency of NTRK fusions in subjects with locally advanced/unresectable or metastatic solid tumors.\",\"Retrospective analysis between January 2019 and December 2020\",\"Completed\",,\"August 29, 2022\"\n",
      "943,\"Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs)\",\"Adverse events were collected and reported from the time of receiving first dose of derazantinib to the end of study assessment and follow-up period (30-day post-treatment)\",\"Completed\",,\"March 9, 2022\"\n",
      "944,\"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.\",\"4 years|4 years|4 years\",\"Completed\",,\"November 7, 2022\"\n",
      "945,\"Incidence of Dose Limiting Toxicities (DLTs)|Incidence of treatment emergent adverse events|Incidence of changes in clinical laboratory abnormalities|Investigator-assessed objective response rate (ORR) by RECIST 1.1 and immune ORR by iRECIST (for solid tumors) or response by Lugano criteria (for lymphomas)\",\"4 weeks|24 months|24 months|24 months\",\"Recruiting\",,\"March 16, 2023\"\n",
      "946,\"Maximum Tolerated Dose\",\"4 Weeks\",\"Completed\",,\"December 8, 2020\"\n",
      "947,\"Dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Toxicity Criteria|Maximum tolerated dose, defined as one dose level below the dose that induces DLT in more than 1/6 patients\",\"28 days|28 days\",\"Completed\",,\"July 2, 2013\"\n",
      "948,\"Evaluate Safety and Tolerability|Define the Recommended Phase 2 Dose (RP2D)|Define the objective response rate (ORR)\",\"Three years|Approximately 22 months|Two to three years after first dose of Repotrectinib in combination with other anticancer therapies\",\"Active, not recruiting\",,\"November 9, 2022\"\n",
      "949,\"Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)|Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)|Part B: Cmax: Maximum Observed Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food|Part B: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food|Part B: Cmax: Maximum Plasma Concentration for Alisertib Oral Solution Following Multiple-Dose Administration|Part B: Tmax: Time of First Occurrence of Cmax Over the Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration|Part B: AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration|Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food|Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food|Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%|Number of Participants With Abnormal Vital Signs Reported as Adverse Events\",\"Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual adverse event (AE) that was judged by the investigator to be treatment related.|Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.|Up to 30 days after the last dose of study drug (up to 27.4 months)|Up to 30 days after the last dose of study drug (up to 27.4 months)|Up to 30 days after the last dose of study drug (up to 24 months approximately)\",\"Completed\",,\"March 12, 2019\"\n",
      "950,\"Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part A: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0)|Part A: Number of Participants With Clinically Relevant Findings in Vital Signs|Part A: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)|Part A: Maximum Tolerated Dose (MTD) of M4344 Administered Twice Weekly (BIW)|Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)|Part A2: Number of Participants With Clinically Relevant Findings in Vital Signs|Part A2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)|Part A2: Maximum Tolerated Dose (MTD) of M4344 Administered With a Dose Dense Schedule|Part B1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0)|Part B1: Number of Participants With Clinically Relevant Findings in Vital Signs|Part B1: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)|Part B1: Maximum Tolerated Dose (MTD) of M4344 (Monotherapy) Administered in Combination With Carboplatin|Part C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Related AEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0|Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)|Part C: Number of Participants With Clinically Relevant Findings in Vital Signs|Part C: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)|Part C: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator\",\"up to safety follow-up visit (Week 124.9)|up to safety follow-up visit (Week 124.9)|up to safety follow-up visit (Week 124.9)|up to safety follow-up visit (Week 124.9)|up to Cycle 1 (each cycle is of 21 days)|up to safety follow-up visit (Week 39)|up to safety follow-up visit (Week 39)|up to safety follow-up visit (Week 39)|up to safety follow-up visit (Week 39)|up to Cycle 1 (each cycle is of 21 days)|up to Safety follow-up (Week 92.3)|up to Safety follow-up (Week 92.3)|up to Safety follow-up (Week 92.3)|up to Safety follow-up (Week 92.3)|up to Cycle 1 (each cycle is of 21 days)|up to Safety follow-up (Week 31.1)|up to Safety follow-up (Week 31.1)|up to Safety follow-up (Week 31.1)|up to Safety follow-up (Week 31.1)|Time from first dose of study treatment up to 6.4 years\",\"Completed\",,\"March 16, 2023\"\n",
      "951,\"Frequency of dose limiting toxicities of tegavivint|Frequency of adverse events attributable to tegavivint|Area under the drug concentration curve of tegavivint\",\"Up to 28 days|Up to 60 months|Up to 2 days\",\"Recruiting\",,\"March 10, 2023\"\n",
      "952,\"Maximum tolerated dose (MTD)\",\"4 weeks\",\"Completed\",,\"September 19, 2019\"\n",
      "953,\"Phase 1 Maximum Tolerated Dose|Phase 1 Dosing Schedule|Phase 2 Anti-neoplastic Activity\",\"28 days|28 days|16 weeks\",\"Not yet recruiting\",,\"February 21, 2023\"\n",
      "954,\"Safety measurements|Safety Measurements|Anti-tumor activity\",\"28 days|time on trial, average of 6 months|Through study completion up to 24 months\",\"Recruiting\",,\"June 30, 2022\"\n",
      "955,\"Standardized uptake value (SUV)|standardized uptake value ratio (SUVR)|Radiation dose\",\"Day 0-7|Day 0-7|Day 0-7\",\"Not yet recruiting\",,\"April 12, 2021\"\n",
      "956,\"Overall response rate assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\",\"Up to 52 weeks\",\"Withdrawn\",,\"February 18, 2022\"\n",
      "957,\"accuracy of algorithm|A quantitative study on usability\",\"This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients.|This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients.\",\"Completed\",,\"September 13, 2021\"\n",
      "958,\"Frequency of adverse events (AEs) and serious adverse events (SAEs)|Maximum Tolerated dose of ZV0203\",\"From the day of ICF sign to 30 days after the day of the last treatment|21 days after first treatment\",\"Enrolling by invitation\",,\"June 21, 2022\"\n",
      "959,\"Estimate the maximum tolerated dose (MTD) of imetelstat given as a 2-hour IV infusion on D1 and D8 every 21 days.|Define the toxicities and characterize pharmacokinetics\",,\"Withdrawn\",,\"November 21, 2012\"\n",
      "960,\"Dose limiting toxicity rate during cycle 1 of treatment with oral ONC201\",\"Day 21\",\"Completed\",,\"May 22, 2019\"\n",
      "961,\"Maximum tolerated dose (MTD) of vatalanib and everolimus|Safety and tolerability|Safety and tolerability at the MTD in patients with metastatic renal cell carcinoma (RCC)\",\"Day 1 - 28|Duration of study treatment|Duration of study treatment\",\"Completed\",,\"March 3, 2016\"\n",
      "962,\"Percentage of Participants Experiencing Adverse Events According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0|Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE Version 5.0|Objective response rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)\",\"First dose date up to 3 years|First dose date up to 3 years|Up to 6 months\",\"Recruiting\",,\"March 2, 2023\"\n",
      "963,\"Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors\",,\"Completed\",,\"April 8, 2013\"\n",
      "964,\"Maximum tolerated dose (MTD) of RO4929097 determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|MTD of RO4929097 administered with dexamethasone determined according to DLTs graded using CTCAE v4.0\",\"28 days|28 days\",\"Terminated\",,\"November 5, 2014\"\n",
      "965,\"immune-related objective response rate\",\"every 2 cycles (3 weeks cycles); that is before every third dose of pembrolizumab\",\"Active, not recruiting\",,\"November 21, 2022\"\n",
      "966,\"Number of participants with adverse events|To determine the dose limiting toxicity (DLT)|To determine the maximum tolerated dose(MTD)|To determine the recommended dose of phase II|Objective response rate as determined by the Invertigator using RECIST V1.1\",\"From the day of first dose to 21 days after last dose|In the dose escalation part, from the day of first dose to 21 days after last dose|In the dose escalation part, from the day of first dose to 21 days after last dose|In the dose escalation part, from the day of first dose to 21 days after last dose|In the dose escalation part, from the day of first dose to 21 days after last dose\",\"Recruiting\",,\"November 29, 2022\"\n",
      "967,\"safety endpoint|Overall Response Rate|Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.\",\"one year|one year|one year\",\"Unknown status\",\"Not yet recruiting\",\"August 14, 2017\"\n",
      "968,\"Safety and Tolerability of intravenous ALN-VSP02\",\"up to 16 weeks (4 cycles)\",\"Completed\",,\"August 24, 2011\"\n",
      "969,\"Dose limiting toxicities(DLT)|Maximum Tolerated Dose\",\"12 months|12 months\",\"Recruiting\",,\"December 29, 2022\"\n",
      "970,\"Part 1-MTD|Part 2-RECIST|Part 2-RANO|Part 3 - RECIST\",\"12 months|12 months|12 months|12 months\",\"Completed\",,\"July 22, 2021\"\n",
      "971,\"Number of participants with treatment-emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and their severity|Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level in the dose escalation part of the study|Recommended Phase 2 dose (RP2D) of BAY2965501|Maximum concentration (Cmax) of the respective dosing interval of BAY2965501 after single dose|Area under the curve [AUC (0 - 24)] for once daily (QD) dosing of BAY2965501 after single dose in Cycle 1|Area under the curve [AUC(0-12)] for 2 times daily (BID) dosing after single dose in Cycle 1 (if applicable))|Maximum concentration (Cmax,md) of the respective dosing interval of BAY2965501 after multiple dose|Area under the curve [AUC(0-24)md] for QD dosing of BAY2965501 after multiple dose|Area under the curve [AUC(0-12)md] for BID dosing of BAY2965501 after multiple dose (if applicable)\",\"Up to 90 days after the last administration of study treatment|From first dose of study treatment to the end of Cycle 1 (each cycle is 21 days)|Up to 90 days after the last administration of study treatment|From pre-dose up to 24 hours after administration on Cycle 1 Day 1 (each cycle is 21 days)|From pre-dose up to 24 hours after administration on Cycle 1 Day 1 (each cycle is 21 days)|From pre-dose up to 24 hours after administration on Cycle 1 Day 1 (each cycle is 21 days)|From pre-dose up to 24 hours after administration on Cycle 1 Day 15 (each cycle is 21 days)|From pre-dose up to 24 hours after administration on Cycle 1 Day 15 (each cycle is 21 days)|From pre-dose up to 24 hours after administration on Cycle 1 Day 15 (each cycle is 21 days)\",\"Recruiting\",,\"March 20, 2023\"\n",
      "972,\"Maximum Tolerated Dose (MTD) of Lipotecan|Number of Participants With Adverse Events|Maximum Observed Dose-normalized Plasma Concentration (Cmax) of S,R-TLC388|Maximum Observed Dose-normalized Plasma Concentration (Cmax) of S,S-TLC388|Maximum Observed Dose-normalized Plasma Concentration (Cmax) of Topotecan|Maximum Observed Dose-normalized Plasma Concentration (Cmax) of TLC-U1|Maximum Observed Dose-normalized Plasma Concentration (Cmax) of TLC-U2|Time to Reach Maximum Observed Plasma Concentration (Tmax) of S,R-TLC388|Time to Reach Maximum Observed Plasma Concentration (Tmax) of S,S-TLC388|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Topotecan|Time to Reach Maximum Observed Plasma Concentration (Tmax) of TLC-U1|Time to Reach Maximum Observed Plasma Concentration (Tmax) of TLC-U2|Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of S,R-TLC388|Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of S,S-TLC388|Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Topotecan|Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of TLC-U1|Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of TLC-U2|Plasma Decay Half-Life (t1/2) of S,R-TLC388|Plasma Decay Half-Life (t1/2) of S,S-TLC388|Plasma Decay Half-Life (t1/2) of Topotecan|Plasma Decay Half-Life (t1/2) of TLC-U1|Plasma Decay Half-Life (t1/2) of TLC-U2\",\"First treatment to toxicity up to 42 days|an average of 6 months|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1h, 1h30m, 2h, 4h, 8h|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose|0, 15m, 29m, 33m, 40m, 50m, 1 h, 1h 30m, 2h, 4h, 8h post-dose\",\"Completed\",,\"November 18, 2019\"\n",
      "973,\"To evaluate the safety.|recommended Phase II dose (RP2D) of LAE005 and afuresertib and nab-paclitaxel as a combination treatment in patients with advanced solid tumours (including mTNBC)|To evaluate the tolerability.|To determine the maximum tolerated dose (MTD)\",\"1year|1year|1year|1year\",\"Recruiting\",,\"May 25, 2022\"\n",
      "974,\"DLT's and MTD Safety and Toxicity profile\",\"During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years\",\"Terminated\",,\"November 14, 2019\"\n",
      "975,\"Incidence of Dose Limiting Toxicities (DLTs)|Number of Participants with Adverse Events (AEs)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with laboratory value abnormalities and/or adverse events (AEs)|Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)|Number of Participants with vital sign abnormalities and/or adverse events (AEs)|Number of Participants with physical exam abnormalities and/or adverse events|Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status\",\"Up to 21 Days|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months\",\"Recruiting\",,\"March 24, 2023\"\n",
      "976,\"Maximum Tolerated Dose(MTD)|Overall Response Rate (ORR) in stage 2\",\"At the end of Cycle 1 (each cycle is 28 days)|up to approximately 2 years\",\"Not yet recruiting\",,\"November 8, 2022\"\n",
      "977,\"Frequency and characteristics of Dose limiting toxicities at each dose level\",\"2 years\",\"Terminated\",,\"December 21, 2020\"\n",
      "978,\"Dose limiting toxicity (DLT) of PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007)|Incidence of adverse events\",\"After first cycle (28 days)|Up to 2 years\",\"Recruiting\",,\"December 9, 2022\"\n",
      "979,\"Pharmacokinetics of Olaparib (Cmax and tmax)|Pharmacokinetics of Olaparib (AUC0-t)|Pharmacokinetics of Olaparib (AUC)|Pharmacokinetics of Olaparib Pharmacokinetics of Olaparib (CL/F, Vz/F, λz and t½)\",\"Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose|Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.|Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose|Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose.\",\"Completed\",,\"August 28, 2017\"\n",
      "980,\"Phase 1a: Dose Limiting Toxicities (DLT)|Phase 1b: Objective Response Rate (ORR)\",\"From data of initial dose until up to 21 days for treatment|Up to 2 years\",\"Recruiting\",,\"May 16, 2022\"\n",
      "981,\"Part 1: Maximum tolerated dose (MTD) of RX108|Part 2: Incidence of adverse events (AEs) and serious adverse events (SAEs).\",\"Day 1 to 30|Day 1 to 30 days post last dose\",\"Recruiting\",,\"April 13, 2022\"\n",
      "982,\"Maximum tolerated dose (MTD) (for Part 1a)|Recommended phase 2 dose (RP2D）(for Part 1a)|Overall Response Rate (ORR) (for Part 1b)\",\"Up to 3 weeks|Up to 3 weeks|Up to 2-3 years\",\"Not yet recruiting\",,\"March 16, 2023\"\n",
      "983,\"Determination of MTAP status in tumors\",\"From initiation of the Pre-Screen study until the Phase 1 study of AG-270 is activated at each study site, up to 9 months\",\"Completed\",,\"March 16, 2020\"\n",
      "984,\"Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0|Adverse events, graded according to the NCI CTC v3.0\",\"Up to day 28|Up to 2 years\",\"Completed\",,\"January 24, 2013\"\n",
      "985,\"Description of regions of interest (ROI) 89Zr-KN035 by measuring standardized uptake value (SUV) on 89Zr-KN035 PET scans\",\"6 months\",\"Unknown status\",\"Recruiting\",\"December 5, 2018\"\n",
      "986,\"To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors\",\"3 years\",\"Completed\",,\"October 27, 2016\"\n",
      "987,\"Estimated Maximum Tolerated Dose of gimatecan\",\"1.8 years\",\"Completed\",,\"December 19, 2020\"\n",
      "988,\"Relative dose-intensity (RDI) of the myelosupressive therapy course\",\"12 months\",\"Unknown status\",\"Recruiting\",\"March 23, 2021\"\n",
      "989,\"Recommended phase 2 dose of veliparib/dinaciclib\",\"Up to day 28\",\"Recruiting\",,\"February 6, 2023\"\n",
      "990,\"Circulating levels of myeloid derived suppressor cells\",\"Up to 2 years\",\"Unknown status\",\"Active, not recruiting\",\"February 24, 2021\"\n",
      "991,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) of at least Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 severity, and discontinuations due to AEs.|The maximum tolerated dose (MTD) of SAIT301 and the dose level of SAIT301 where dose limiting toxicity (DLT) is observed in subjects with advanced solid tumors|A recommended Phase II dose (RP2D) as an alternative to establishing the MTD.\",\"Up to 25 weeks for each subject|Up to 25 weeks for each subject|Up to 25 weeks for each subject\",\"Completed\",,\"January 17, 2018\"\n",
      "992,\"Identify recommended phase 2 dose by measuring incidence of dose limiting toxicities at increasing dose levels. Determine the safety and tolerability of VT1021 in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36 high cohort.\",\"2 doses weekly for 4 week cycle\",\"Active, not recruiting\",,\"October 25, 2022\"\n",
      "993,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)\",\"through first treatment cycle (an average of 21 days)\",\"Recruiting\",,\"July 7, 2022\"\n",
      "994,\"Number of participants experiencing serious adverse events (SAEs) and/or adverse events (AEs) regardless of causality\",\"14 months\",\"Completed\",,\"May 5, 2021\"\n",
      "995,\"Feasibility of TIL-ACT in combination with LDI - successful Rapid Expansion Protocol (REP): Number of patients for whom TIL cultures|Feasibility of TIL-ACT in combination with LDI - successful infusion: Number of patients receiving a complete TIL-ACT infusion|Toxicity of TIL-ACT and LDI\",\"Evaluated for each patient at day 0. After day 0 of the last patient, the number of patients with successful TIL-ACT infusion will be calculated.|Evaluated for each patient at day 0, up to 60 mins after start of TIL-ACT infusion. At day 0 of the last patient, the number of patients with successful TIL-ACT infusion will be calculated.|Treatment limiting toxicity (TLT) period: from chemotherapy start until Day30\",\"Terminated\",,\"March 18, 2021\"\n",
      "996,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants with Dose-limiting Toxicities (DLT)|Number of Participants with TEAEs Resulting in Permanent Discontinuation of MEDI5395|Number of Participants with TEAEs Resulting in Permanent Discontinuation of Durvalumab|Number of Participants With Abnormal Vital Signs Reported as TEAEs|Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs|Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Maximum Reduction From Baseline in Global Longitudinal Strain (GLS) Values|Number of Participants With at Least 1-Grade Shift From Baseline to Worst Post-baseline in Eastern Co-operative Oncology Group Performance Status (ECOG-PS) Score\",\"From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|Day 1 to Day 28 of first dose of MEDI5395|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of durvalumab through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)|From first dose of MEDI5395 through 14.4 months (corresponding to maximum observed duration)\",\"Completed\",,\"February 21, 2023\"\n",
      "997,\"Response rate|Dose limiting toxicity\",\"Up to 2.5 years|At the end of Cycle 1 (each cycle is 21 days)\",\"Active, not recruiting\",,\"March 15, 2023\"\n",
      "998,\"Dose-limiting toxicity (DLT)|MTD (or recommended phase II dose), defined as one dose level below that which produces two instances of DLT during the first 28-day course and the level at which no more than one of six patients experiences DLT during course 1\",\"28 days|28 days\",\"Terminated\",,\"December 16, 2013\"\n",
      "999,\"Quality and quantity of adverse events due to administration of erlotinib + 5-azacytidine, as therapy for the treatment of advanced or metastatic cancer.\",\"4 years\",\"Completed\",,\"May 1, 2013\"\n",
      "1000,\"Number of participants with adverse events\",\"From the day of first dose to 30 days after last dose of CS1002\",\"Completed\",,\"December 16, 2022\"\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# FETCH THE CSV DATA FROM THE API\n",
    "\n",
    "from requests import get\n",
    "import pandas as pd\n",
    "\n",
    "base_url = \"https://clinicaltrials.gov/api/query/study_fields?\" # base url for our endpoint\n",
    "\n",
    "expr = \"solid tumor\" # basic search term\n",
    "actual_expr = expr.replace(' ', '+') # replace spaces in expr with '+'\n",
    "\n",
    "fields = [\"PrimaryOutcomeMeasure\", \"PrimaryOutcomeTimeFrame\", \"OverallStatus\", \"LastKnownStatus\", \"LastUpdatePostDate\"] # fields we want to get\n",
    "actual_fields = \",\".join(fields) # join fields with commas\n",
    "\n",
    "fmt = \"csv\" # get in csv format\n",
    "\n",
    "num_results = 1000 # number of results we want\n",
    "\n",
    "params = {\n",
    "    \"expr\": actual_expr,\n",
    "    \"fields\": actual_fields,\n",
    "    \"min_rnk\": \"1\",\n",
    "    \"max_rnk\": str(num_results),\n",
    "    \"fmt\": fmt\n",
    "}\n",
    "\n",
    "response = get(base_url, params=params)\n",
    "\n",
    "if response.ok:\n",
    "    print(\"Request successful!\")\n",
    "else:\n",
    "    print(\"Request failed!\")\n",
    "print(response.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "# WRITE THE CSV DATA TO A FILE\n",
    "\n",
    "import csv\n",
    "lines = response.text.split('\\n') # split by newlines\n",
    "\n",
    "with open('output.csv', mode='w', newline='') as file: # open a file to write to\n",
    "    writer = csv.writer(file, delimiter=';') # create a csv writer\n",
    "    headers = ['Rank'] + fields # create headers\n",
    "    writer.writerow(headers) # write headers\n",
    "\n",
    "    for line in lines[11:]: # skip first 11 lines\n",
    "        row = line.split(',\\\"') # split by commas followed by a quote\n",
    "        \n",
    "        for i,r in enumerate(row):\n",
    "            row[i] = r.replace('\\\"', '') # remove quotes\n",
    "            \n",
    "        writer.writerow(row) # write row"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>PrimaryOutcomeMeasure</th>\n",
       "      <th>PrimaryOutcomeTimeFrame</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>LastKnownStatus</th>\n",
       "      <th>LastUpdatePostDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Relief degree of tumors</td>\n",
       "      <td>The last injection</td>\n",
       "      <td>Not yet recruiting,</td>\n",
       "      <td>February 28, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Prevalence of solid tumors in RASopathies</td>\n",
       "      <td>5 years</td>\n",
       "      <td>Recruiting,</td>\n",
       "      <td>March 9, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Solid tumor biological insights</td>\n",
       "      <td>Study completion</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>June 12, 2014</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Adverse Events(AE)|Objective Response Rate (OR...</td>\n",
       "      <td>6 month|Up to 36 months|Up to 36 months|Up to ...</td>\n",
       "      <td>Recruiting,</td>\n",
       "      <td>December 21, 2022</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>To Establish the Safety and Tolerability of Si...</td>\n",
       "      <td>Date treatment consent signed to date off stud...</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>July 26, 2021</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>996</th>\n",
       "      <td>997</td>\n",
       "      <td>Response rate|Dose limiting toxicity</td>\n",
       "      <td>Up to 2.5 years|At the end of Cycle 1 (each cy...</td>\n",
       "      <td>Active, not recruiting,</td>\n",
       "      <td>March 15, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>997</th>\n",
       "      <td>998</td>\n",
       "      <td>Dose-limiting toxicity (DLT)|MTD (or recommend...</td>\n",
       "      <td>28 days|28 days</td>\n",
       "      <td>Terminated,</td>\n",
       "      <td>December 16, 2013</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>998</th>\n",
       "      <td>999</td>\n",
       "      <td>Quality and quantity of adverse events due to ...</td>\n",
       "      <td>4 years</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>May 1, 2013</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>999</th>\n",
       "      <td>1000</td>\n",
       "      <td>Number of participants with adverse events</td>\n",
       "      <td>From the day of first dose to 30 days after la...</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>December 16, 2022</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1000</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1001 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Rank                              PrimaryOutcomeMeasure  \\\n",
       "0        1                            Relief degree of tumors   \n",
       "1        2          Prevalence of solid tumors in RASopathies   \n",
       "2        3                    Solid tumor biological insights   \n",
       "3        4  Adverse Events(AE)|Objective Response Rate (OR...   \n",
       "4        5  To Establish the Safety and Tolerability of Si...   \n",
       "...    ...                                                ...   \n",
       "996    997               Response rate|Dose limiting toxicity   \n",
       "997    998  Dose-limiting toxicity (DLT)|MTD (or recommend...   \n",
       "998    999  Quality and quantity of adverse events due to ...   \n",
       "999   1000         Number of participants with adverse events   \n",
       "1000   NaN                                                NaN   \n",
       "\n",
       "                                PrimaryOutcomeTimeFrame  \\\n",
       "0                                    The last injection   \n",
       "1                                               5 years   \n",
       "2                                      Study completion   \n",
       "3     6 month|Up to 36 months|Up to 36 months|Up to ...   \n",
       "4     Date treatment consent signed to date off stud...   \n",
       "...                                                 ...   \n",
       "996   Up to 2.5 years|At the end of Cycle 1 (each cy...   \n",
       "997                                     28 days|28 days   \n",
       "998                                             4 years   \n",
       "999   From the day of first dose to 30 days after la...   \n",
       "1000                                                NaN   \n",
       "\n",
       "                OverallStatus    LastKnownStatus LastUpdatePostDate  \n",
       "0         Not yet recruiting,  February 28, 2023                NaN  \n",
       "1                 Recruiting,      March 9, 2023                NaN  \n",
       "2                  Completed,      June 12, 2014                NaN  \n",
       "3                 Recruiting,  December 21, 2022                NaN  \n",
       "4                  Completed,      July 26, 2021                NaN  \n",
       "...                       ...                ...                ...  \n",
       "996   Active, not recruiting,     March 15, 2023                NaN  \n",
       "997               Terminated,  December 16, 2013                NaN  \n",
       "998                Completed,        May 1, 2013                NaN  \n",
       "999                Completed,  December 16, 2022                NaN  \n",
       "1000                      NaN                NaN                NaN  \n",
       "\n",
       "[1001 rows x 6 columns]"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# READ INTO A PANDAS DATAFRAME\n",
    "df = pd.read_csv(\"output.csv\", delimiter=';')\n",
    "df"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "TODO:\n",
    "1. Separate the individual `PrimaryOutcomeMeasure` & `PrimaryOutcomeTimeFrame` points into their own pieces of data (separated by `|` right now)\n",
    "2. Any more data cleaning (ex. remove `,` from the `LastKnownStatus` column)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>PrimaryOutcomeMeasure</th>\n",
       "      <th>PrimaryOutcomeTimeFrame</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>LastKnownStatus</th>\n",
       "      <th>LastUpdatePostDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Relief degree of tumors</td>\n",
       "      <td>The last injection</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>February 28, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Prevalence of solid tumors in RASopathies</td>\n",
       "      <td>5 years</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>March 9, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Solid tumor biological insights</td>\n",
       "      <td>Study completion</td>\n",
       "      <td>Completed</td>\n",
       "      <td>June 12, 2014</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Adverse Events(AE)|Objective Response Rate (OR...</td>\n",
       "      <td>6 month|Up to 36 months|Up to 36 months|Up to ...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>December 21, 2022</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>To Establish the Safety and Tolerability of Si...</td>\n",
       "      <td>Date treatment consent signed to date off stud...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>July 26, 2021</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>996</th>\n",
       "      <td>997</td>\n",
       "      <td>Response rate|Dose limiting toxicity</td>\n",
       "      <td>Up to 2.5 years|At the end of Cycle 1 (each cy...</td>\n",
       "      <td>Active not recruiting</td>\n",
       "      <td>March 15, 2023</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>997</th>\n",
       "      <td>998</td>\n",
       "      <td>Dose-limiting toxicity (DLT)|MTD (or recommend...</td>\n",
       "      <td>28 days|28 days</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>December 16, 2013</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>998</th>\n",
       "      <td>999</td>\n",
       "      <td>Quality and quantity of adverse events due to ...</td>\n",
       "      <td>4 years</td>\n",
       "      <td>Completed</td>\n",
       "      <td>May 1, 2013</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>999</th>\n",
       "      <td>1000</td>\n",
       "      <td>Number of participants with adverse events</td>\n",
       "      <td>From the day of first dose to 30 days after la...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>December 16, 2022</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1000</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1001 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Rank                              PrimaryOutcomeMeasure  \\\n",
       "0        1                            Relief degree of tumors   \n",
       "1        2          Prevalence of solid tumors in RASopathies   \n",
       "2        3                    Solid tumor biological insights   \n",
       "3        4  Adverse Events(AE)|Objective Response Rate (OR...   \n",
       "4        5  To Establish the Safety and Tolerability of Si...   \n",
       "...    ...                                                ...   \n",
       "996    997               Response rate|Dose limiting toxicity   \n",
       "997    998  Dose-limiting toxicity (DLT)|MTD (or recommend...   \n",
       "998    999  Quality and quantity of adverse events due to ...   \n",
       "999   1000         Number of participants with adverse events   \n",
       "1000   NaN                                                NaN   \n",
       "\n",
       "                                PrimaryOutcomeTimeFrame  \\\n",
       "0                                    The last injection   \n",
       "1                                               5 years   \n",
       "2                                      Study completion   \n",
       "3     6 month|Up to 36 months|Up to 36 months|Up to ...   \n",
       "4     Date treatment consent signed to date off stud...   \n",
       "...                                                 ...   \n",
       "996   Up to 2.5 years|At the end of Cycle 1 (each cy...   \n",
       "997                                     28 days|28 days   \n",
       "998                                             4 years   \n",
       "999   From the day of first dose to 30 days after la...   \n",
       "1000                                                NaN   \n",
       "\n",
       "              OverallStatus    LastKnownStatus LastUpdatePostDate  \n",
       "0        Not yet recruiting  February 28, 2023                NaN  \n",
       "1                Recruiting      March 9, 2023                NaN  \n",
       "2                 Completed      June 12, 2014                NaN  \n",
       "3                Recruiting  December 21, 2022                NaN  \n",
       "4                 Completed      July 26, 2021                NaN  \n",
       "...                     ...                ...                ...  \n",
       "996   Active not recruiting     March 15, 2023                NaN  \n",
       "997              Terminated  December 16, 2013                NaN  \n",
       "998               Completed        May 1, 2013                NaN  \n",
       "999               Completed  December 16, 2022                NaN  \n",
       "1000                    NaN                NaN                NaN  \n",
       "\n",
       "[1001 rows x 6 columns]"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['OverallStatus']=df['OverallStatus'].str.replace(',','')\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:>"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.OverallStatus.value_counts().plot.bar()\n",
    "# We probably should remove everything that is \"Unknown Status\" or random dates or other nonsense"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Clean up by the overallstatus column\n",
    "df = df[df['OverallStatus'].isin(['Completed', 'Terminated', 'Withdrawn', 'Active, not recruiting', 'Recruiting', 'Enrolling by invitation', 'Suspended'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:>"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAigAAAInCAYAAACyW6JQAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjUuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8qNh9FAAAACXBIWXMAAA9hAAAPYQGoP6dpAABKoklEQVR4nO3dd3QV1f7//9dJBUISEkqKxhCqQkApSlEhFAMI0vxcUBBpFuo1lKuiImAJiNKuBa5epEP8egXkiiJBSBCRC0Q6SEeCJkQhJARigGR+f7g8Pw6hBU6Ymfh8rDVrcWZ2Du8zCzKvs2fP3g7DMAwBAABYiIfZBQAAAFyKgAIAACyHgAIAACyHgAIAACyHgAIAACyHgAIAACyHgAIAACyHgAIAACzHy+wCbkRBQYF++eUX+fv7y+FwmF0OAAC4DoZh6PTp0woPD5eHx9X7SGwZUH755RdFRESYXQYAALgBqampuv3226/axpYBxd/fX9IfHzAgIMDkagAAwPXIzs5WRESE8zp+NbYMKH/e1gkICCCgAABgM9czPINBsgAAwHIIKAAAwHIIKAAAwHIIKAAAwHJuKqCMHz9eDodDcXFxzn2GYWjs2LEKDw9X6dKlFRMTo127drn8XF5enoYOHaoKFSrIz89PHTt21LFjx26mFAAAUILccEDZtGmTPvzwQ9WtW9dl/8SJEzV58mS999572rRpk0JDQ/XQQw/p9OnTzjZxcXFasmSJEhIStG7dOuXk5KhDhw7Kz8+/8U8CAABKjBsKKDk5OerZs6c++ugjBQUFOfcbhqGpU6fq5ZdfVteuXRUdHa05c+bo7NmzWrhwoSQpKytLM2fO1KRJk9S6dWvVq1dP8+fP144dO7Rq1Sr3fCoAAGBrNxRQBg8erPbt26t169Yu+w8fPqz09HTFxsY69/n6+qp58+Zav369JCklJUXnz593aRMeHq7o6Ghnm0vl5eUpOzvbZQMAACVXkSdqS0hI0A8//KBNmzYVOpaeni5JCgkJcdkfEhKin376ydnGx8fHpeflzzZ//vylxo8fr3HjxhW1VAAAYFNF6kFJTU3Vc889p/nz56tUqVJXbHfpDHGGYVxz1rirtRk1apSysrKcW2pqalHKBgAANlOkgJKSkqKMjAw1aNBAXl5e8vLyUnJysv75z3/Ky8vL2XNyaU9IRkaG81hoaKjOnTunzMzMK7a5lK+vr3Nae6a3BwCg5CtSQGnVqpV27NihrVu3OreGDRuqZ8+e2rp1q6pUqaLQ0FAlJiY6f+bcuXNKTk5W06ZNJUkNGjSQt7e3S5u0tDTt3LnT2QYAAPy1FWkMir+/v6Kjo132+fn5qXz58s79cXFxio+PV/Xq1VW9enXFx8erTJky6tGjhyQpMDBQ/fv314gRI1S+fHkFBwdr5MiRqlOnTqFBtwAA4K/J7asZP//888rNzdWgQYOUmZmpRo0aaeXKlS5LK0+ZMkVeXl7q1q2bcnNz1apVK82ePVuenp7uLgcAANiQwzAMw+wiiio7O1uBgYHKyspy63iUyi8ud9t7FZcjE9qbXQIAADekKNdv1uIBAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWQ0ABAACWU6SAMn36dNWtW1cBAQEKCAhQkyZN9NVXXzmP9+nTRw6Hw2Vr3Lixy3vk5eVp6NChqlChgvz8/NSxY0cdO3bMPZ8GAACUCEUKKLfffrsmTJigzZs3a/PmzWrZsqU6deqkXbt2Odu0bdtWaWlpzu3LL790eY+4uDgtWbJECQkJWrdunXJyctShQwfl5+e75xMBAADb8ypK40ceecTl9Ztvvqnp06drw4YNql27tiTJ19dXoaGhl/35rKwszZw5U/PmzVPr1q0lSfPnz1dERIRWrVqlNm3a3MhnAAAAJcwNj0HJz89XQkKCzpw5oyZNmjj3JyUlqVKlSqpRo4aefvppZWRkOI+lpKTo/Pnzio2Nde4LDw9XdHS01q9ff8W/Ky8vT9nZ2S4bAAAouYocUHbs2KGyZcvK19dXAwYM0JIlS1SrVi1JUrt27bRgwQKtXr1akyZN0qZNm9SyZUvl5eVJktLT0+Xj46OgoCCX9wwJCVF6evoV/87x48crMDDQuUVERBS1bAAAYCNFusUjSTVr1tTWrVt16tQpffbZZ+rdu7eSk5NVq1Ytde/e3dkuOjpaDRs2VGRkpJYvX66uXbte8T0Nw5DD4bji8VGjRmn48OHO19nZ2YQUAABKsCIHFB8fH1WrVk2S1LBhQ23atEnTpk3Tv/71r0Jtw8LCFBkZqf3790uSQkNDde7cOWVmZrr0omRkZKhp06ZX/Dt9fX3l6+tb1FIBAIBN3fQ8KIZhOG/hXOrEiRNKTU1VWFiYJKlBgwby9vZWYmKis01aWpp27tx51YACAAD+WorUg/LSSy+pXbt2ioiI0OnTp5WQkKCkpCStWLFCOTk5Gjt2rB599FGFhYXpyJEjeumll1ShQgV16dJFkhQYGKj+/ftrxIgRKl++vIKDgzVy5EjVqVPH+VQPAABAkQLK8ePH1atXL6WlpSkwMFB169bVihUr9NBDDyk3N1c7duzQ3LlzderUKYWFhalFixb65JNP5O/v73yPKVOmyMvLS926dVNubq5atWql2bNny9PT0+0fDgAA2JPDMAzD7CKKKjs7W4GBgcrKylJAQIDb3rfyi8vd9l7F5ciE9maXAADADSnK9Zu1eAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUQUAAAgOUUKaBMnz5ddevWVUBAgAICAtSkSRN99dVXzuOGYWjs2LEKDw9X6dKlFRMTo127drm8R15enoYOHaoKFSrIz89PHTt21LFjx9zzaQAAQIlQpIBy++23a8KECdq8ebM2b96sli1bqlOnTs4QMnHiRE2ePFnvvfeeNm3apNDQUD300EM6ffq08z3i4uK0ZMkSJSQkaN26dcrJyVGHDh2Un5/v3k8GAABsy2EYhnEzbxAcHKy3335b/fr1U3h4uOLi4vTCCy9I+qO3JCQkRG+99ZaeffZZZWVlqWLFipo3b566d+8uSfrll18UERGhL7/8Um3atLmuvzM7O1uBgYHKyspSQEDAzZTvovKLy932XsXlyIT2ZpcAAMANKcr1+4bHoOTn5yshIUFnzpxRkyZNdPjwYaWnpys2NtbZxtfXV82bN9f69eslSSkpKTp//rxLm/DwcEVHRzvbXE5eXp6ys7NdNgAAUHIVOaDs2LFDZcuWla+vrwYMGKAlS5aoVq1aSk9PlySFhIS4tA8JCXEeS09Pl4+Pj4KCgq7Y5nLGjx+vwMBA5xYREVHUsgEAgI0UOaDUrFlTW7du1YYNGzRw4ED17t1bu3fvdh53OBwu7Q3DKLTvUtdqM2rUKGVlZTm31NTUopYNAABspMgBxcfHR9WqVVPDhg01fvx43X333Zo2bZpCQ0MlqVBPSEZGhrNXJTQ0VOfOnVNmZuYV21yOr6+v88mhPzcAAFBy3fQ8KIZhKC8vT1FRUQoNDVViYqLz2Llz55ScnKymTZtKkho0aCBvb2+XNmlpadq5c6ezDQAAgFdRGr/00ktq166dIiIidPr0aSUkJCgpKUkrVqyQw+FQXFyc4uPjVb16dVWvXl3x8fEqU6aMevToIUkKDAxU//79NWLECJUvX17BwcEaOXKk6tSpo9atWxfLBwQAAPZTpIBy/Phx9erVS2lpaQoMDFTdunW1YsUKPfTQQ5Kk559/Xrm5uRo0aJAyMzPVqFEjrVy5Uv7+/s73mDJliry8vNStWzfl5uaqVatWmj17tjw9Pd37yQAAgG3d9DwoZmAeFAAA7OeWzIMCAABQXAgoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcggoAADAcooUUMaPH697771X/v7+qlSpkjp37qy9e/e6tOnTp48cDofL1rhxY5c2eXl5Gjp0qCpUqCA/Pz917NhRx44du/lPAwAASoQiBZTk5GQNHjxYGzZsUGJioi5cuKDY2FidOXPGpV3btm2Vlpbm3L788kuX43FxcVqyZIkSEhK0bt065eTkqEOHDsrPz7/5TwQAAGzPqyiNV6xY4fJ61qxZqlSpklJSUtSsWTPnfl9fX4WGhl72PbKysjRz5kzNmzdPrVu3liTNnz9fERERWrVqldq0aVPUzwAAAEqYmxqDkpWVJUkKDg522Z+UlKRKlSqpRo0aevrpp5WRkeE8lpKSovPnzys2Nta5Lzw8XNHR0Vq/fv1l/568vDxlZ2e7bAAAoOS64YBiGIaGDx+uBx54QNHR0c797dq104IFC7R69WpNmjRJmzZtUsuWLZWXlydJSk9Pl4+Pj4KCglzeLyQkROnp6Zf9u8aPH6/AwEDnFhERcaNlAwAAGyjSLZ6LDRkyRNu3b9e6detc9nfv3t355+joaDVs2FCRkZFavny5unbtesX3MwxDDofjssdGjRql4cOHO19nZ2cTUgAAKMFuqAdl6NChWrZsmdasWaPbb7/9qm3DwsIUGRmp/fv3S5JCQ0N17tw5ZWZmurTLyMhQSEjIZd/D19dXAQEBLhsAACi5ihRQDMPQkCFDtHjxYq1evVpRUVHX/JkTJ04oNTVVYWFhkqQGDRrI29tbiYmJzjZpaWnauXOnmjZtWsTyAQBASVSkWzyDBw/WwoUL9fnnn8vf3985ZiQwMFClS5dWTk6Oxo4dq0cffVRhYWE6cuSIXnrpJVWoUEFdunRxtu3fv79GjBih8uXLKzg4WCNHjlSdOnWcT/UAAIC/tiIFlOnTp0uSYmJiXPbPmjVLffr0kaenp3bs2KG5c+fq1KlTCgsLU4sWLfTJJ5/I39/f2X7KlCny8vJSt27dlJubq1atWmn27Nny9PS8+U8EAABsz2EYhmF2EUWVnZ2twMBAZWVluXU8SuUXl7vtvYrLkQntzS4BAIAbUpTrN2vxAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAyyGgAAAAy/EyuwCUTJVfXG52Cdd0ZEJ7s0sAAFwBPSgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByCCgAAMByihRQxo8fr3vvvVf+/v6qVKmSOnfurL1797q0MQxDY8eOVXh4uEqXLq2YmBjt2rXLpU1eXp6GDh2qChUqyM/PTx07dtSxY8du/tMAAIASoUgBJTk5WYMHD9aGDRuUmJioCxcuKDY2VmfOnHG2mThxoiZPnqz33ntPmzZtUmhoqB566CGdPn3a2SYuLk5LlixRQkKC1q1bp5ycHHXo0EH5+fnu+2QAAMC2vIrSeMWKFS6vZ82apUqVKiklJUXNmjWTYRiaOnWqXn75ZXXt2lWSNGfOHIWEhGjhwoV69tlnlZWVpZkzZ2revHlq3bq1JGn+/PmKiIjQqlWr1KZNGzd9NAAAYFc3NQYlKytLkhQcHCxJOnz4sNLT0xUbG+ts4+vrq+bNm2v9+vWSpJSUFJ0/f96lTXh4uKKjo51tLpWXl6fs7GyXDQAAlFw3HFAMw9Dw4cP1wAMPKDo6WpKUnp4uSQoJCXFpGxIS4jyWnp4uHx8fBQUFXbHNpcaPH6/AwEDnFhERcaNlAwAAG7jhgDJkyBBt375dixYtKnTM4XC4vDYMo9C+S12tzahRo5SVleXcUlNTb7RsAABgAzcUUIYOHaply5ZpzZo1uv322537Q0NDJalQT0hGRoazVyU0NFTnzp1TZmbmFdtcytfXVwEBAS4bAAAouYoUUAzD0JAhQ7R48WKtXr1aUVFRLsejoqIUGhqqxMRE575z584pOTlZTZs2lSQ1aNBA3t7eLm3S0tK0c+dOZxsAAPDXVqSneAYPHqyFCxfq888/l7+/v7OnJDAwUKVLl5bD4VBcXJzi4+NVvXp1Va9eXfHx8SpTpox69OjhbNu/f3+NGDFC5cuXV3BwsEaOHKk6deo4n+oBAAB/bUUKKNOnT5ckxcTEuOyfNWuW+vTpI0l6/vnnlZubq0GDBikzM1ONGjXSypUr5e/v72w/ZcoUeXl5qVu3bsrNzVWrVq00e/ZseXp63tynAQAAJYLDMAzD7CKKKjs7W4GBgcrKynLreJTKLy5323sVlyMT2ptdwnXhXAIALlWU6zdr8QAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMspckBZu3atHnnkEYWHh8vhcGjp0qUux/v06SOHw+GyNW7c2KVNXl6ehg4dqgoVKsjPz08dO3bUsWPHbuqDAACAkqPIAeXMmTO6++679d57712xTdu2bZWWlubcvvzyS5fjcXFxWrJkiRISErRu3Trl5OSoQ4cOys/PL/onAAAAJY5XUX+gXbt2ateu3VXb+Pr6KjQ09LLHsrKyNHPmTM2bN0+tW7eWJM2fP18RERFatWqV2rRpU9SSAABACVMsY1CSkpJUqVIl1ahRQ08//bQyMjKcx1JSUnT+/HnFxsY694WHhys6Olrr16+/7Pvl5eUpOzvbZQMAACWX2wNKu3bttGDBAq1evVqTJk3Spk2b1LJlS+Xl5UmS0tPT5ePjo6CgIJefCwkJUXp6+mXfc/z48QoMDHRuERER7i4bAABYSJFv8VxL9+7dnX+Ojo5Ww4YNFRkZqeXLl6tr165X/DnDMORwOC57bNSoURo+fLjzdXZ2NiEFAIASrNgfMw4LC1NkZKT2798vSQoNDdW5c+eUmZnp0i4jI0MhISGXfQ9fX18FBAS4bAAAoOQq9oBy4sQJpaamKiwsTJLUoEEDeXt7KzEx0dkmLS1NO3fuVNOmTYu7HAAAYANFvsWTk5OjAwcOOF8fPnxYW7duVXBwsIKDgzV27Fg9+uijCgsL05EjR/TSSy+pQoUK6tKliyQpMDBQ/fv314gRI1S+fHkFBwdr5MiRqlOnjvOpHgAA8NdW5ICyefNmtWjRwvn6z7EhvXv31vTp07Vjxw7NnTtXp06dUlhYmFq0aKFPPvlE/v7+zp+ZMmWKvLy81K1bN+Xm5qpVq1aaPXu2PD093fCRAACA3RU5oMTExMgwjCse//rrr6/5HqVKldK7776rd999t6h/PQAA+AtgLR4AAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5RQ4oa9eu1SOPPKLw8HA5HA4tXbrU5bhhGBo7dqzCw8NVunRpxcTEaNeuXS5t8vLyNHToUFWoUEF+fn7q2LGjjh07dlMfBAAAlBxFDihnzpzR3Xffrffee++yxydOnKjJkyfrvffe06ZNmxQaGqqHHnpIp0+fdraJi4vTkiVLlJCQoHXr1iknJ0cdOnRQfn7+jX8SAABQYngV9QfatWundu3aXfaYYRiaOnWqXn75ZXXt2lWSNGfOHIWEhGjhwoV69tlnlZWVpZkzZ2revHlq3bq1JGn+/PmKiIjQqlWr1KZNm5v4OAAAoCRw6xiUw4cPKz09XbGxsc59vr6+at68udavXy9JSklJ0fnz513ahIeHKzo62tnmUnl5ecrOznbZAABAyeXWgJKeni5JCgkJcdkfEhLiPJaeni4fHx8FBQVdsc2lxo8fr8DAQOcWERHhzrIBAIDFFMtTPA6Hw+W1YRiF9l3qam1GjRqlrKws55aamuq2WgEAgPW4NaCEhoZKUqGekIyMDGevSmhoqM6dO6fMzMwrtrmUr6+vAgICXDYAAFByuTWgREVFKTQ0VImJic59586dU3Jyspo2bSpJatCggby9vV3apKWlaefOnc42AADgr63IT/Hk5OTowIEDzteHDx/W1q1bFRwcrDvuuENxcXGKj49X9erVVb16dcXHx6tMmTLq0aOHJCkwMFD9+/fXiBEjVL58eQUHB2vkyJGqU6eO86keAADw11bkgLJ582a1aNHC+Xr48OGSpN69e2v27Nl6/vnnlZubq0GDBikzM1ONGjXSypUr5e/v7/yZKVOmyMvLS926dVNubq5atWql2bNny9PT0w0fCQAA2J3DMAzD7CKKKjs7W4GBgcrKynLreJTKLy5323sVlyMT2ptdwnXhXAIALlWU6zdr8QAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMshoAAAAMvxMrsAAFdW+cXlZpdwXY5MaG92CQBKGHpQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5bg9oIwdO1YOh8NlCw0NdR43DENjx45VeHi4SpcurZiYGO3atcvdZQAAABsrlh6U2rVrKy0tzbnt2LHDeWzixImaPHmy3nvvPW3atEmhoaF66KGHdPr06eIoBQAA2FCxBBQvLy+FhoY6t4oVK0r6o/dk6tSpevnll9W1a1dFR0drzpw5Onv2rBYuXFgcpQAAABsqloCyf/9+hYeHKyoqSo899pgOHTokSTp8+LDS09MVGxvrbOvr66vmzZtr/fr1V3y/vLw8ZWdnu2wAAKDkcntAadSokebOnauvv/5aH330kdLT09W0aVOdOHFC6enpkqSQkBCXnwkJCXEeu5zx48crMDDQuUVERLi7bAAAYCFuDyjt2rXTo48+qjp16qh169Zavny5JGnOnDnONg6Hw+VnDMMotO9io0aNUlZWlnNLTU11d9kAAMBCiv0xYz8/P9WpU0f79+93Ps1zaW9JRkZGoV6Vi/n6+iogIMBlAwAAJVexB5S8vDzt2bNHYWFhioqKUmhoqBITE53Hz507p+TkZDVt2rS4SwEAADbh5e43HDlypB555BHdcccdysjI0BtvvKHs7Gz17t1bDodDcXFxio+PV/Xq1VW9enXFx8erTJky6tGjh7tLAQAANuX2gHLs2DE9/vjj+u2331SxYkU1btxYGzZsUGRkpCTp+eefV25urgYNGqTMzEw1atRIK1eulL+/v7tLAQAANuX2gJKQkHDV4w6HQ2PHjtXYsWPd/VcDAIASgrV4AACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5RBQAACA5XiZXQAA3AqVX1xudgnXdGRCe7NLACyDHhQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5BBQAAGA5PMUDACgSnojCrUAPCgAAsBxTA8oHH3ygqKgolSpVSg0aNNC3335rZjkAAMAiTAson3zyieLi4vTyyy9ry5YtevDBB9WuXTsdPXrUrJIAAIBFmDYGZfLkyerfv7+eeuopSdLUqVP19ddfa/r06Ro/frxZZQEAcEvYYSyPZN54HlMCyrlz55SSkqIXX3zRZX9sbKzWr19fqH1eXp7y8vKcr7OysiRJ2dnZbq2rIO+sW9+vOLj7MxcXzqV72OE8SpxLd7HDeZQ4l+5ih/Moufdc/vlehmFcu7Fhgp9//tmQZHz33Xcu+998802jRo0ahdqPGTPGkMTGxsbGxsZWArbU1NRrZgVTHzN2OBwurw3DKLRPkkaNGqXhw4c7XxcUFOjkyZMqX778ZdtbRXZ2tiIiIpSamqqAgACzy7EtzqP7cC7dh3PpHpxH97HDuTQMQ6dPn1Z4ePg125oSUCpUqCBPT0+lp6e77M/IyFBISEih9r6+vvL19XXZV65cueIs0a0CAgIs+4/FTjiP7sO5dB/OpXtwHt3H6ucyMDDwutqZ8hSPj4+PGjRooMTERJf9iYmJatq0qRklAQAACzHtFs/w4cPVq1cvNWzYUE2aNNGHH36oo0ePasCAAWaVBAAALMK0gNK9e3edOHFCr732mtLS0hQdHa0vv/xSkZGRZpXkdr6+vhozZkyh21MoGs6j+3Au3Ydz6R6cR/cpaefSYRjX86wPAADArcNaPAAAwHIIKAAAwHIIKAAAwHIIKAAAwHIIKAAAwHJMneoegPtdvCzEtUyePLkYKwFQnI4fP66RI0fqm2++UUZGRqEF+PLz802qzD0IKDeJiwGsZsuWLS6vU1JSlJ+fr5o1a0qS9u3bJ09PTzVo0MCM8mzrzJkzmjBhgvNiUFBQ4HL80KFDJlVmD127dr3utosXLy7GSkqOPn366OjRoxo9erTCwsIsvTbdjSCg3CQuBsVn2bJll93vcDhUqlQpVatWTVFRUbe4Kutbs2aN88+TJ0+Wv7+/5syZo6CgIElSZmam+vbtqwcffNCsEm3pqaeeUnJysnr16lUiLwbF7eL1VwzD0JIlSxQYGKiGDRtK+uN356lTp4oUZP7q1q1bp2+//Vb33HOP2aUUCyZqc6PJkycrKSnpiheDESNGmFyhvXh4eMjhcBTqtvxzn8Ph0AMPPKClS5c6zzdc3XbbbVq5cqVq167tsn/nzp2KjY3VL7/8YlJl9lOuXDktX75c999/v9ml2N4LL7ygkydPasaMGfL09JT0x+2IQYMGKSAgQG+//bbJFdpDrVq1tGDBAtWrV8/sUooFg2TdaNKkSRo/frzLxTIoKEhvvPGGJk2aZGJl9pSYmKh7771XiYmJysrKUlZWlhITE3Xffffpiy++0Nq1a3XixAmNHDnS7FItKzs7W8ePHy+0PyMjQ6dPnzahIvsKCgpScHCw2WWUCB9//LFGjhzpDCeS5OnpqeHDh+vjjz82sTJ7mTp1ql588UUdOXLE7FKKBbd43OjPi8Gl31a5GNyY5557Th9++KHLCtetWrVSqVKl9Mwzz2jXrl2aOnWq+vXrZ2KV1talSxf17dtXkyZNUuPGjSVJGzZs0D/+8Q+60ovo9ddf16uvvqo5c+aoTJkyZpdjaxcuXNCePXuct8L/tGfPnkJje3Bl3bt319mzZ1W1alWVKVNG3t7eLsdPnjxpUmXuQUBxIy4G7nXw4EEFBAQU2h8QEOAckFi9enX99ttvt7o025gxY4ZGjhypJ554QufPn5ckeXl5qX///nSjF9GkSZN08OBBhYSEqHLlyoUuBj/88INJldlP37591a9fPx04cMDld+WECRPUt29fk6uzj6lTp5pdQrFiDIobnT17ViNHjtTHH3982YuBn5+fyRXaywMPPCB/f3/NnTtXFStWlCT9+uuvevLJJ3XmzBmtXbtWq1at0qBBg7Rv3z6Tq7W2M2fO6ODBgzIMQ9WqVePf4g0YN27cVY+PGTPmFlVifwUFBXrnnXc0bdo0paWlSZLCwsL03HPPacSIES63fvDXRUApBlwM3GPv3r3q1KmTDh8+rIiICDkcDh09elRVqlTR559/rho1amjp0qU6ffq0evXqZXa5lnbgwAEdPHhQzZo1U+nSpZ2DjAGzZWdnS9Jle0txbfn5+Vq6dKn27Nkjh8OhWrVqqWPHjiUi5BFQigEXA/cxDENff/219u3bJ8MwdOedd+qhhx6Shwfju6/HiRMn1K1bN61Zs0YOh0P79+9XlSpV1L9/f5UrV47B20Xw8ssvKyYmRvfffz9jUNzgwoULSkpK0sGDB9WjRw/5+/vrl19+UUBAgMqWLWt2ebZw4MABPfzww/r5559Vs2ZNGYahffv2KSIiQsuXL1fVqlXNLvGmEFDciIsBrObJJ59URkaG/v3vf+uuu+7Stm3bVKVKFa1cuVLDhg3Trl27zC7RNtq2bav169crLy9P9evXV0xMjJo3b64HHniAC2oR/fTTT2rbtq2OHj2qvLw87du3T1WqVFFcXJx+//13zZgxw+wSbeHhhx+WYRhasGCB8wmzEydO6IknnpCHh4eWL19ucoU3h0GybjRs2DB5e3vr6NGjuuuuu5z7u3fvrmHDhhFQbsA333xzxZk7eRzx2lauXKmvv/5at99+u8v+6tWr66effjKpKntasWKF8vPztXHjRiUnJyspKUkffPCBcnNzVb9+fW3YsMHsEm3jueeeU8OGDbVt2zaVL1/eub9Lly566qmnTKzMXpKTk7VhwwaXx9/Lly+vCRMmlIj5eggobsTFwL3GjRun1157TQ0bNmTmzht05syZy96O+O233+Tr62tCRfbm6empJk2aKDg4WEFBQfL399fSpUt18OBBs0uzlXXr1um7776Tj4+Py/7IyEj9/PPPJlVlP76+vpedwiInJ6fQubUjAoobcTFwrxkzZmj27NkMgL0JzZo109y5c/X6669L+mMW3oKCAr399ttq0aKFydXZy/Tp05WcnKzk5GTl5+frwQcfVPPmzTV69GjVrVvX7PJspaCg4LIL2R07dkz+/v4mVGRPHTp00DPPPKOZM2fqvvvukyT973//04ABA9SxY0eTq7t5jEFxo/bt26t+/fp6/fXX5e/vr+3btysyMlKPPfaYCgoK9J///MfsEm2lfPny2rhxo+0Heplp9+7diomJUYMGDbR69Wp17NhRu3bt0smTJ/Xdd99xbovAw8NDFStW1IgRIzRgwACeOrkJ3bt3V2BgoD788EPn78qKFSuqU6dOuuOOOzRr1iyzS7SFU6dOqXfv3vrvf//rnJfnwoUL6tixo2bPnu2y/pEdEVDciIuBe73wwgsqW7asRo8ebXYptpaenq7p06crJSVFBQUFql+/vgYPHqywsDCzS7OVpUuXau3atUpKStLu3bt19913KyYmRjExMXrwwQcZKFsEv/zyi1q0aCFPT0/t379fDRs21P79+1WhQgWtXbtWlSpVMrtEW9m/f79+/PFHGYahWrVqqVq1amaX5BYEFDfjYuA+zz33nObOnau6deuqbt26hWbunDx5skmV2cfRo0edc8hc7tgdd9xhQlX2l5WVpW+//Vb/+c9/tHDhQjkcDuXl5Zldlq3k5uZq0aJF+uGHH5y/K3v27KnSpUubXRosgoDiRlwM3OtqYyQcDodWr159C6uxJ09PT6WlpRX6RnrixAlVqlTpsuMAcGUnT550PsGTlJSknTt3qnz58mrevLk+/fRTs8vDX8Dw4cP1+uuvy8/PT8OHD79qW7t/iWOQrBtFRUVd8WIQFRXFxaCI1qxZY3YJtnelSQJzcnJUqlQpEyqyr7p162r37t0KDg5Ws2bN9PTTTysmJkbR0dFml2YLy5Ytu+62JWGAZ3HZsmWLcymVLVu2mFxN8SKguBEXA1jFn9+sHA6HRo8e7fJ0WX5+vv73v//pnnvuMak6e3rmmWcIJDehc+fOLq8dDocu7cD/8/cnX+au7OIvbiX9SxwBxQ24GLhP165dNXv2bAUEBFxzBejFixffoqrs589vVoZhaMeOHS5zIvj4+Ojuu+/WyJEjzSrPloYMGWJ2CbZ28USLq1at0gsvvKD4+Hg1adJEDodD69ev1yuvvKL4+HgTq7SXfv36adq0aYUezT5z5oyGDh1q+8ksCShuwMXAfQIDA53fogICApic7Qb9+c2qb9++mjZtGo/EusmxY8e0bNkyHT16VOfOnXM5Zvf7/bdSXFycZsyYoQceeMC5r02bNipTpoyeeeYZ7dmzx8Tq7GPOnDmaMGFCoYCSm5uruXPnElDAxcCdLp7/YPbs2eYVUkIwn4T7fPPNN+rYsaOioqK0d+9eRUdH68iRIzIMQ/Xr1ze7PFs5ePDgZefoCAwM1JEjR259QTaTnZ0twzBkGIZOnz7tMoQgPz9fX375ZYl4VJuneIoBqxm7R8uWLbV48WKVK1fOZX92drY6d+7MUzzXadOmTfr0008v+62f22TX77777lPbtm312muvyd/fX9u2bVOlSpXUs2dPtW3bVgMHDjS7RNto1qyZvL29NX/+fOcUDOnp6erVq5fOnTun5ORkkyu0Ng8Pj6teUxwOh8aNG6eXX375FlblfgQUNzp58qT+9re/sZqxm3h4eCg9Pb3QN4GMjAzddtttzpHsuLKEhAQ9+eSTio2NVWJiomJjY7V//36lp6erS5cu9LAUgb+/v7Zu3aqqVasqKChI69atU+3atbVt2zZ16tSJb/5FcODAAXXp0kV79+51Tr9w9OhR1ahRQ0uXLi0xE40Vl+TkZBmGoZYtW+qzzz5zWSzQx8dHkZGRCg8PN7FC9+AWjxvFxcWxmrEbbN++3fnn3bt3Kz093fk6Pz9fK1as0G233WZGabYTHx+vKVOmaPDgwfL399e0adMUFRWlZ599lskDi8jPz885GVt4eLgOHjyo2rVrS/pjvS1cv2rVqmn79u1KTEx0mQG1devW9DZfh+bNm0uSDh8+rIiICHl4eJhcUfEgoLgRqxm7xz333COHwyGHw6GWLVsWOl66dGm9++67JlRmPwcPHlT79u0l/bHy6ZkzZ+RwODRs2DC1bNlS48aNM7lC+2jcuLG+++471apVS+3bt9eIESO0Y8cOLV68WI0bNza7PNtxOByKjY1VbGys2aXYVmRkpCTp7Nmzl72Fa/dFLAkobsRqxu5x+PBhGYahKlWqaOPGjapYsaLzmI+PjypVqiRPT08TK7SP4OBg53Lst912m3bu3Kk6dero1KlTOnv2rMnV2cvkyZOVk5MjSRo7dqxycnL0ySefqFq1apoyZYrJ1dnPN998o2+++UYZGRkujyBLsv3TJ7fKr7/+qr59++qrr7667HG7zydDQHEjlrZ3jz+/FVz6SwtF9+CDDyoxMVF16tRRt27d9Nxzz2n16tVKTExUq1atzC7PNvLz85Wamur8RlqmTBl98MEHJldlX+PGjdNrr72mhg0bKiwsjNs6NyguLk6ZmZnasGGDWrRooSVLluj48eN64403SsSQAgbJuhGrGd+8ZcuWqV27dvL29r7m1NhMh31tJ0+e1O+//67w8HAVFBTonXfe0bp161StWjWNHj1aQUFBZpdoG6VKldKePXsUFRVldim2FxYWpokTJ6pXr15ml2JrYWFh+vzzz3XfffcpICBAmzdvVo0aNbRs2TJNnDhR69atM7vEm0JAcTNWM745Fz+5c7WBXw6Hw/bdl7CXe++9VxMmTKDnyQ3Kly+vjRs38qXtJgUEBGj79u2qXLmyKleurAULFuj+++/X4cOHVbt2bdvfxuUWj5uFhoYy8PAmXHxbh1s87lFQUKADBw5c9l5/s2bNTKrKft58802NHDlSr7/+uho0aCA/Pz+X40zQeP2eeuopLVy4UKNHjza7FFurWbOm9u7dq8qVK+uee+7Rv/71L1WuXFkzZswoEV+K6UG5SRc/Enstdh9RDfvZsGGDevTooZ9++umyC7PRC3X9Lu7Ru3jMxJ8TMXIur99zzz2nuXPnqm7duqpbt668vb1djrNswPVZsGCBzp8/rz59+mjLli1q06aNTpw4IR8fH82ePVvdu3c3u8SbQkC5SX/O6Het08gvsKJ77bXXrnr81VdfvUWV2Nc999yjGjVqaNy4cZcdjHi56cZxedea3fTPuSlwbVd7aMDhcDBL9A06e/asfvzxR91xxx2qUKGC2eXcNALKTSrK/CZ/Pp2C61OvXj2X1+fPn9fhw4fl5eWlqlWr6ocffjCpMvvw8/PTtm3bmJkTKIFee+01jRw5stD0Frm5uXr77bdt/yWOgAJbyc7OVp8+fdSlSxeeALgOLVu21PPPP6+2bduaXYotcQu3eLFu2c3x9PRUWlpaoeVATpw4oUqVKtm+155Bsm62d+9evfvuu9qzZ48cDofuvPNODR06VDVr1jS7tBIhICBAr732mjp06EBAuQ5Dhw7ViBEjlJ6erjp16hS6189F9er+nNX4ei6cdr8Y3EonTpxQt27dCq1b9tRTT7FuWRFc6d/ltm3bXNbnsSsCihv95z//0eOPP66GDRuqSZMmkv4YpBgdHa2FCxfqb3/7m8kVlgynTp1SVlaW2WXYwqOPPipJ6tevn3PfxRdcLqpXd/jwYeeft2zZopEjR+of//iH8//3999/r0mTJmnixIlmlWhLw4YNY92ymxAUFORcDqRGjRouISU/P185OTkaMGCAiRW6B7d43KhKlSp64oknCg3uHDNmjObNm6dDhw6ZVJk9/fOf/3R5bRiG0tLSNG/ePDVr1kyLFi0yqTL7uNYYKcZFXb/77rtPY8eO1cMPP+yy/8svv9To0aOVkpJiUmX2Exoaqq+//lp33323/P39tW3bNlWpUkWHDx9WnTp1nEsK4PLmzJkjwzDUr18/TZ061WWwu4+PjypXruwM0XZGD4obpaen68knnyy0/4knntDbb79tQkX2dun6Jh4eHqpYsaJ69+6tUaNGmVSVvRBA3GfHjh2XnUU2KipKu3fvNqEi+2LdspvTu3dvSX/822vatGmhW7clBQHFjWJiYvTtt98WemJi3bp1evDBB02qyr4u7l7H9WO5gOJx11136Y033tDMmTNVqlQpSVJeXp7eeOMNl9sUuDbWLbtx2dnZzkkB69Wrp9zcXOXm5l62rd0nD+QWjxvNmDFDr776qrp16+Zcfn3Dhg369NNPNW7cOIWHhzvbcmG4ugsXLqhUqVLaunWroqOjzS7HVlguoHhs3LhRjzzyiAoKCnT33XdL+mMwosPh0BdffKH77rvP5Artg3XLbtzFT+78OQ/XpUrKGDMCihtd7WJwsZLwD+dWqFq1qhYvXuy8GABmO3v2rObPn68ff/xRhmGoVq1a6tGjR6Fp73FtrFt2Y5KTk3X//ffLy8tLSUlJV326zO6TBxJQYFmzZs3Sp59+qvnz55eIR+YAANePgALLqlevng4cOKDz588rMjKy0LdUZpK9Phs3blRSUtJlFwtkzZOi2bdv3xXPpd1n7bzVMjMzNXPmTOecUXfddZf69u3Ll5EiqFKlinr27KknnniiRM61RUBxMy4G7nOtVaHHjBlziyqxr/j4eL3yyiuqWbOmQkJCXLqDWfOkaD766CMNHDhQFSpUUGhoaKFzSWC+fsnJyerUqZMCAgLUsGFDSVJKSopOnTqlZcuW2f7WxK0yefJkLVq0SCkpKapXr5569eql7t27l5jbZAQUN+JiAKsJCQnRW2+9pT59+phdiu1FRkZq0KBBeuGFF8wuxfaio6PVtGlTTZ8+XZ6enpL+mGBs0KBB+u6777Rz506TK7SXffv2acGCBUpISNChQ4fUokULPfHEE5ed9sJOCChuxMXAvTZt2qSCggI1atTIZf///vc/eXp6Or954crCwsK0du1aVa9e3exSbC8gIEBbt25VlSpVzC7F9kqXLq2tW7cWui2xd+9e3XPPPVd8bBbXtmHDBg0cOFDbt2+3/cMY1/fYCa6Lh4eH7r//frPLKDEGDx6s1NTUQvt//vlnDR482ISK7GfYsGF6//33zS6jRPjb3/6mlStXml1GiVC/fn3t2bOn0P49e/bonnvuufUFlQAbN25UXFycunTpor179+r//u//zC7pptGD4kYTJ07UL7/8oqlTp5pdSolQtmxZbd++vdA31sOHD6tu3bo6ffq0SZXZR0FBgdq3b699+/apVq1ahWacXLx4sUmV2cPFyy2cOXNGkydPVvv27S+78OLf//73W12ebX3yySd6/vnnNXToUJc5o95//31NmDDBZeI7FrS8sj9v7SxcuFBHjhxRixYt1LNnT3Xt2lX+/v5ml3fTCChuxMXAvcqXL68vvvii0JoS69evV/v27ZWZmWlSZfYxePBgzZw5Uy1atCg0Lkr641FuXNnlpra/HIfDwVpbRXCtOaNY0PL6eHh4qGHDhurRo4cee+wxhYaGml2SWxFQ3IiLgXs99thjSk9P1+eff+5cDOvUqVPq3LmzKlWqpP/3//6fyRVan7+/vxISEtS+fXuzSwGcrrWI5cVYT+rK9u3bpxo1aphdRrEhoLgRFwP3+vnnn9WsWTOdOHFC9erVkyRt3bpVISEhSkxMVEREhMkVWl9kZKS+/vpr3XnnnWaXYnuvvfaaRo4cWWiRu9zcXL399tvMgwLTnDt37rJTW9xxxx0mVeQeBBQ34mLgfmfOnNGCBQu0bds2lS5dWnXr1tXjjz9eYlfvdLdZs2ZpxYoVmjVr1mVXj8X1u3gNlIudOHFClSpV4lZEEcyZM0cVKlRwfpl7/vnn9eGHH6pWrVpatGgRvSbXaf/+/erXr5/Wr1/vsr+k3B4joLgRFwNYTb169XTw4EEZhqHKlSsXCnZMLnb9PDw8dPz4cVWsWNFl/+rVq9W9e3f9+uuvJlVmPzVr1tT06dPVsmVLff/992rVqpWmTp2qL774Ql5eXozXu05/rsnz4osvKiwsrNCwAruvY+ZldgElyT//+U8dPHhQISEhXAzcZN68efrXv/6lQ4cO6fvvv1dkZKSmTJmiKlWqqFOnTmaXZ3mdO3c2uwTbCwoKksPhkMPhUI0aNVwuAvn5+crJydGAAQNMrNB+UlNTVa1aNUnS0qVL9X//93965plndP/99ysmJsbc4mxk69atSklJKbG99gQUN+Ji4F7Tp0/Xq6++qri4OL3xxhvO7sqgoCBNnTqVgHINFy5ckCT169eP8To3YerUqTIMQ/369dO4ceOcA7YlycfHR5UrVy70pBmurmzZsjpx4oTuuOMOrVy5UsOGDZMklSpViknaiqBWrVr67bffzC6j2HCLB5ZVq1YtxcfHq3PnzvL399e2bdtUpUoV7dy5UzExMSX6P6a7+Pv7a8eOHapcubLZpdhecnKymjZtyvgnN+jZs6d+/PFH1atXT4sWLdLRo0dVvnx5LVu2TC+99BJT3V+n1atX65VXXlF8fPxl5+YJCAgwqTL3oAelGKSkpDhX6KxVq5bzCRQUzeHDhy977nx9fXXmzBkTKrKfVq1aKSkpieUXblB2drbzl3y9evWUm5t7xW/4dr8Y3Ervv/++XnnlFaWmpuqzzz5T+fLlJf3xu/Pxxx83uTr7aN26taQ//p9frKQMkiWguFFGRoYee+wxJSUlqVy5cjIMQ1lZWWrRooUSEhIKDa7D1UVFRWnr1q2FRvR/9dVXLjNN4sratWunUaNGaefOnWrQoIH8/Pxcjnfs2NGkyuwhKCjI+eROuXLlCg1ClErOxeBWKleunN57771C+6+1gjlcrVmzxuwSihUBxY2GDh2q7Oxs7dq1y3kB3b17t3r37q2///3vWrRokckV2ss//vEPDR48WL///rsMw9DGjRu1aNEixcfHa+bMmWaXZwsDBw6U9Mey7Jfionptq1evVnZ2tipVqlTiLwa30tq1a696vFmzZreoEntr3ry52SUUK8aguFFgYKBWrVqle++912X/xo0bFRsbq1OnTplTmI199NFHeuONN5yLBt52220aN26c2rRpo9tuu83k6vBX4OHhodtuu00tWrRwbozpuTmXm+r+0qejcHnbt29XdHS0PDw8tH379qu2tfs6RgQUN/L399e3335baDXOLVu2qHnz5srOzjansBLgt99+U0FBgfLz8xUfH69///vfjPYvot9//12lSpUyuwzb+fbbb5WcnKykpCR9//33+v3333XHHXeoZcuWzsBCWC6arKwsl9fnz5/Xli1bNHr0aL355puFxlTg/+fh4aH09HRVqlRJHh4eznWLLlUSekgJKG7UqVMnnTp1SosWLVJ4eLikP6Zr79mzp4KCgrRkyRKTK7SHU6dOafDgwVq5cqW8vb314osvasiQIRo3bpzeeecd1apVS8OHD2cw3XX4M9DNmDFDx48f1759+1SlShWNHj1alStXVv/+/c0u0VbOnz+v77//XklJSUpKStKGDRuUl5enatWqae/evWaXZ3tr167VsGHDlJKSYnYplvXTTz/pjjvukMPhuOaaRrafkdeA2xw9etSoV6+e4e3tbVSpUsWoWrWq4e3tbdSvX99ITU01uzzbGDhwoHH77bcbI0aMMGrXrm14eHgY7dq1M1q0aGEkJSWZXZ6tjBs3zqhSpYoxf/58o3Tp0sbBgwcNwzCMTz75xGjcuLHJ1dnX2bNnjZUrVxojRowwAgICDA8PD7NLKhF2795t+Pn5mV0GLIIelGKQmJioH3/8UYZhqFatWs5HwXB9IiMjNXPmTLVu3VqHDh1StWrV9Pe//11Tp041uzTbqVatmv71r3+pVatWLnPJ/Pjjj2rSpIkyMzPNLtEWfv/9d61fv15r1qxRUlKSNm3apKioKDVv3lzNmjVT8+bNuc1TBJeOnTAMQ2lpaZowYYLOnz+v7777zqTKYCUEFDdYvXq1hgwZog0bNhSaCyErK0tNmzbVjBkz9OCDD5pUob14e3vrp59+ct4mK1OmjDZu3Kjo6GiTK7Of0qVL68cff1RkZKRLQNm9e7fuu+8+5eTkmF2i5TVv3lybNm1S1apVnWGkefPmCgkJMbs027rS2InGjRvr448/LrFTt6NoeMzYDaZOnaqnn376shM1BQYG6tlnn9XkyZMJKNepoKDAZUZET0/PQvN34PrUrl1b3377baF70Z9++ikTCF6n9evXKywsTC1atFBMTIyaNWumChUqmF2WrR0+fNjltYeHhypWrMggbrggoLjBtm3b9NZbb13xeGxsrN55551bWJG9GYahPn36yNfXV9If3esDBgwoFFJY8fTK+vXrp2nTpmnMmDHq1auXfv75ZxUUFGjx4sXau3ev5s6dqy+++MLsMm3h1KlT+vbbb5WUlKS33npLjz/+uGrUqKHmzZsrJiZGzZs3ZxLG6/S///1PJ0+eVLt27Zz75s6dqzFjxujMmTPq3Lmz3n33Xef/ffy1cYvHDUqVKqWdO3c6V+e81IEDB1SnTh0ei71Offv2va52s2bNKuZK7MvT09M5A+rXX3+t+Ph4paSkqKCgQPXr19err76q2NhYs8u0pdOnT2vdunXO8Sjbtm1T9erVWT/mOrRr104xMTF64YUXJEk7duxQ/fr11adPH9111116++239eyzz2rs2LHmFmoTffr0Ub9+/UrsxHb0oLjBbbfdph07dlwxoGzfvl1hYWG3uCr7InjcvIu/d7Rp00Zt2rQxsZqSxc/PT8HBwQoODlZQUJC8vLy0Z88es8uyha1bt+r11193vk5ISFCjRo300UcfSZIiIiI0ZswYAsp1On36tGJjYxUREaG+ffuqd+/eJWqwduHp/FBkDz/8sF599VX9/vvvhY7l5uZqzJgx6tChgwmV4a/scuvGoOgKCgq0ceNGTZw4Ue3atVO5cuXUtGlTffDBBwoNDdX777+vQ4cOmV2mLWRmZroMLk5OTlbbtm2dr++9917nrNG4ts8++0w///yzhgwZok8//VSVK1dWu3bt9J///Efnz583u7ybxi0eNzh+/Ljq168vT09PDRkyRDVr1pTD4dCePXv0/vvvKz8/Xz/88AOj/nHLeHh4KDAw8Joh5eTJk7eoIvsKCAjQmTNnFBYWppiYGMXExKhFixaqWrWq2aXZTmRkpObNm6dmzZrp3LlzKleunP773/86Z47dsWOHmjdvzr/LG7RlyxZ9/PHH+ve//62yZcvqiSee0KBBg1S9enWzS7sh3OJxg5CQEK1fv14DBw7UqFGjnN3rDodDbdq00QcffEA4wS03btw4BQYGml2G7b399ttq0aKFatSoYXYptte2bVu9+OKLeuutt7R06VKVKVPG5enG7du3E/xuUFpamlauXKmVK1fK09NTDz/8sHbt2qVatWpp4sSJGjZsmNklFhk9KG6WmZmpAwcOyDAMVa9eXUFBQWaXhL+gi9frAKzi119/VdeuXfXdd9+pbNmymjNnjrp06eI83qpVKzVu3FhvvvmmiVXax/nz57Vs2TLNmjVLK1euVN26dfXUU0+pZ8+e8vf3l/THOJ+BAwfaclJGAgpQAl38FA9gNVlZWSpbtqw8PT1d9p88eVJly5aVj4+PSZXZS4UKFVRQUKDHH39cTz/9dKGFaqU/vjTXr1+/0NwzdkBAAUogelCAkm/evHn629/+VmInuCOgAABgc6mpqXI4HLr99tvNLsVteMwYAAAbunDhgkaPHq3AwEBVrlxZkZGRCgwM1CuvvFIiHjPmKR4AAGxoyJAhWrJkiSZOnKgmTZpIkr7//nuNHTtWv/32m2bMmGFyhTeHWzwAANhQYGCgEhISXNY2kqSvvvpKjz32mLKyskyqzD24xQMAgA2VKlVKlStXLrS/cuXKJeJJKAIKAAA2NHjwYL3++uvKy8tz7svLy9Obb76pIUOGmFiZezAGBQAAm+jatavL61WrVun222/X3XffLUnatm2bzp0751w+wM4IKAAA2MSly1c8+uijLq8jIiJuZTnFikGyAADAchiDAgAALIeAAgAALIeAAgAALIeAAgAALIeAAgAALIfHjAEAsKF//vOfl93vcDhUqlQpVatWTc2aNZOnp+ctrsw9eMwYAAAbioqK0q+//qqzZ88qKChIhmHo1KlTKlOmjMqWLauMjAxVqVJFa9asseX8KNziAQDAhuLj43Xvvfdq//79OnHihE6ePKl9+/apUaNGmjZtmo4eParQ0FANGzbM7FJvCD0oAADYUNWqVfXZZ5/pnnvucdm/ZcsWPfroozp06JDWr1+vRx99VGlpaeYUeRPoQQEAwIbS0tJ04cKFQvsvXLig9PR0SVJ4eLhOnz59q0tzCwIKAAA21KJFCz377LPasmWLc9+WLVs0cOBAtWzZUpK0Y8cORUVFmVXiTSGgAABgQzNnzlRwcLAaNGggX19f+fr6qmHDhgoODtbMmTMlSWXLltWkSZNMrvTGMAYFAAAb+/HHH7Vv3z4ZhqE777xTNWvWNLsktyCgAAAAy2GiNgAAbCg/P1+zZ8/WN998o4yMDBUUFLgcX716tUmVuQcBBQAAG3ruuec0e/ZstW/fXtHR0XI4HGaX5Fbc4gEAwIYqVKiguXPn6uGHHza7lGLBUzwAANiQj4+PqlWrZnYZxYaAAgCADY0YMULTpk1TSb0Rwi0eAABsqEuXLlqzZo2Cg4NVu3ZteXt7uxxfvHixSZW5B4NkAQCwoXLlyqlLly5ml1Fs6EEBAACWwxgUAABgOdziAQDAJurXr69vvvlGQUFBqlev3lXnPvnhhx9uYWXuR0ABAMAmOnXqJF9fX0lS586dzS2mmDEGBQAAWA5jUAAAgOVwiwcAAJsICgq67jV3Tp48WczVFC8CCgAANjF16lSzS7hlGIMCAAAshx4UAABsIjs7+7rbBgQEFGMlxY8eFAAAbMLDw+OaY1AMw5DD4VB+fv4tqqp40IMCAIBNrFmzxuwSbhl6UAAAgOXQgwIAgE2dOnVKM2fO1J49e+RwOFSrVi3169dPgYGBZpd20+hBAQDAhjZv3qw2bdqodOnSuu+++2QYhjZv3qzc3FytXLlS9evXN7vEm0JAAQDAhh588EFVq1ZNH330kby8/rghcuHCBT311FM6dOiQ1q5da3KFN4eAAgCADZUuXVpbtmzRnXfe6bJ/9+7datiwoc6ePWtSZe7BWjwAANhQQECAjh49Wmh/amqq/P39TajIvQgoAADYUPfu3dW/f3998sknSk1N1bFjx5SQkKCnnnpKjz/+uNnl3TSe4gEAwIbeeecdORwOPfnkk7pw4YIkydvbWwMHDtSECRNMru7mMQYFAACbyc/P17p161SnTh2VKlVKBw8elGEYqlatmsqUKWN2eW5BQAEAwIZKlSqlPXv2KCoqyuxSigVjUAAAsKE6dero0KFDZpdRbOhBAQDAhlauXKkXXnhBr7/+uho0aCA/Pz+X46xmDAAAbjkPj///JsjFKxyzmjEAADBNSV/ZmB4UAABgOfSgAABgU6dOndLGjRuVkZGhgoICl2NPPvmkSVW5Bz0oAADY0H//+1/17NlTZ86ckb+/v8s4FIfDoZMnT5pY3c0joAAAYEM1atTQww8/rPj4+BIzOdvFCCgAANiQn5+fduzYoSpVqphdSrFgojYAAGyoTZs22rx5s9llFBsGyQIAYEPt27fXP/7xD+3evVt16tSRt7e3y/GOHTuaVJl7cIsHAAAbuniitkuVhInaCCgAAMByGIMCAAAsh4ACAICNPPzww8rKynK+fvPNN3Xq1Cnn6xMnTqhWrVomVOZe3OIBAMBGPD09lZaWpkqVKkn6Y9XirVu3Oh83Pn78uMLDw20/BoUeFAAAbOTSfoWS2s9AQAEAAJZDQAEAwEYcDofLujt/7itpmKgNAAAbMQxDffr0ka+vryTp999/14ABA+Tn5ydJysvLM7M8t2GQLAAANtK3b9/rajdr1qxirqR4EVAAAIDlMAYFAABYDgEFAABYDgEFAABYDgEFAABYDgEFAABYDgEFAABYDgEFAABYDgEFAABYDgEFAABYzv8HLY/uBajS33YAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.OverallStatus.value_counts().plot.bar()\n",
    "# So much better"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
